NZ622335B2 - Yeast-muc1 immunotherapeutic compositions and uses thereof - Google Patents
Yeast-muc1 immunotherapeutic compositions and uses thereof Download PDFInfo
- Publication number
- NZ622335B2 NZ622335B2 NZ622335A NZ62233512A NZ622335B2 NZ 622335 B2 NZ622335 B2 NZ 622335B2 NZ 622335 A NZ622335 A NZ 622335A NZ 62233512 A NZ62233512 A NZ 62233512A NZ 622335 B2 NZ622335 B2 NZ 622335B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- yeast
- muc1
- mucl
- seq
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 279
- 230000001024 immunotherapeutic Effects 0.000 title claims abstract description 152
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 431
- 201000011510 cancer Diseases 0.000 claims abstract description 208
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 427
- 239000000427 antigen Substances 0.000 claims description 358
- 108091007172 antigens Proteins 0.000 claims description 356
- 102000038129 antigens Human genes 0.000 claims description 356
- 102000004169 proteins and genes Human genes 0.000 claims description 242
- 108090000623 proteins and genes Proteins 0.000 claims description 242
- 101700052761 MUC1 Proteins 0.000 claims description 158
- 101700010580 FLO11 Proteins 0.000 claims description 157
- 102100006037 MUC1 Human genes 0.000 claims description 157
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 156
- 210000004027 cells Anatomy 0.000 claims description 146
- 150000001413 amino acids Chemical class 0.000 claims description 136
- 239000000556 agonist Substances 0.000 claims description 95
- 230000001225 therapeutic Effects 0.000 claims description 35
- 230000004044 response Effects 0.000 claims description 31
- 210000002421 Cell Wall Anatomy 0.000 claims description 29
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 27
- 210000004881 tumor cells Anatomy 0.000 claims description 23
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 20
- -1 BCR-Abl Proteins 0.000 claims description 20
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 20
- 102100011842 CEACAM5 Human genes 0.000 claims description 15
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 15
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 claims description 14
- 230000003612 virological Effects 0.000 claims description 14
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 230000001603 reducing Effects 0.000 claims description 9
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 8
- 102000006108 VHL Human genes 0.000 claims description 8
- 108060009310 VHL Proteins 0.000 claims description 8
- 108010080146 androgen receptors Proteins 0.000 claims description 8
- 230000001394 metastastic Effects 0.000 claims description 8
- 210000001519 tissues Anatomy 0.000 claims description 8
- 239000003607 modifier Substances 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 210000002919 epithelial cells Anatomy 0.000 claims description 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 230000023298 conjugation with cellular fusion Effects 0.000 claims description 5
- 230000003248 secreting Effects 0.000 claims description 5
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 claims description 5
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 4
- 102100017392 ANO7 Human genes 0.000 claims description 4
- 101700064647 ANO7 Proteins 0.000 claims description 4
- 210000000805 Cytoplasm Anatomy 0.000 claims description 4
- 102100007097 DCT Human genes 0.000 claims description 4
- 101710004105 DCT Proteins 0.000 claims description 4
- 102000003425 EC 1.14.18.1 Human genes 0.000 claims description 4
- 108060008724 EC 1.14.18.1 Proteins 0.000 claims description 4
- 108060002563 EPCAM Proteins 0.000 claims description 4
- 101710009074 FLT3 Proteins 0.000 claims description 4
- 102100008453 FOLH1 Human genes 0.000 claims description 4
- 101700036477 FOLH1 Proteins 0.000 claims description 4
- 241000578472 Human endogenous retrovirus H Species 0.000 claims description 4
- 102100013951 MUC2 Human genes 0.000 claims description 4
- 101700036633 MUC2 Proteins 0.000 claims description 4
- 101710025567 PSAT1 Proteins 0.000 claims description 4
- 101700008337 PSMA Proteins 0.000 claims description 4
- 101700044827 RNMT Proteins 0.000 claims description 4
- 102100017680 SMAD4 Human genes 0.000 claims description 4
- 108010050282 Smad4 Protein Proteins 0.000 claims description 4
- 101710009757 UROD Proteins 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 102000003735 mesothelin Human genes 0.000 claims description 4
- 108090000015 mesothelin Proteins 0.000 claims description 4
- 200000000023 metastatic cancer Diseases 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 206010056981 Adenomatous polyposis coli Diseases 0.000 claims description 3
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 3
- 101700025368 ERBB2 Proteins 0.000 claims description 3
- 102100016662 ERBB2 Human genes 0.000 claims description 3
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 102100010912 EPCAM Human genes 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 101700058542 KLK3 Proteins 0.000 claims description 2
- 210000003734 Kidney Anatomy 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100006044 MUC16 Human genes 0.000 claims description 2
- 101700008449 MUC16 Proteins 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010028549 Myeloid leukaemia Diseases 0.000 claims description 2
- 102100002997 NPEPPS Human genes 0.000 claims description 2
- 101710027788 NPEPPS Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 2
- 102000001307 androgen receptors Human genes 0.000 claims 2
- 102100014001 ABCB1 Human genes 0.000 claims 1
- 102100001891 CTAG1A Human genes 0.000 claims 1
- 101710004449 CTAG1A Proteins 0.000 claims 1
- 102100008857 MLANA Human genes 0.000 claims 1
- 101710012533 MLANA Proteins 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102100007096 TYRP1 Human genes 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 108010010447 trophoblastin Proteins 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 96
- 230000002018 overexpression Effects 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 102000007298 Mucin-1 Human genes 0.000 abstract description 3
- 108010008707 Mucin-1 Proteins 0.000 abstract description 3
- 108020001507 fusion proteins Proteins 0.000 description 112
- 102000037240 fusion proteins Human genes 0.000 description 112
- 238000009169 immunotherapy Methods 0.000 description 109
- 239000003981 vehicle Substances 0.000 description 80
- 230000002163 immunogen Effects 0.000 description 65
- 150000007523 nucleic acids Chemical class 0.000 description 65
- 206010028980 Neoplasm Diseases 0.000 description 54
- 238000002560 therapeutic procedure Methods 0.000 description 53
- 108020004707 nucleic acids Proteins 0.000 description 51
- 239000003795 chemical substances by application Substances 0.000 description 47
- 230000028993 immune response Effects 0.000 description 37
- 150000002500 ions Chemical class 0.000 description 36
- 210000001744 T-Lymphocytes Anatomy 0.000 description 32
- 230000001264 neutralization Effects 0.000 description 32
- 229920001850 Nucleic acid sequence Polymers 0.000 description 31
- 108090001123 antibodies Proteins 0.000 description 29
- 102000004965 antibodies Human genes 0.000 description 29
- 230000000875 corresponding Effects 0.000 description 26
- 239000012528 membrane Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- 230000004927 fusion Effects 0.000 description 24
- 230000027455 binding Effects 0.000 description 23
- 230000001086 cytosolic Effects 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 230000003042 antagnostic Effects 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000002708 enhancing Effects 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 108010029697 CD40 Ligand Proteins 0.000 description 13
- 102100003729 CD40LG Human genes 0.000 description 13
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 13
- 101700063429 NID1 Proteins 0.000 description 13
- 229960005486 vaccines Drugs 0.000 description 13
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 11
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 11
- 229940045145 Uridine Drugs 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000006011 modification reaction Methods 0.000 description 11
- 230000000051 modifying Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 101000249131 MUC1 Proteins 0.000 description 9
- 102000021488 human MUC1 protein Human genes 0.000 description 9
- 102000027675 major histocompatibility complex family Human genes 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 102100010782 EGFR Human genes 0.000 description 8
- 101700039191 EGFR Proteins 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 101710025952 adhT Proteins 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 230000016396 cytokine production Effects 0.000 description 8
- 230000004059 degradation Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000001105 regulatory Effects 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 7
- 210000001185 Bone Marrow Anatomy 0.000 description 7
- 102100006400 CSF2 Human genes 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 230000014564 chemokine production Effects 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 230000003899 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001965 increased Effects 0.000 description 7
- 230000021633 leukocyte mediated immunity Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000002271 resection Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 230000004083 survival Effects 0.000 description 7
- 102100007495 AR Human genes 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- 101710038745 EEF1A2 Proteins 0.000 description 6
- 102000026088 HLA-A2 Antigen Human genes 0.000 description 6
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 6
- 210000000987 Immune System Anatomy 0.000 description 6
- 241000235648 Pichia Species 0.000 description 6
- 102100005038 SPOP Human genes 0.000 description 6
- 101700060127 SPOP Proteins 0.000 description 6
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 101710005270 TEF1 Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000003308 immunostimulating Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 210000000349 Chromosomes Anatomy 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101710008404 GAPDH Proteins 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 229940117681 Interleukin-12 Drugs 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229910000365 copper sulfate Inorganic materials 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 230000001809 detectable Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000001717 pathogenic Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102200094548 PIGA P93L Human genes 0.000 description 4
- 108091005771 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 230000002519 immonomodulatory Effects 0.000 description 4
- 239000000367 immunologic factor Substances 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000003211 malignant Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000000770 pro-inflamatory Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 102100017224 AGRN Human genes 0.000 description 3
- 101710004990 AGRN Proteins 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229960000643 Adenine Drugs 0.000 description 3
- 101700005748 Agrin Proteins 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 3
- 102100019451 CD80 Human genes 0.000 description 3
- 101700080477 CD80 Proteins 0.000 description 3
- 102100008186 CD83 Human genes 0.000 description 3
- 101700013105 CD83 Proteins 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 108010013369 EC 3.4.21.9 Proteins 0.000 description 3
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101710037135 GAPC2 Proteins 0.000 description 3
- 101710037116 GAPC3 Proteins 0.000 description 3
- 101710025049 GAPDG Proteins 0.000 description 3
- 102100006425 GAPDH Human genes 0.000 description 3
- 101710010461 Gapdh1 Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102100014204 IL22 Human genes 0.000 description 3
- 102100014203 IL23A Human genes 0.000 description 3
- 102100014198 IL27 Human genes 0.000 description 3
- 108010065637 Interleukin-23 Proteins 0.000 description 3
- 108010066979 Interleukin-27 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 101710025050 MK0970 Proteins 0.000 description 3
- 102400000108 N-terminal peptide Human genes 0.000 description 3
- 101800000597 N-terminal peptide Proteins 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 102000035443 Peptidases Human genes 0.000 description 3
- 102000011755 Phosphoglycerate kinases Human genes 0.000 description 3
- 108020004454 Phosphoglycerate kinases Proteins 0.000 description 3
- 102100009508 TMPRSS15 Human genes 0.000 description 3
- 102100009594 TPI1 Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 102200026925 YV020_HUMAN P97L Human genes 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101710025091 cbbGC Proteins 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000000139 costimulatory Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 101710025070 gapdh-2 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000415 inactivating Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000002101 lytic Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 102000025475 oncoproteins Human genes 0.000 description 3
- 108091008124 oncoproteins Proteins 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000023 polynucleotide Polymers 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 230000020978 protein processing Effects 0.000 description 3
- 230000002797 proteolythic Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 108020000411 toll-like receptors Proteins 0.000 description 3
- 102000002689 toll-like receptors Human genes 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N Bis-tris methane Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 101800000655 C-terminal peptide Proteins 0.000 description 2
- 101710004053 CWINV2 Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 108020004445 Glyceraldehyde-3-Phosphate Dehydrogenases Proteins 0.000 description 2
- 102000006602 Glyceraldehyde-3-Phosphate Dehydrogenases Human genes 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 241000192019 Human endogenous retrovirus K Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 229960000367 Inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 family Proteins 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 2
- 241000235650 Kluyveromyces marxianus Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 108060004270 LAG3 Proteins 0.000 description 2
- 102100017213 LAG3 Human genes 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M Lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 229940071257 Lithium acetate Drugs 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 210000003470 Mitochondria Anatomy 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 2
- 101700016532 SUC2 Proteins 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 description 2
- 102100012087 TLR4 Human genes 0.000 description 2
- 101700022711 TLR4 Proteins 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- 229960003433 Thalidomide Drugs 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 229940035893 Uracil Drugs 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulators Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002665 ion therapy Methods 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 230000004301 light adaptation Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000001938 protoplasts Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000003252 repetitive Effects 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- 101710025069 yplQ Proteins 0.000 description 2
- CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
- JMGOORYWTOXUQE-XOBOFAKPSA-N (6Z)-4-amino-3-[(4-nitrophenyl)diazenyl]-5-oxo-6-(phenylhydrazinylidene)naphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC=2C=C(S(O)(=O)=O)\C(=N/NC=3C=CC=CC=3)C(=O)C=2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 JMGOORYWTOXUQE-XOBOFAKPSA-N 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006256 Breast hyperplasia Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L D-glyceraldehyde 3-phosphate(2-) Chemical compound O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010082433 EC 2.7.7.12 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 102100004572 FLT3LG Human genes 0.000 description 1
- 101710022257 FLT3LG Proteins 0.000 description 1
- 101700064140 FOXP3 Proteins 0.000 description 1
- 102100011855 FOXP3 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101700058973 GAL4 Proteins 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 101700032527 GRAP Proteins 0.000 description 1
- 101700046691 GRB2 Proteins 0.000 description 1
- 102000016876 Galactokinase Human genes 0.000 description 1
- 108091000074 Galactokinase Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101710006488 HSPA4 Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710006493 Hsp70Bb Proteins 0.000 description 1
- 210000004754 Hybrid Cells Anatomy 0.000 description 1
- 210000004408 Hybridomas Anatomy 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 101700051176 ICAM1 Proteins 0.000 description 1
- 102100014201 IL23R Human genes 0.000 description 1
- 102100008627 IL27RA Human genes 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SFEOKXHPFMOVRM-BQYQJAHWSA-N Ionone Chemical compound CC(=O)\C=C\C1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-BQYQJAHWSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100011539 LGALS4 Human genes 0.000 description 1
- 101710015850 LGALS4 Proteins 0.000 description 1
- 206010051589 Large intestine polyp Diseases 0.000 description 1
- 229940087875 Leukine Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 101710028471 MFGE8 Proteins 0.000 description 1
- 102100006993 MFGE8 Human genes 0.000 description 1
- 108060004994 MLP Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 210000004897 N-terminal region Anatomy 0.000 description 1
- 101700062818 NP Proteins 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 229940116542 OTHER NUTRIENTS in ATC Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 210000003463 Organelles Anatomy 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100004939 PDGFRB Human genes 0.000 description 1
- 101710018346 PDGFRB Proteins 0.000 description 1
- 102100010734 PRL Human genes 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 210000001322 Periplasm Anatomy 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229940120975 Revlimid Drugs 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000223254 Rhodotorula mucilaginosa Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 101700062671 SIAE Proteins 0.000 description 1
- 101710009384 SRC Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 240000007697 Saccharomyces cerevisiae W303 Species 0.000 description 1
- 235000011859 Saccharomyces cerevisiae W303 Nutrition 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000030429 T-helper 17 type immune response Effects 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091005908 Type I transmembrane proteins Proteins 0.000 description 1
- 108010075202 UDPglucose 4-Epimerase Proteins 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010025188 alcohol oxidase Proteins 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 108010035432 cytochrome C(L) Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000020173 dendritic cell cytokine production Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 210000003162 effector T lymphocyte Anatomy 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
- 108010027445 interleukin-22 receptor Proteins 0.000 description 1
- 102000009548 interleukin-22 receptor activity proteins Human genes 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 108040010248 interleukin-25 receptor activity proteins Proteins 0.000 description 1
- 108040010246 interleukin-27 receptor activity proteins Proteins 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 101700061289 mnn9 Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001400 myeloablative Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 102000027730 retinoid hormone receptors Human genes 0.000 description 1
- 108091008001 retinoid hormone receptors Proteins 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
Abstract
Disclosed are yeast-based immunotherapeutic compositions comprising mucin- 1 (MUCl), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin- 1 (MUCl).
Description
Yeast-MUCl Immunotherapeutic Compositions and Uses Thereof
GOVERNMENT RIGHTS
This invention was created in the performance of a Cooperative Research and
Development Agreement with the National Institutes of Health, an Agency of the
Department of Health and Human Services. The Government of the United States has
certain rights in this invention.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority under 35 U.S.C. §119(e) to US.
Provisional Patent Application No. 61/524,407, filed August 17, 2011. The entire
disclosure of US. Provisional Patent Application No. ,407 is incorporated herein by
nce.
STATEMENT REGARDING JOINT RESEARCH AGREEMENT
This invention was made by or on behalf of parties to a Cooperative ch
and Development Agreement, executed May 8, 2008. The parties to the Cooperative
Research and Development Agreement are: GlobeImmune, Inc. and the US. ment
of Health and Human Services, as represented by National Cancer Institute, an Institute,
Center or Division of the National Institutes of Health.
NCE TO A SEQUENCE LISTING
This application contains a Sequence Listing submitted electronically as a text
file by EFS-Web. The text file, named "3923PCT_ST25", has a size in bytes of 89
KB, and was recorded on 16 August 2012. The information contained in the text file is
incorporated herein by reference in its entirety pursuant to 37 CFR § )(5).
FIELD OF THE INVENTION
The t invention generally relates to yeast-based immunotherapeutic
compositions and methods for the prevention and/or treatment of cancers characterized by
the expression or overexpression of mucin-I (MUCI).
BACKGROUND OF THE INVENTION
Cancer is a leading cause of death worldwide, and the development of
effective ies for cancer continues to be one of the most active areas of research and
clinical development. Although a y of tive approaches to treat and prevent
cancers have been proposed, many s continue to have a high rate of mortality and
may be difficult to treat or relatively onsive to conventional therapies.
A large number of human carcinomas and hematologic malignancies are
characterized, at least in part, by aberrant overexpression of a protein known as mucin-l
(MUCl) whose normal function is to help protect epithelial cells from toxins,
microorganisms and other types of al environment stresses (Kufe et al., Hybridoma
1984; 3223-32). MUCl is a heterodimeric protein formed from the noncovalent
interaction of two subunits which are encoded by a single transcript and then processed
into ts post—translationally, known as MUCl-N and MUCl-C. MUCl is normally
found at the apical s of secretory epithelial cells, and when the cells lose polarity in
response to stress, a reversible process for normal cells, MUCl can interact with
molecules that usually ze at the basolateral borders. In addition, in se to stress
nments, the MUCl-N t, a large protein containing a variable number of
tandem repeats (VNTR) that are extensively glycosylated with O-linked glycans, can be
shed. The other subunit of MUCl, known as MUCl-C, has an ellular domain, a
transmembrane domain and a cytoplasmic tail, and can bind to a ligand that is responsible
for physically associating MUCI with the epidermal growth factor receptor (EGFR) (Li et
al., JBz'ol Chem 2001; 276:35239-42; der et al., JBz'ol Chem 2001; 276:13057-64)
as well as other receptor tyrosine kinases, such as 4,20 FGFR321 and PDGFR (Li
et al., M0! Cancer Res 2003; 12765-75; Ren et al., M01 Cancer Res 2006; 42873-83; Singh
et al., Cancer Res 2007; 67:5201-10). In addition, MUCl-C has been associated with a
variety of signaling pathways that include ErbB ors, c-Src, B-catenin, transcription
factors (p53, ERor) and other effectors, such as Grb2/SOS (Pandey et al., Cancer Res 1995;
55:4000-3; Kinlough et al., JBz'ol Chem 2004; 279:53071-7).
In transformed epithelial cells, membrane polarity is irreversible and MUCl
sion is upregulated over the entire surface of oma cells (Kufe et al., 1984,
supra). MUCl overexpression is associated with decreased MUCl-N O—glycosylation,
and the high levels of MUCl-N at the cell surface sterically block cell-cell and cell-
extracellular matrix interactions, which are associated with the malignant phenotype
(Ligtenberg et al., Cancer Res 1992; 52:223-32; van de Wiel-van Kemenade et al., J
Immunol 1993; 151:767—76; Wesseling et al., Mol Biol Cell 1996; 72565-77). The MUCl—
C subunit is now considered to be an oncoprotein, based on its involvement in diverse
signaling pathways associated with tumorigenesis, and its overexpression has been shown
to be involved in blocking induction of apoptosis in the response to DNA damage (Ren et
al., Cancer Cell 2004; 52163-75; Raina et al., J Biol Chem 2004; 279:20607-12), ive
stress (Yin and Kufe, J Biol Chem 2003; 278:35458-64; Yin et al., JBz'ol Chem 2004;
279:45721-7), and hypoxia (Yin et al., J Biol Chem 2007; 282:257-66), as well as
conferring anchorage-independent growth and genicity (Li et al., Oncogene 2003;
22:6107-10; Huang et al., Cancer Biol Ther 2003; 2:702—6; Huang et al., Cancer Res
2005; 65:10413-22; Schroeder et al., Oncogene 2004; 23:5739-47).
As discussed above, data from various laboratories indicate that the MUC1—N
(0t subunit) plays a role in cancer by conferring cellular properties that allow immune
evasion and potentially metastatic spread. The MUC1-C ([3 subunit) engages signaling
pathways responsible for tumor initiation and progression. These dual functions of MUC1
may explain the differing roles this antigen s to play in different cancer indications.
For example, MUC1 appears to be an early marker in cancers such as breast cancer and
colon cancer (e.g., see Kretschmer et al., Mol Cancer. 2011 Feb 11;10(1):15;
Mukhopadhyay et al., Biochz'm BiOphys Acta. 2011 Apr;1815(2):224—40; Saeki et al.,
enterology. 2011 Mar;140(3):892-902), while MUC1 is associated with epithelial—
mesenchymal tion (EMT) pathways and metastatic spread in cancers such as
pancreas cancer and esophageal cancer (e.g., see Xu et al., Life Sci. 2011 Jun 6;88(23-
63-9; Besmer et al., Cancer Res. 2011 Jul 1;71(13):4432-42; Roy et al., Oncogene
2011 Mar 24;30(12):1449-59; Ye et al., Lab . 2011 May;91(5):778-87), and prevents
al differentiation by ve oxygen species in acute myeloid ia (AML)
(e.g., see Yin et al., Blood. 2011 May 5,1 17(18):4863-70; Fatrai et al., Exp Hematol. 2008
Oct;36(10):1254-65), thereby allowing unlimited self renewal of these cancer cells.
Given the apparent role of MUC1 in the malignant phenotype of cancer cells,
MUC1, and particularly MUC1-N, has been the focus of anti-cancer therapeutic
approaches. Indeed, the majority of therapeutic approaches have targeted MUC1-N, the
extracellular portion of the MUC1 heterodimer. However, such approaches targeting
MUC1-N have not been sful in the clinic so far, possibly due to interference from
MUC1-N that is shed from the cells. More recent studies have proposed targeting the
MUC1-C subunit with antibodies against the extracellular domain, or with peptides,
peptides conjugated with a carbohydrate r, small les, with preparations of
tumor cells expressing MUC1, and with dendritic cell/tumor cell fusions. However, there
are presently no approved cancer therapies that specifically target MUC1. Accordingly,
there remains a need in the art for new products that ively treat and/or prevent
cancers associated with MUC1 expression or overexpression.
SUMMARY OF THE ION
One embodiment of the invention relates to a MUCl immunotherapeutic
composition, comprising: (a) a yeast vehicle; and (b) a fitsion protein sed by the
yeast vehicle and comprising at least one MUCl antigen. In one aspect, the MUCl
antigen consists of, in order from N— to C-terminus, a MUCl SEA/extracellular domain
(ED), wherein the MUCl SEA/ED domain comprises a MUCI ED flanked at the N-
terminus by one or more amino acids from the non-ED portion of the MUCl SEA domain;
at least two variable number of tandem repeat (VNTR) domains; a MUCl transmembrane
(TM) domain; and a MUCl cytoplasmic domain (CD).
[0012] In one aspect, the antigen includes two VNTR domains. In one aspect, the
VNTR domain has an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or
100% identical to positions 126-145 of SEQ ID NO:11; any consecutive 20 amino acids
between positions 61 and 1020 of SEQ ID NO:ll; any consecutive 20 amino acids
between positions 126 and 965 of SEQ ID NO:11; SEQ ID NO:12; any consecutive 20
amino acids n positions 90 and 130 of SEQ ID NO:14; any consecutive 20 amino
acids between positions 60 and 100 of SEQ ID NO:15; and a corresponding ce
from a different human MUCl n. In one aspect, the VNTR domain has an amino
acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to any
consecutive 20 amino acids between positions 90 and 130 of SEQ ID NO:14 or any
consecutive 20 amino acids between positions 60 and 100 of SEQ ID NO:15. In one
aspect, the fusion protein has two VNTR domains, and the amino acid sequence of the two
VNTR s is positions 90 and 130 of SEQ ID NO:14 or positions 60 and 100 of SEQ
ID NO:15.
In one aspect, the MUCl ED has an amino acid sequence that is at least 95%,
96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected from:
ons 116-173 of SEQ ID NO:2; positions 107-164 of SEQ ID NO:4; positions 107-
164 of SEQ ID N026; positions 98-155 of SEQ ID N028; positions 1098—1155 of SEQ ID
NO:11; ons 32-89 of SEQ ID NO:14; positions 2-59 of SEQ ID NO:15; and a
corresponding sequence from a different human MUCl protein. In one aspect, the MUCl
ED has an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100%
identical to positions 32-89 of SEQ ID NO:14 or positions 2-59 of SEQ ID NO:15. In one
aspect, the MUCl ED has an amino acid sequence of positions 32-89 of SEQ ID NO:14 or
positions 2-59 of SEQ ID NO:15. In one aspect, the MUCl SEA/ED has an amino acid
ce that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid
sequence selected from: positions 115—173 of SEQ ID N0z2; positions 4 of SEQ
ID N024; positions 106-164 of SEQ ID NO:6, positions 97—155 of SEQ ID N0:8;
positions 1097-1155 of SEQ ID N0:11; positions 31-89 of SEQ ID N0:14; ons 1—59
of SEQ ID N015; and a corresponding sequence from a different human MUC1 n.
In one aspect, the MUC1 SEA/ED has an amino acid sequence of positions 31-89 of SEQ
ID N0:14 or positions l-59 of SEQ ID N0:15.
In one aspect, the MUC1 TM domain has an amino acid sequence that is at
least 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected
from: positions 174-201 of SEQ ID N022 165-192 of SEQ ID N0:4, positions
, ons
2 of SEQ ID NO:6, positions 156-183 of SEQ ID N0:8, positions 1156-1183 of
SEQ ID N0:11, positions 131-158 of SEQ ID N0:14, positions 8 of SEQ ID
N0215, and a corresponding sequence from a ent human MUC1 protein. In one
aspect, the MUC1 TM domain has an amino acid sequence that is at least 95%, 96%, 97%,
98%, 99%, or 100% identical to positions 131-158 of SEQ ID N0:14 or positions 101-128
of SEQ ID N0:15. In one aspect, the MUC1 TM domain has an amino acid sequence of
positions 8 of SEQ ID N0:14 or positions 101—128 ofSEQ ID N0:15.
In one aspect, the MUC1 CD domain has an amino acid sequence that is at
least 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected
from: positions 202-273 of SEQ ID N0:2, positions 193-264 of SEQ ID N0:4, positions
193—264 of SEQ ID NO:6, positions 184-255 of SEQ ID N028, positions 1184-1255 of
SEQ ID N0:11, positions 0 of SEQ ID N0:14, positions 129-200 of SEQ ID
N0215, positions 7-78 of SEQ ID N0:17, positions 79-150 of SEQ ID N0:17, positions
151-222 of SEQ ID N0:17, positions l-72 of SEQ ID N0:18, positions 73—144 of SEQ ID
N0:18, positions 145-216 of SEQ ID N018, and a corresponding sequence from a
different human MUC1 protein. In one aspect, the MUC1 CD domain has an amino acid
ce that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid
sequence of positions 159—230 of SEQ ID N0:14 or positions 129-200 of SEQ ID N0:15.
In one aspect, the MUC1 CD domain has an amino acid sequence of positions 159-230 of
SEQ ID NO: 14 or positions 129-200 of SEQ ID N0:15.
[0016] In one aspect of this embodiment of the invention, the MUC1 n has an
amino acid sequence that is at least 95%, 96%, 97%, or 98% identical to SEQ ID N0:15.
In one aspect, the MUC1 antigen comprises SEQ ID N0:15 or an amino acid sequence
that is at least 99% identical to SEQ ID N0:15. In one aspect, the MUC1 antigen has an
amino acid sequence of SEQ ID NO: 15.
In one aspect of this embodiment of the invention, the fusion protein further
comprises a MUCl signal sequence appended to the N—terminus of the MUCl SEA/ED.
In one aspect, the MUCl signal sequence has an amino acid sequence that is at least 95%,
96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence ed from:
positions 1-27 of SEQ ID N022, positions 1—32 of SEQ ID N024, positions 1-32 of SEQ
ID NO:6, positions 1-27 of SEQ ID NO:8, ons l-23 of SEQ ID NO:ll, positions 1-
of SEQ ID NO:l4, and a corresponding sequence from a different human MUCl
protein. In one , the MUCl signal sequence has an amino acid sequence that is at
least 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence of
positions 1—30 of SEQ ID NO:l4. In one aspect, the MUCl signal sequence has an amino
acid sequence of positions 1-30 of SEQ ID NO:l4. In one aspect, the fusion n has
an amino acid sequence that is at least 95%, 96%, 97%, or 98% identical to SEQ ID
NO:l4. In one aspect, the fusion protein comprises SEQ ID NO:l4 or an amino acid
sequence that is at least 99% identical to SEQ ID NO: 14. In one aspect, the fusion protein
has an amino acid sequence of SEQ ID NO: 14.
In one aspect of this embodiment of the invention, the MUCl antigen
ses 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or more amino acid substitutions, as compared to
a wild-type MUCl sequence, to form between one and 11 t epitopes within the
MUCl antigen, also referred to herein as a MUCl agonist antigen. In one aspect of this
embodiment of the invention, the amino acid substitutions are selected from: A96Y, P97L,
G104V, S105Y, T106L, A147Y, Cl6lV, Tl99L, D200F, S215Y, and T239L, with respect
to the MUCl antigen portion of SEQ ID NO:l4 or SEQ ID NO:lS. In one aspect, the
MUCl agonist antigen has an amino acid sequence that is at least 95%, 96%, 97%, or 98%
identical to SEQ ID NO:23. In one aspect, the MUCl antigen comprises SEQ ID NO:23
or an amino acid ce that is at least 99% identical to SEQ ID NO:23. In one aspect,
the MUCl antigen has an amino acid sequence of SEQ ID NO:23. The Yeast-MUCl
immunotherapeutic composition of Claim 1, n the MUCl antigen comprises
n one and eleven amino acid substitutions to create a MUCl agonist antigen.
Another embodiment of the invention relates to a yeast-MUCl
immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a fusion protein
expressed by the yeast vehicle and comprising at least one MUCl antigen. The MUCl
antigen consists of two or more cytoplasmic s (CD) of MUCl. In one aspect, the
MUCl antigen consists of three cytoplasmic domains (CD) of MUCl. In one , the
three CDs are from the same MUCl protein. In one aspect, each CD domain comprises an
amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to an
amino acid ce selected from: positions 202-273 of SEQ ID N0:2, positions 193—
264 of SEQ ID N024, positions 193-264 of SEQ ID N0:6, positions 184-255 of SEQ ID
N0:8, positions 1184-1255 of SEQ ID NO:ll, positions 159-230 of SEQ ID NO:l4,
positions 129-200 of SEQ ID N0215, positions 7-78 of SEQ ID NO:l7, positions 79—150
of SEQ ID NO:l7, positions 151-222 of SEQ ID NO:l7, positions l-72 of SEQ ID NO:l8,
positions 73-144 of SEQ ID NO:l8, positions 145-216 of SEQ ID NO:l8, and a
corresponding ce from a different human MUCl protein. In one aspect, each CD
domain comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or
100% identical to an amino acid ce selected from: positions 129-200 of SEQ ID
N0215, positions 7-78 of SEQ ID NO:l7, positions 79-150 of SEQ ID NO:l7, positions
151-222 of SEQ ID N0:l7; positions l-72 of SEQ ID NO:l8, positions 73—144 of SEQ ID
N018, and positions 145-216 of SEQ ID NO:l8.
In one aspect of this embodiment, the MUCl antigen has an amino acid
sequence that is at least 95%, 96%, 97%, or 98% identical to SEQ ID NO:l8. In one
aspect, the MUCl antigen has an amino acid sequence of SEQ ID N0:l8 or an amino acid
sequence that is at least 99% identical to SEQ ID NO:l8. In one , the MUCl
antigen has an amino acid ce of SEQ ID NO:l8. In one , the fusion protein
has an amino acid sequence that is at least 95%, 96%, 97%, or 98% identical to SEQ ID
N0: 17. In one aspect, the fusion protein has an amino acid sequence of SEQ ID NO: 17 or
an amino acid sequence that is at least 99% identical to SEQ ID N0: 17. In one aspect, the
fusion protein has an amino acid sequence of SEQ ID N0: 17.
Another ment of the invention relates to a yeast-MUCl
immunotherapeutic ition comprising: (a) a yeast vehicle; and (b) a fusion protein
expressed by the yeast vehicle and comprising at least one MUCl agonist antigen. In one
aspect of this ment of the invention, the MUCl agonist antigen comprises 1, 2, 3, 4,
, 6, 7, 8, 9, 10, 11, or more amino acid substitutions, as compared to a Wild—type MUCl
sequence, to form between one and 11 agonist epitopes within the MUCl antigen, also
referred to herein as a MUCl agonist antigen. In one aspect, the MUCl agonist antigen
has an amino acid sequence that is at least 95%, 96%, 97%, or 98% identical to SEQ ID
N0223 or SEQ ID N0:25. In one aspect, the MUCl antigen ses SEQ ID N0:23 or
SEQ ID N0125 or an amino acid sequence that is at least 99% identical to SEQ ID N0:23
or SEQ ID N0:25. In one , the MUCl antigen has an amino acid sequence of SEQ
ID N0z23 or SEQ ID N0z25.
Yet another ment of the invention relates to a method to reduce tumor
burden, inhibit tumor growth, and/or increase survival of an individual who has a cancer
that expresses MUCl. The method includes the step of administering to the individual a
MUCI immunotherapeutic ition described above or elsewhere herein. In
one aspect, MUCl expression is detected in the individual’s cancer at the time the
composition is first stered. In one aspect, the individual has a stage I cancer. In
one aspect, the individual has a stage II cancer. In one , the individual has a stage
III cancer. In one aspect, the individual has a stage IV cancer.
Another embodiment of the invention relates to the use of any of the yeast—
MUCl immunotherapeutic compositions bed herein to treat a disease. In one aspect,
the disease is cancer.
Yet another embodiment of the invention relates to the use of any of the yeast-
MUCl immunotherapeutic compositions bed herein to reduce, arrest, reverse or
prevent the metastatic progression of cancer in an individual who has cancer.
[0025] Yet another embodiment of the invention relates to the use of any of the yeast-
MUCl therapeutic compositions described herein to prevent or delay the onset of
a MUC 1 -expressing cancer.
Another embodiment of the invention relates to the use of a combination of
therapeutic compositions to treat cancer, the immunotherapeutic itions
comprising: (a) a first composition that is any of the yeast-MUCI immunotherapeutic
compositions bed herein; and (b) at least one additional immunotherapeutic
composition comprising a yeast vehicle and an antigen that is not a MUCl antigen. In one
aspect, the antigen that is not a MUCl antigen is selected from d Ras,
carcinoembryonic antigen (CEA), and/or Brachyury.
[0027] In one aspect of any of the embodiments related to a method or use related to a
yeast-MUCl immunotherapy composition described herein, the individual is being treated
or has been treated with r therapy for cancer, which can include, but is not limited
to, herapy, targeted cancer therapy, radiation therapy, adoptive T cell transfer,
surgical resection of a tumor from the individual, and/or the administration of one or more
additional immunotherapeutic compositions. In one aspect, the onal
immunotherapeutic compositions comprise a second cancer antigen that is a MUCl
antigen or a cancer antigen that is not a MUCl antigen. In one aspect, the additional
immunotherapeutic compositions comprise a yeast vehicle and a second cancer antigen
that does not include MUCl antigen. In one aspect, the additional immunotherapeutic
compositions comprise a second cancer antigen that includes, but is not limited to, mutated
Ras, oembryonic antigen (CEA), Brachyury, EGFR, BCR-Abl, MART-l, MAGE-l,
, GAGE, GP-lOO, MUC—2, PSMA, tyrosinase, TRP-l (gp75), NY-ESO—l, TRP-2,
TAG72, KSA, CA-l25, PSA, HER-Z/neu/c-erb/BZ, hTERT, p73, B-RAF, atous
polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL), Rb-l, Rb—2, androgen
receptor (AR), Smad4, MDRl, Flt-3, BRCA-l, BRCA-2, an3-fl<hr, ews-fli-l, HERV-H,
, TWIST, Mesothelin, and/or NGEP. In one aspect, the second cancer antigen is
selected from the group consisting of: mutated Ras, oembryonic antigen (CEA) and
ury. In one aspect, the additional therapeutic composition is a viral vector
vaccine. In one aspect, the additional therapeutic composition is a dendritic
cell/tumor cell fusion.
Yet another embodiment of the invention relates to a method to prevent or
delay the onset of a xpressing cancer. The method es a step of
administering to an individual any of the yeast-MUCl immunotherapeutic compositions
described herein. In one aspect, cancer has not been detected in the individual. In one
aspect, the individual is at high risk for developing cancer. In one aspect, the individual
has a pre-cancerous lesion. In one aspect, the individual has cancer, but MUCl-
sing cancer cells have not been detected in the cancer.
In any of the methods or uses related to a yeast-MUCl immunotherapy
composition described herein, in one aspect, the cancer is of epithelial cell origin. In one
aspect, the cancer can include, but is not limited to: breast cancer, small intestine cancer,
stomach cancer, pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, ovarian
cancer, testicular cancer, lung cancer, colon cancer, prostate cancer, melanoma, multiple
myelogenous leukemia (MML), chronic lymphocytic leukemia (CLL), acute d
leukemia (AML), Burkitt’s lymphoma, Hodgkin’s lymphoma, cancers of secretory tissues,
and metastatic cancers thereof. In one aspect, the cancer is selected from breast cancer
and colon cancer. In one aspect, the cancer is selected from breast cancer, colon cancer,
pancreas cancer, ovarian cancer, geal cancer, and AML. In one aspect, the cancer
is AML, and the yeast-MUCl immunotherapeutic composition is administered to both
donor and recipient of bone marrow transplantation (BMT) therapy. In one , the
cancer is AML, and the yeast—MUCl immunotherapeutic composition is stered to
the individual in conjunction with cytarabine and anthracycline therapy.
In any of the embodiments of the invention described above or elsewhere
herein, in one aspect, the yeast e is a whole yeast. In one , the yeast vehicle is
heat-inactivated. In one aspect, the yeast vehicle is from a mutant yeast strain that
produces underglycosylated proteins, as compared to a wild-type yeast strain. In one
aspect, the MUC1 n is expressed on the cell wall of the yeast vehicle. In one aspect,
the MUC1 antigen is expressed in the periplasm or cytoplasm of the yeast e. In one
aspect, the yeast vehicle is from Saccharomyces . In one aspect, the yeast e is from
Saccharomyces siae.
In any of the ments of the invention described above or elsewhere
herein, in one , the immunotherapeutic ition has been produced by culturing
a whole yeast expressing the MUC1 antigen in a medium that was maintained at a pH
level of between 5.5 and 8. In one aspect, the medium was buffered with a buffering agent.
In one aspect, the yeast was cultured in a medium that was maintained at a pH level of
between 6 and 8.
In any of the embodiments of the ion described above or elsewhere
herein, in one aspect, the composition further comprises at least one biological response
modifier.
In any of the embodiments of the invention described above or elsewhere
herein, in one aspect, the composition further comprises a pharmaceutically acceptable
excipient.
In any of the embodiments of the invention described above or elsewhere
herein, in one aspect, the ition has been formulated for ion.
[0034A] Another embodiment of the invention relates to a Yeast-MUC1
immunotherapeutic composition, wherein the immunotherapeutic composition comprises:
a) a yeast vehicle; and
b) at least one MUC1 agonist antigen expressed by the yeast vehicle, wherein
the MUC1 agonist antigen comprises an amino acid sequence that is at least 95% identical
to SEQ ID NO:25 or to positions 92-566 of SEQ ID NO:25, and wherein the MUC1
agonist antigen comprises at least one of the following amino acid substitutions: T184L,
A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
[0034B] Another embodiment of the invention relates to a Yeast-MUC1
immunotherapeutic composition, n the immunotherapeutic ition comprises:
a) a yeast vehicle; and
b) a MUC1 agonist antigen expressed by the yeast vehicle, wherein the MUC1
agonist antigen comprises an amino acid sequence that is at least 98% identical to SEQ ID
NO:25 or to positions 92-566 of SEQ ID NO:25.
[0034C] Another embodiment of the invention relates to a Yeast-MUC1
immunotherapeutic ition, wherein the therapeutic composition comprises:
a) a yeast vehicle; and
b) a MUC1 agonist antigen expressed by the yeast vehicle, wherein the MUC1
agonist antigen comprises an amino acid ce that is at least 99% identical to SEQ ID
NO:25 or to positions 92-566 of SEQ ID NO:25.
[0034D] Another embodiment of the invention relates to a Yeast-MUC1
immunotherapeutic composition, wherein the immunotherapeutic composition
comprises:
a) a yeast; and
b) a MUC1 agonist antigen that has been expressed by the yeast, wherein
the MUC1 agonist antigen comprises an amino acid sequence that differs from an
amino acid sequence of a wild-type MUC1 protein having Accession No.
NP_001191214 by an amino acid substitution at 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 of the
following amino acid ons of the wild-type MUC1 amino acid sequence: T93,
A161, P162, G169, S170, T171, A392, C406, T444, D445, and S460.
[0034E] r embodiment of the invention s to a use of the Yeast-MUC1
immunotherapeutic composition according to the present disclosure in the preparation of a
medicament to treat a disease.
[0034F] Another ment of the invention relates to a use of an immunotherapeutic
ition according to the present disclosure in the preparation of a medicament to
prevent or delay the onset of a MUC1-expressing cancer.
BRIEF PTION OF THE DRAWINGS
Fig. 1A is a schematic drawing showing the structure of full-length MUC1
protein.
Fig. 1B is a schematic drawing g the structure of the fusion protein
expressed in the yeast-based immunotherapeutic ition known as 1.
Fig. 1C is a schematic drawing showing the structure of the fusion protein
expressed in the yeast-based immunotherapeutic composition known as GI-6104.
Fig. 2A is a digitized image showing expression of MUC1 fusion protein by
GI-6101.
Fig. 2B is a digitized image showing expression of MUC1 fusion proteins
from GI-6101 and 6104 before and after deglycosylation.
[0040] Fig. 2C is a digitized image showing expression of MUC1 fusion protein by
GI-6104.
Fig. 3 is a digitized image showing sion of MUC1 fusion n by GI-
6105.
DETAILED DESCRIPTION OF THE INVENTION
[0041A] Throughout this specification the word "comprise", or ions such as
ises" or ising", will be understood to imply the inclusion of a stated
element, integer or step, or group of elements, integers or steps, but not the exclusion of
any other element, integer or step, or group of elements, integers or steps.
[0041B] Any discussion of documents, acts, materials, devices, articles or the like
which has been included in the present specification is not to be taken as an admission that
any or all of these s form part of the prior art base or were common general
knowledge in the field relevant to the present disclosure as it existed before the ty
date of each claim of this application.
This invention generally relates to yeast-based immunotherapeutic
compositions and methods for the prevention and/or treatment of cancers that express or
overexpress mucin-1 (which may generally be referred to herein as “MUC1”, and which is
also known or has been known as “DF3 antigen” or “HMFG”). The invention includes the
use of a yeast-based immunotherapeutic composition (also referred to as yeast-based
therapy composition or product) comprising a yeast e and novel MUC1
antigens (also referred to herein as “yeast-MUC1 immunotherapy composition”, “yeast-
MUC1 immunotherapy product” or “yeast-MUC1 immunotherapeutic compositions”).
The inventors describe herein the construction and production of novel yeast-MUC1
therapy products, and demonstrate that yeast-MUC1 immunotherapy matures
human tic cells (DCs), increases cytokine production from DCs that is associated
with immune responses expected to be beneficial in the ent of tumors, and elicits the
activation of MUC1-specific T cell lines. Taken together, the data presented herein show
that yeast-MUC1 therapy is useful for the elicitation of MUC1-specific cellular
immune responses (CD4+ and CD8+) and that yeast-MUC1 therapy is expected to
be useful for the prevention and treatment of MUC1-expressing tumors.
Yeast-MUC1 immunotherapy is readily adaptable to the use of additional
tumor antigens within the same yeast composition, or to use in combination with other
yeast-based immunotherapeutics that target other tumor antigens (sequentially or
concurrently) or other immunotherapeutics and treatments/therapies for cancer.
Accordingly, the Yeast-MUC1 immunotherapy can be adapted to the cancer type, the
cancer stage, the cancer grade, the antigens expressed by the tumor, and the l
medical status of the individual (i.e., the therapy is easily personalized), and for the
dual who already has cancer, its use can be modified as cancer progresses in an
individual, in order to provide maximum efficacy at a variety of tumor stages. Yeast-
MUC1 immunotherapy offers the opportunity for the broad-based prophylactic and/or
therapeutic treatment of a wide range of cancers.
, yeast-MUC1 immunotherapy can be used in a flexible manner to treat
various ositive cancers by tailoring the yeast-MUC1 immunotherapy to the
particular role this antigen plays in each type of cancer indication. For example, since
MUCl has been bed as an early marker in cancers such as breast cancer or colon
cancer, yeast-based immunotherapy may be used prophylactically in patients with MUCl
positive premalignant breast hyperplasia or colonic polyps. As another example, since
MUCl has been associated with epithelial-mesenchymal transition (EMT) pathways and
metastatic spread in cancers such as pancreas , ovarian cancer, and esophageal
cancer, yeast-MUCl immunotherapy can be used as a therapeutic add-on to standard of
care therapy in these cancers to promote the arrest of atic spread in MUCl—positive
stage 3 pancreas, ovarian, and esophageal cancers. As yet another example, since MUCl
has been shown to prevent terminal differentiation by reactive oxygen species in acute
myeloid ia (AML), thereby allowing ted self renewal of these cancer cells,
yeast-MUCl immunotherapy can be used as an add-on to standard therapy in MUCl—
positive AML to promote apoptosis and prevent the ted self renewal of the
malignant cells. A clinical trial using yeast-MUCl immunotherapy in AML patients is
described in the examples.
[0045] Yeast-MUCl compositions described herein induce innate immune responses,
as well as adaptive immune responses against the target n (MUCl), including CD4—
dependent THl7 and THl T cell responses and antigen-specific CD8+ T cell responses,
which include cytotoxic T lymphocyte (CTL) responses, all without the use of exogenous
adjuvants, cytokines, or other immunostimulatory molecules, many of which have to
toxicity issues. In addition, Yeast-MUCl immunotherapeutic compositions t
regulatory T cell (Treg) numbers and/or onality, thereby ing effector T cell
responses that might normally be suppressed by the presence of the tumor, for example.
Moreover, as compared to immunotherapeutic compositions that ze by generating
antibody responses, the n-specific, broad-based, and potent cellular immune
responses elicited by Yeast-MUCl immunotherapy are believed to be particularly
effective in targeting tumor cells. Indeed, numerous studies have shown that
immunotherapeutic approaches are enhanced when tumor cells are targeted via CD8+
CTLs which recognize tumor es in the context of MHC Class I les. Yeast-
MUCl immunotherapy is highly adept at activating antigen presenting cells, and has a
unique ability to prime the immune response, generating CD8+ CTL responses that
are typically effective against tumors, even in the face of what may otherwise be a
suppressive environment. Since this type of immunotherapy utilizes the natural ability of
the antigen presenting cell to present nt immunogens, it is not necessary to know the
precise identity of CTL epitopes or MHC Class II epitopes of MUCl to produce an
effective immunotherapeutic according to the t invention. In fact, multiple CD4+
and CD8+ T cell epitopes can be targeted in a single Yeast-MUCl therapeutic
composition, and so the Yeast-MUCl immunotherapeutics of the invention are not d
to the use of short peptides. Indeed, the use of longer polypeptides and fusion proteins
containing multiple domains of the target antigen in these compositions is efficacious.
Accordingly, by using MUCl immunotherapy, the use of algorithms and complex
as to identify ve T cell epitopes is ated.
Yeast-MUCl can be effectively utilized in an zation protocol
(prophylactic or therapeutic) without the use of exogenous adjuvants, immunostimulatory
agents or molecules, costimulatory molecules, or cytokines, gh such agents may be
included, if desired. Moreover, Yeast-MUCl immunotherapy can be administered
repeatedly without losing efficacy, as may be problematic with other types of
immunotherapy.
Camgositions 01 the Invention
[0047] One embodiment of the present invention relates to a yeast-based
therapy composition which can be used to prevent and/or treat cancers
characterized by MUCl expression or overexpression (including cancers that may not
contain cells expressing detectable MUCl initially, but which may or will contain cells
expressing MUCl at later stages of the development of the cancer). The composition is a
Yeast—MUCl immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a
cancer antigen comprising one or more MUCl antigen(s) and/or immunogenic domain(s)
thereof. The MUCl antigen or immunogenic domain thereof is most typically expressed
as a recombinant protein by the yeast vehicle (e.g., by an intact yeast or yeast spheroplast,
which can optionally be further processed to a yeast cytoplast, yeast ghost, or yeast
membrane extract or fraction thereof), although it is an embodiment of the invention that
one or more MUCl antigens are loaded into a yeast vehicle or otherwise complexed with,
attached to, mixed with or administered with a yeast vehicle as described herein to form a
composition of the present invention.
A “Yeast-MUG] immunotherapeutic composition” is a specific type of —
based immunotherapeutic composition” that contains at least one MUCl antigen or
genic domain f The phrase, “yeast-based immunotherapeutic composition”
may be used interchangeably with “yeast-based immunotherapy product”, “yeast-based
immunotherapy composition”, “yeast—based composition”, “yeast-based
immunotherapeutic”, “yeast-based vaccine”, or derivatives of these phrases. An
“immunotherapeutic composition” is a composition that s an immune response
sufficient to achieve at least one therapeutic benefit in a t. As used herein, yeast—
based therapeutic composition refers to a composition that includes a yeast vehicle
component and that elicits an immune response sufficient to achieve at least one
therapeutic benefit in a subject. More particularly, a yeast—based immunotherapeutic
composition is a composition that es a yeast vehicle component and typically, an
antigen component, and can elicit or induce an immune response, such as a cellular
immune response, including without tion a T cell-mediated cellular immune
response. In one aspect, a yeast-based immunotherapeutic composition useful in the
invention is capable of inducing a CD8+ and/or a CD4+ T cell-mediated immune response
and in one aspect, a CD8+ and a CD4+ T cell-mediated immune response, particularly
against a target antigen (e.g., a cancer antigen). A CD4+ immune response can include
THl immune responses, TH2 immune responses, TH17 immune responses, or any
combination of the above. Yeast-based immunotherapeutics are particularly capable of
generating THl and TH17 responses. A CD8+ immune response can include a cytotoxic T
cyte (CTL) response, and yeast-based immunotherapeutics are capable of
generating such responses. In one aspect, a yeast-based immunotherapeutic composition
tes the number and/or functionality of regulatory T cells (Tregs) in a subject.
based immunotherapy can also be modified to promote one type of response over
another, e.g., by the addition of cytokines, antibodies, and/or modulating the
manufacturing process for the yeast. Optionally, a yeast-based immunotherapeutic
composition is capable of eliciting a humoral immune response.
Yeast-MUCl immunotherapeutic compositions of the invention may be either
"prophylactic" or "therapeutic". When provided prophylactically, the compositions of the
present invention are provided in advance of the development of, or the detection of the
development of, a cancer that expresses MUCl, with the goal of preventing, inhibiting or
delaying the pment of xpressing tumors; and/or preventing, inhibiting or
ng ases of such tumors and/or generally preventing or inhibiting progression
of cancer in an individual. As discussed herein, MUCl is expressed in several cancers.
Therefore, prophylactic compositions can be administered to individuals that appear to be
cancer-free (healthy, or normal, duals), to individuals with pre-cancerous (pre—
malignant lesions), and also to duals who have cancer, but in which MUCl has not
yet been detected (1'. e. prior to the expression of MUCl by tumor cells in the ).
Individuals who are at high risk for developing a cancer, particularly a cancer with which
MUCl expression and/or metastases are typically associated, may be treated
lactically with a composition of the invention. When provided therapeutically, the
immunotherapy compositions are provided to an individual with a MUCl-expressing
cancer, with the goal of ameliorating the cancer, such as by reducing tumor burden in the
individual; inhibiting tumor growth in the individual; increasing al of the individual;
and/or ting, ting, reversing or delaying progression of the cancer in the
dual.
Typically, a Yeast-MUCl immunotherapy composition includes a yeast
vehicle and at least one cancer antigen comprising a MUCl antigen or immunogenic
domain thereof, where the cancer n is expressed by, attached to, loaded into, or
mixed with the yeast vehicle. In some embodiments, the cancer antigen, MUCl antigen,
or genic domain thereof is provided as a fusion n. Several MUCl proteins
and fusion proteins suitable for use in the compositions and methods of the invention are
described below. In some embodiments, the cancer antigen and the MUCl antigen are the
same element. In some embodiments, the cancer antigen includes other antigens,
including other cancer antigens, in addition to the MUCl antigen. In one aspect of the
invention, a filSlOIl protein useful as a cancer antigen can include two or more antigens,
e.g, a MUCl antigen and another cancer antigen that is not a MUCl antigen, or two
different MUCl antigens. In one aspect, the fusion protein can e two or more
immunogenic domains of one or more antigens, such as two or more immunogenic
domains of a MUC] antigen, or two or more epitopes of one or more antigens, such as two
or more epitopes of a MUCl antigen.
According to the present invention, a yeast vehicle used in a Yeast-MUCl
immunotherapy composition is any yeast cell (e.g, a whole or intact cell) or a tive
thereof (see below) that can be used in conjunction with one or more antigens,
immunogenic domains thereof or epitopes thereof in a composition of the invention (e.g.,
a therapeutic or prophylactic composition). The yeast vehicle can therefore include, but is
not limited to, a live intact (whole) yeast microorganism (i.e., a yeast cell having all its
ents including a cell wall), a killed (dead) or inactivated intact yeast
microorganism, or derivatives of intact yeast including: a yeast plast (i.e., a yeast
cell lacking a cell wall), a yeast cytoplast (i.e., a yeast cell lacking a cell wall and s),
a yeast ghost (z'.e., a yeast cell lacking a cell wall, nucleus and cytoplasm), a subcellular
yeast membrane t or fraction thereof (also referred to as a yeast membrane particle
and previously as a subcellular yeast particle), any other yeast particle, or a yeast cell wall
preparation.
Yeast spheroplasts are typically produced by enzymatic digestion of the yeast
cell wall. Such a method is described, for example, in Franzusoff et al., 1991, Meth.
Enzymol. 194, 662—674., orated herein by reference in its entirety.
Yeast cytoplasts are typically produced by enucleation of yeast cells. Such a
method is described, for example, in Coon, 1978, Natl. Cancer Inst. Monogr. 48, 45-55
orated herein by reference in its entirety.
Yeast ghosts are typically produced by ing a permeabilized or lysed cell
and can, but need not, contain at least some of the organelles of that cell. Such a method
is described, for example, in Franzusoff et al., 1983, J. Biol. Chem. 258, 3608-3614 and
Bussey et al., 1979, Biochim. Biophys. Acta 553, 185—196, each of which is incorporated
herein by reference in its entirety.
A yeast membrane particle (subcellular yeast membrane t or fraction
thereof) refers to a yeast membrane that lacks a l nucleus or cytoplasm. The particle
can be of any size, including sizes ranging from the size of a natural yeast membrane to
microparticles produced by sonication or other ne disruption methods known to
those skilled in the art, followed by resealing. A method for ing subcellular yeast
membrane extracts is described, for example, in Franzusoff et al., 1991, Meth. Enzymol.
194, 662-674. One may also use fractions of yeast membrane particles that contain yeast
ne portions and, when the n or other n was expressed recombinantly
by the yeast prior to preparation of the yeast membrane particles, the antigen or other
protein of interest. Antigens or other proteins of interest can be carried inside the
membrane, on either surface of the membrane, or combinations thereof (i.e., the protein
can be both inside and outside the membrane and/or spanning the membrane of the yeast
membrane particle). In one embodiment, a yeast membrane le is a recombinant
yeast membrane particle that can be an intact, disrupted, or disrupted and resealed yeast
membrane that includes at least one desired antigen or other protein of interest on the
surface of the membrane or at least partially embedded within the membrane.
[0056] An example of a yeast cell wall ation is a preparation of isolated yeast
cell walls carrying an antigen on its e or at least partially embedded within the cell
wall such that the yeast cell wall preparation, when stered to an animal, stimulates a
desired immune response against a disease target.
Any yeast strain can be used to produce a yeast vehicle of the present
invention. Yeast are unicellular microorganisms that belong to one of three classes:
Ascomycetes, Basidiomycetes and Fungi Imperfecti. One consideration for the selection
of a type of yeast for use as an immune modulator is the pathogenicity of the yeast. In one
embodiment, the yeast is a non-pathogenic strain such as Saccharomyces cerevisiae. The
selection of a non-pathogenic yeast strain minimizes any adverse effects to the individual
to whom the yeast e is administered. However, pathogenic yeast may be used if the
pathogenicity of the yeast can be negated by any means known to one of skill in the art
(e.g., mutant strains). In accordance with one aspect of the present invention, non—
enic yeast strains are used.
Genera of yeast strains that may be used in the invention e but are not
limited to Saccharomyces, Candida (which can be pathogenic), Cryptococcus, Hansenula,
Kluyveromyces, Pichia, Rhodotorula, Schizosaccharomyces and Yarrowia. In one ,
yeast genera are selected from Saccharomyces, a, Hansenula, Pichia or
Schizosaccharomyces, and in one aspect, romyces is used. Species of yeast s
that may be used in the invention e but are not limited to Saccharomyces cerevisiae,
Saccharomyces carlsbergensis, Candida ns, Candida kefyr, Candida tropicalis,
Cryptococcus laurentii, coccus neoformans, Hansenula a, Hansenula
polymorpha, Kluyveromycesfragilis, Kluyveromyces lactis, Kluyveromyces nus var.
lactis, Pichia pastoris, Rhodotorula rubra, Schizosaccharomyces pombe, and Yarrowia
lipolytica. It is to be appreciated that a number of these species e a variety of
subspecies, types, subtypes, etc. that are intended to be included within the
aforementioned species. In one , yeast species used in the invention include S.
cerevisiae, C. albicans, H. polymorpha, P. pastoris and S. pombe. S. cerevisiae is useful
as it is relatively easy to manipulate and being "Generally Recognized As Safe" or
"GRAS" for use as food additives (GRAS, FDA proposed Rule 62FR18938, April 17,
1997). One embodiment of the present invention is a yeast strain that is capable of
replicating ds to a particularly high copy number, such as a S. cerevisiae cir° strain.
The S. cerevisiae strain is one such strain that is capable of supporting expression vectors
that allow one or more target antigen(s) and/or antigen fusion protein(s) and/or other
proteins to be expressed at high levels. Another yeast strain is useful in the invention is
Saccharomyces cerevisiae W303 or. In addition, any mutant yeast strains can be used in the
present invention, including those that exhibit reduced post-translational modifications of
expressed target antigens or other proteins, such as mutations in the enzymes that extend
N-linked ylation. In one aspect of the invention, a yeast-MUCl therapy
composition is produced using a mutant yeast strain that es the MUCl n as an
underglycosylated protein as compared to the same antigen produced by the wild-type
strain (with normal glycosylation). Such a MUCl antigen may be more similar to MUl
antigens expressed by tumor cells, which can then be processed into unique T cell epitopes
by antigen presenting cells, thus enhancing the specific anti-tumor se.
The Yeast-MUCl immunotherapy composition of the invention includes at
least one cancer antigen comprising a MUCl antigen. According to the present invention,
the general use herein of the term "antigen" refers: to any portion of a protein (e.g.,
peptide, partial protein, full-length protein), wherein the protein is naturally occurring or
synthetically derived or designed, to a cellular composition (whole cell, cell lysate or
disrupted cells), to an organism (whole organism, lysate or disrupted cells) or to a
carbohydrate, or other molecule, or a portion thereof. An n may elicit an antigen—
specific immune response (e.g., a humoral and/or a cell-mediated immune response)
against the same or similar antigens that are encountered in vitro, in vivo, or ex vivo by an
element of the immune system (e.g., T cells, antibodies).
An n can be as small as a single epitope, a single immunogenic domain
or larger, and can include multiple epitopes or immunogenic domains. As such, the size of
an antigen can be as small as about 8-11 amino acids (z‘.e., a peptide) and as large as: a
domain of a protein, a ength protein, a multimer, a fusion protein, a chimeric protein,
a whole cell, a whole microorganism, or any portions thereof (e.g., n fragments
eptides) lysates of whole cells or extracts of microorganisms). Antigens useful in
the Yeast-MUCl immunotherapeutic of the present invention are peptides, polypeptides,
protein domain(s), protein subunits, fiill-length proteins, multimers, fusion proteins and
chimeric proteins. In addition, antigens can include carbohydrates, which can be loaded
into a yeast vehicle or into a composition of the invention. It will be appreciated that in
some embodiments (e.g., when the antigen is expressed by the yeast vehicle from a
recombinant nucleic acid molecule), the antigen is a n (including fragments, domains,
subunits, and full-length proteins), fusion protein, chimeric protein, or fragment thereof,
rather than an entire cell or rganism. For expression in yeast, in one embodiment,
an antigen is of a minimum size capable of being expressed recombinantly in yeast if the
antigen is the entire protein to be expressed by the yeast (in other words, the protein that is
expressed by the yeast, which may include or consist of the antigen, is preferably at least
amino acids in ), and is lly at least or r than 25 amino acids in length,
or at least or greater than 26 amino acids, at least or greater than 27 amino acids, at least or
greater than 28 amino acids, at least or greater than 29 amino acids, at least or greater than
amino acids, at least or greater than 31 amino acids, at least or greater than 32 amino
acids, at least or greater than 33 amino acids, at least or greater than 34 amino acids, at
least or greater than 35 amino acids, at least or greater than 36 amino acids, at least or
greater than 37 amino acids, at least or greater than 38 amino acids, at least or greater than
39 amino acids, at least or greater than 40 amino acids, at least or greater than 41 amino
acids, at least or greater than 42 amino acids, at least or greater than 43 amino acids, at
least or greater than 44 amino acids, at least or greater than 45 amino acids, at least or
greater than 46 amino acids, at least or greater than 47 amino acids, at least or greater than
48 amino acids, at least or greater than 49 amino acids, or at least or greater than 50 amino
acids in length, or at least 25-50 amino acids in length, at least 30-50 amino acids in ,
or at least 35-50 amino acids in length, or at least 40-50 amino acids in length, or at least
45-50 amino acids in length, although smaller proteins may be expressed, and
considerably larger proteins (e.g, hundreds of amino acids in length or even a few
thousand amino acids in length) may be expressed. In one aspect, a full-length protein or
domain of a protein that is lacking between 1 and 20 amino acids from the N— and/or the
C—terminus may be expressed. Fusion ns and ic proteins are also antigens that
may be expressed in the invention. A “target antigen” is an antigen that is specifically
targeted by an immunotherapeutic composition of the invention (i.e., an antigen, usually
the native antigen, against which elicitation of an immune response is desired). A “cancer
antigen” is an n that comprises at least one antigen that is associated with a cancer
such as an antigen expressed by a tumor cell, so that ing the antigen also targets the
tumor cell and/or cancer. A cancer antigen can include one or more antigens from one or
more proteins, including one or more tumor-associated proteins. A “MUCl antigen” is an
antigen derived, designed, or produced from a MUCl protein (including MUCl-N,
MUCl-C or both MUCl-N and ).
When referring to stimulation of an immune se, the term “immunogen”
is a subset of the term “antigen”, and ore, in some instances, can be used
interchangeably with the term "antigen". An immunogen, as used , bes an
antigen which elicits a humoral and/or cell-mediated immune response (i.e., is
immunogenic), such that administration of the immunogen to an individual mounts an
antigen-specific immune response against the same or r ns that are
encountered by the immune system of the individual. In one embodiment, the immunogen
elicits a cell-mediated immune response, including a CD4+ T cell response (e.g., THl,
TH2 and/or TH17) and/or a CD8+ T cell response (e.g., a CTL response).
An “immunogenic domain” or “immunological domain” of a given n
can be any portion, fragment or epitope of an antigen (e.g., a e fragment or subunit
or an antibody epitope or other conformational epitope) that contains at least one epitope
that can act as an immunogen when administered to an . ore, an
immunogenic domain is larger than a single amino acid and is at least of a size sufficient
to contain at least one epitope that can act as an immunogen. For example, a single
protein can contain multiple different immunogenic domains. Immunogenic domains need
not be linear ces within a protein, such as in the case of a humoral immune response,
where conformational domains are contemplated.
An epitope is defined herein as a single immunogenic site within a given
antigen that is sufficient to elicit an immune response when ed to the immune
system in the context of appropriate costimulatory signals and/or activated cells of the
immune . In other words, an epitope is the part of an antigen that is recognized by
components of the immune system, and may also be referred to as an antigenic
determinant. Those of skill in the art will recognize that T cell epitopes are ent in
size and composition from B cell or antibody epitopes, and that epitopes presented h
the Class I MHC pathway differ in size and ural attributes from epitopes presented
through the Class II MHC pathway. For example, T cell epitopes presented by Class I
MHC molecules are typically between 8 and 11 amino acids in length, whereas es
presented by Class II MHC molecules are less restricted in length and may be up to 25
amino acids or longer. In addition, T cell epitopes have predicted structural teristics
depending on the specific MHC molecules bound by the epitope. Epitopes can be linear
sequence epitopes or conformational epitopes (conserved binding regions). Most
antibodies recognize conformational epitopes.
MUCl (which may also be referred to as -l” and also “DF3 antigen” or
“HMFGl”) is a large glycoprotein expressed by most epithelial secretory tissues at basal
levels and is expressed at high levels by malignancies of epithelial cell origin. MUCl is
most typically found as a polymorphic, type I transmembrane protein with a large
extracellular domain (also referred to as MUCl-N subunit) that includes variable numbers
of tandem repeats (VNTR; typically between 20 and 125 repeats) that are highly
glycosylated through O-linkages. The MUCl protein is encoded as a single transcript, and
then sed into subunits ranslationally, known as MUCl-N and MUCl—C, or or
and [3 subunits, respectively, which then form a heterodimeric protein by a strong
noncovalent interaction of the two subunits. MUCl is cleaved into its N- and C-subunits
within the “sea urchin sperm protein, enterokinase and agrin” (SEA) domain, a highly
conserved protein domain that was named based on its initial identification in a sperm
protein, in enterokinase, and in agrin, and that is found in a number of y
glycosylated mucin-like proteins that are typically membrane-tethered. The MUCl
protein is cleaved between e and serine residues present in the sequence GSVVV
(e.g., positions 1097-1101 of SEQ ID NO:ll) within the SEA domain (Lillehoj et al.,
2003, Biochem. Biophys. Res. Commun. 307:743—749; Parry et al., 2001, Biochem.
Biophys. Res. Commun. 283:715—720; Wreschner et al., 2002, Protein Sci. 112698—706).
The MUCl-C subunit includes the extracellular domain (ED), which is
glycosylated and binds the in—3 ligand, which in turn serves as a bridge to physically
associate MUCl with the epidermal growth factor receptor (EGFR) and possibly other
receptor tyrosine s. MUCl-C also comprises a transmembrane (TM) domain, and a
cytoplasmic domain (CD) which contains several tyrosine residues which, when
orylated, could act as binding motifs for proteins with SH2 domains (for a detailed
discussion of the MUCl n and known and putative functions, see Kufe, 2008,
Cancer Biol. & Ther. 7:81—84). Alternative splice variants of MUCl (known as MUCl/Y
and MUCl/X, for e) are “short” ns of MUCl that lack most of MUCl-N,
including the large VNTR , but that e the ED, TM and CD regions, as well as
the SEA domain and portions of the N—terminal region signal sequence region. Cleavage
within the SEA domain may not occur in these short versions.
The isolation and sequencing of DNA and cDNA encoding human MUCl has
been reported (see, e.g., Siddiqui et al., 1998, PNAS 85:2320-2323; Abe and Kufe, 1993,
PNAS 90:282-286; Hareuveni et al., 1990, Eur..]. Biochem. 189(3) 475-486; Gendler et al.,
1990, J. Biol. Chem. 265 (25) 15286-15293; Lan et al., 1990, J. Biol. Chem 265(25)
15294-15299; Tsarfaty et al., 1990, Gene 93(2) 8; Lancaster, 1990, Biochem.
s. Res. Commun. 173(3) 1019-1029). An example of a full-length human MUCl
precursor protein containing both the MUCl-N and MUCl-C regions is described in
SwissProt Accession No. P159413 (GI:296439295), and is represented here by SEQ ID
NO:11. 10 different MUCl isoforms can be created from the gene encoding SEQ ID
NO:11 by alternative transcript splicing. For example, an isoform known as MUCl/Y
lacks positions 54-1053 of SEQ ID NO:11. s other ms are described in the
database description of this protein.
For purposes of illustration of the fication of domains within the MUCl
protein, which can be applied to any human MUCl protein as well as other mammalian
MUCl proteins, the following domains can be readily identified in SEQ ID NO:ll. The
MUCl signal ce, also referred to herein as the leader sequence, is located at about
positions 1-23 of SEQ ID NO:ll (the MUCl signal ce is identified as longer in
some MUCl variants, and may include additional amino acids, such as positions 1-32).
The MUCl-N subunit or or subunit comprises approximately positions 24—1097 of SEQ ID
NO:ll, and the MUCl-C subunit or [3 subunit comprises approximately positions 1098-
1255 of SEQ ID NO:ll.
[0068] Within the MUCl-N subunit, the VNTR (variable numbers of tandem repeats)
domain can be found, comprising multiple repeats in this particular n, including
approximately the region from position 126-965, which contains forty—two 20-amino acid
repeats of the sequence PAPGSTAPPAHGVTSAPDTR (e.g., ons 126-145 of SEQ
ID NO:1 l), which is the commonly recognized VNTR sequence (see also SEQ ID NO:l2
below, which designates common polymorphisms within this sequence). Since these are
repeated sequences, one may begin counting from any one of the 20 amino acids in one
VNTR and then t numbering with the repeat of that first amino acid. More
particularly, since a single VNTR domain is an approximately 20 amino acid sequence
that is preceded by and/or followed by another identical, nearly identical, or homologous
20 amino acid sequence, which may be within a large number of such repeated sequences,
for es of describing a single VNTR within a region of VNTRs, one may consider
“position 1” of a given VNTR to be any one of the 20 amino acids in the VNTR, and then
the prior and subsequent flanking amino acids will be numbered accordingly, with the
amino acid that is upstream of (prior to) position 1 being either the last amino acid
ion 20) of the prior VNTR or the last amino acid of the sequence linked to the VNTR
(if such prior sequence is not also a VNTR), and the amino acid that is downstream of
position 1 being position 2 of that VNTR, followed by on 3, and so on, until the
sequence repeats with the next VNTR.
Positions 61-1120 of SEQ ID NO:ll includes the VNTR region sed
above, plus additional regions denoted as “repetitive regions”. For example, positions 81-
100, positions lOl-l20, positions 121-140, positions 141-160, positions 161-180, positions
181-200, positions 201-220, positions 221-240, positions 241-260, ons 261-180,
positions 281-300, and so on, in 20 amino acid increments through positions 120 of
SEQ ID NO: 1 1, ent repetitive regions in this protein.
In the full—length MUCl protein represented by SEQ ID NO:11 (prior to
cleavage into ts), the SEA domain spans positions 152 of SEQ ID N0:11.
Cleavage of the SEA domain between amino acids 1097 and 1098 of SEQ ID N0:11
produces the MUCl-C domain. Within the MUCl-C domain, the extracellular domain
(ED) is found at about positions 1098—1155 of SEQ ID NO:11; the transmembrane (TM)
domain is found at about positions 1156-1183 of SEQ ID N011; and the cytoplasmic
domain (CD, also called the cytoplasmic tail) is found at about positions 255 of
SEQ ID NO:11.
The number ofVNTR in a given MUCl-N subunit is highly polymorphic, and
can vary, e.g., from 20 to 125 repeats. The tandemly repeated icosapeptide typically has a
polymorphism at one or more of three positions (positions 9, 18 and 19 of SEQ ID
N0212): PAPGSTAP[P/A/Q/T]AHGVTSAP[DT/ES]R (SEQ ID N0212, ted
regions indicate common polymorphisms), where the polymorphism at positions 18 and
19 of SEQ ID N0:12 occur with the preference of DT > ES, and where the single
replacements at position 9 occur with the following preference: P > A, P > Q and P > T.
The most frequent replacement, DT > ES, occurs in up to 50% of the s.
A variety of transcript variants of MUCl are known, but the MUCl subunits,
domains, or s described in the exemplary SEQ ID N0:11 above can readily be
fied in the variants, such that a MUCl antigen useful in the invention can be
designed or produced based on a given MUCl sequence, or a ponding sequence
from another MUCl protein. For example, one nucleotide sequence encoding a human
MUCl n is represented herein by SEQ ID NO:1, which corresponds to GENBANK®
Accession No. NM_002456.4 (GI: 65301116). SEQ ID NO:1 encodes a 273 amino acid
human MUCl protein (transcript variant 1, also known as MUCl/ZD), the amino acid
ce of which is represented here as SEQ ID N022 (also found in GENBANK®
Accession No. NP_002447.4; GI:65301117). Within SEQ ID N0:2, the following
domains are present: signal sequence (positions 1-27 of SEQ ID N022); SEA domain
(positions 55-170 of SEQ ID N0:2); ED (positions 116-173 of SEQ ID N0:2); TM
domain (positions 174-201 of SEQ ID N022); and CD (positions 202—273 of SEQ ID
N02). The proteolytic ge site within the SEA domain that cleaves the ED domain
from the N-terminal portion of the SEA domain is between positions 115 and 116 of SEQ
ID N0:2. This transcript variant does not contain the VNTR region as shown in SEQ ID
N0:11.
Another nucleotide sequence encoding another human MUCl protein is
represented herein by SEQ ID N0:3, which corresponds to GENBANK® Accession No.
NM_001018016.1 (GI:67189006). SEQ ID N013 encodes a 264 amino acid human
MUCI n (transcript variant 2, also known as Y”), the amino acid sequence
of which is represented here as SEQ ID NO:4 (also found in GENBANK® Accession No.
NP_001018016.l; GI:67189007). Within SEQ ID NO:4, the following s are
present: signal ce (positions 1—32 of SEQ ID NO:4); SEA domain (positions 45—
161 of SEQ ID NO:4); ED (107-164 of SEQ ID NO:4); TM domain (positions 165-192 of
SEQ ID NO:4); and CD (positions 193-264 of SEQ ID NO:4). The proteolytic ge
site within the SEA domain that cleaves the ED domain from the N-terminal portion of the
SEA domain is n positions 106 and 107 of SEQ ID NO:4. This transcript variant
does not n the VNTR region as shown in SEQ ID N01] 1.
Another nucleotide sequence encoding another human MUCl protein is
represented herein by SEQ ID N0:5, which corresponds to GENBANK® Accession No.
AY327587.1 (GI:33150003). SEQ ID N0:5 encodes a 264 amino acid human MUCI
protein (transcript variant 2, also known as “MUCl/Y”), the amino acid sequence of
which is represented here as SEQ ID N0:6 (also found in GENBANK® Accession No.
AAP97018.1 (GI: 33150004). Within SEQ ID NO:6, the following domains are present:
signal sequence (positions 1-32 of SEQ ID NO:6); SEA domain (positions 45-161 of SEQ
ID NO:6); ED (positions 107 to 164 of SEQ ID NO:6); TM domain (positions 165-192 of
SEQ ID NO:6); and CD (positions 193 to 264 of SEQ ID NO:6). The lytic cleavage
site within the SEA domain that cleaves the ED domain from the N—terminal portion of the
SEA domain is between positions 106 and 107 of SEQ ID NO:6, This transcript variant
does not contain the VNTR region as shown in SEQ ID N0:ll. SEQ ID N06 is 99%
identical to SEQ ID NO:4, illustrating the high degree of homology among MUCl
ces from different sources.
Another nucleotide sequence encoding another human MUCl protein is
represented herein by SEQ ID NO:7, which corresponds to GENBANK® Accession No.
NM_001018017 (GI:324l20954). SEQ ID N027 encodes a 255 amino acid human MUCl
protein (transcript variant 3), the amino acid sequence of which is ented here as SEQ
ID N0:8 (also found in K® Accession No. NP_001018017.1; 89069).
Within SEQ ID N028, the following domains are present: signal sequence (positions l—27
of SEQ ID N028); SEA domain (positions 36-152 of SEQ ID N0:8); ED (positions 98—
155 of SEQ ID N0:8); TM domain (positions 156-183 of SEQ ID N028); and CD
(positions 184-255 of SEQ ID N018). The lytic cleavage site within the SEA
domain that cleaves the ED domain from the inal portion of the SEA domain is
between positions 97 and 98 of SEQ ID NO:6. This transcript variant does not contain the
VNTR region as shown in SEQ ID NO:11.
Human MUCl has high homology with MUCl from other animal species and
therefore, one can expect to be able to identify the domains within a given MUCl protein
based on comparison of sequences. In addition, one could utilize certain sequences of
MUCl from other animal species, and particularly mammalian species, in the preparation
of a Yeast-MUCl immunotherapeutic composition of the invention, particularly where
these sequences are identical or substantially homologous, and where these sequences
elicit an effective immune se against the target antigen (e.g, native MUCl
expressed by a tumor cell). For example, a murine MUCl protein is represented herein by
the amino acid sequence of SEQ ID NO:9. SEQ ID NO:9 ponds to GENBANK®
Accession No. NM_013605 05292). SEQ ID NO:9 encodes a 631 amino acid
murine MUCl protein, the amino acid sequence of which is represented here as SEQ ID
NO:10 (also found in GENBANK® ion No. NP_038633; GI:7305293). Within
SEQ ID NO:10, the following domains are t: signal sequence ximately
positions 1-20 of SEQ ID NO:10); VNTR (identifiable within ons 21-425 of SEQ ID
NO: 10); SEA domain (positions 426-528 of SEQ ID NO: 10); ED (positions 475-536 of
SEQ ID NO:10); TM domain (positions 531-559 of SEQ ID NO: 10); and CD (positions
560-631 of SEQ ID NO: 10). The proteolytic cleavage site within the SEA domain that
cleaves the ED domain from the N—terminal portion of the SEA domain is between
positions 474 and 475 of SEQ ID NO:10. To illustrate the level of conservation of MUCl
sequences within domains, the murine MUCl SEA domain of SEQ ID NO:10 is 62%
identical and 68% homologous or positive (as defined by BLAST) to the human MUCl
SEA domain of SEQ ID NO:11. The murine MUCl ED of SEQ ID NO:10 is 56%
identical and 73% homologous to the human MUCl ED of SEQ ID NO:11. The murine
MUCl TM domain of SEQ ID NO:10 is 89% identical and 93% homologous to the
human MUCl TM domain of SEQ ID NO:11. The murine MUCl CD of SEQ ID NO:10
is 88% identical and 88% homologous to the human MUCl CD of SEQ ID NO:11.
Human MUCl, including the human MUCl proteins and MUCl antigens
described herein, contains various CD4+ and CD8+ T cell epitopes. Such T cell epitopes
have been described, for example, in US. Patent 6,546,643; US. Patent No. 7,118,738;
US. Patent No. 094; US. Patent No. 7,696,306; and US. Patent Application
Publication No. 063653.
In one embodiment of the invention, a MUCl antigen comprises or consists of
a fusion protein comprising multiple domains of a MUCl protein. In one embodiment, the
MUCl antigen is derived or designed from ns of the MUCl-C subunit. In one
embodiment, the MUCl n is derived or designed from portions of the MUCl-N
subunit. In one embodiment, the MUCl antigen is derived or ed from portions of
both the MUCl-C and the MUCl-N subunits.
In one embodiment of the invention, a fusion protein useful in a yeast-based
immunotherapeutic ition of the invention includes at least two, at least three, at
least four, or at least five of the following MUCl antigens, arranged in any order within
the fusion n, and any of which may be repeated two or more times within the fusion
n (e.g, a combination of two or more CD segments): (1) a MUCl signal sequence;
(2) at least one portion of a MUCl SEA domain and/or at least one portion of the MUCI
extracellular domain (ED) or an immunogenic domain thereof, which may e, in one
aspect, most of or the entire ED in addition to flanking one or more flanking amino acids
from the SEA domain; (3) at least two VNTR domains; (4) at least one MUCl
embrane domain or immunogenic domain f; and (5) at least one MUCl
cytoplasmic domain (CD) or immunogenic domain thereof. Such a fusion protein is not
and does not comprise a full-length MUCl protein (i.e., it does not include a complete
MUCl-N subunit and a complete MUCl—C subunit), and such a fusion protein does not
comprise a full-length MUCl-N subunit. In one aspect, such a fusion protein does not
comprise a full—length MUCl-C subunit. In one aspect, the segments of the fusion protein
(e.g., MUCl proteins or domains, including immunogenic s) are arranged in a
different order than the arrangement of the segments as they would occur in a native or
wild-type MUCl protein.
A MUCl signal sequence (or leader sequence) useful in a fusion protein
described above or elsewhere herein can be a signal sequence from any MUCl protein,
and in one aspect, is from a human MUCl protein. In one aspect of the invention, the
MUCl signal sequence used in a fusion protein of the invention has an amino acid
sequence comprising or consisting of an amino acid sequence selected from: positions 1—
27 of SEQ ID NO:2, positions 1—32 of SEQ ID NO:4, positions 1-32 of SEQ ID N016,
positions 1-27 of SEQ ID N028, positions 1-23 of SEQ ID NO:ll, positions 1-30 of SEQ
ID NO:l4, a corresponding sequence from a different MUCl protein such as another
human MUCl protein, or an amino acid sequence that is at least 95% identical, at least
96% identical, at least 97% identical, at least 98% identical, or at least 99% identical, to
any one of these amino acid sequences. The MUCl signal sequence is, in one aspect of
the invention, placed at the N—terminus of a fusion protein usefiil in the invention. In one
aspect of the invention, a non—MUCl ce is used in place of (instead of) a MUCl
signal ce, such as any of the N—terminal synthetic and yeast—derived peptides
bed below for use with a fusion protein of the ion.
A MUCl sea urchin sperm protein, enterokinase and agrin (SEA) domain
useful in a fusion protein described above or elsewhere herein can be an SEA domain, or a
portion thereof that includes at least one immunogenic domain, from any MUCl protein,
and in one aspect, is from a human MUCl protein. In one aspect of the invention, a
portion of the MUCl SEA domain useful in a fusion protein of the invention comprises at
least amino acid sequence from the extracellular domain (ED) of MUCl, but can exclude
sequence upstream of the ED domain. In one aspect of the invention, the MUCl SEA
domain used in a fiision protein of the invention has an amino acid sequence comprising or
consisting of an amino acid sequence selected from: positions 55—170 or positions 116—
170 of SEQ ID N02 or at least one immunogenic domain thereof, positions 45-161 or
positions 1 of SEQ ID NO:4 or at least one immunogenic domain thereof, ons
45-161 or positions 107-161 of SEQ ID NO:6 or at least one immunogenic domain thereof,
positions 36-152 or positions 98—152 of SEQ ID N028 or at least one immunogenic
domain thereof, positions 1034-1152 or positions 1098-1152 of SEQ ID NO:ll or at least
one immunogenic domain thereof, positions 31-86 of SEQ ID NO:l4 or at least one
immunogenic domain thereof, positions l-56 of SEQ ID NO:lS or at least one
immunogenic domain thereof, a corresponding sequence from a different MUCl protein
such as another human MUCl n, or an amino acid sequence that is at least 95%
identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least
99% cal, to any one of these amino acid sequences.
A MUCl extracellular domain (ED) useful in a fusion protein bed above
or elsewhere herein can be an ED or a portion thereof that includes at least one
immunogenic domain from any MUCl protein, and in one aspect, is from a human MUCl
protein. In one aspect of the invention, the MUCl ED used in a fusion protein of the
invention has an amino acid sequence comprising or consisting of an amino acid ce
selected from: ons 116-173 of SEQ ID N02 or at least one immunogenic domain
thereof, positions 107-164 of SEQ ID NO:4 or at least one immunogenic domain thereof,
positions 107-164 of SEQ ID NO:6 or at least one immunogenic domain f, positions
98-155 of SEQ ID N028 or at least one immunogenic domain thereof, positions 1098-
1155 of SEQ ID NO:ll or at least one immunogenic domain f, positions 32-89 of
SEQ ID NO:14 or at least one immunogenic domain thereof, positions 2-59 of SEQ ID
NO:15 or at least one immunogenic domain thereof, a corresponding sequence from a
different MUC1 protein such as another human MUC1 protein, or an amino acid sequence
that is at least 95% identical, at least 96% identical, at least 97% cal, at least 98%
identical, or at least 99% identical, to any one of these amino acid sequences.
A MUC1 single variable number of tandem repeat (VNTR) domain useful in a
fusion protein described above or elsewhere herein can be a VNTR domain from any
MUC1 protein, and in one aspect, is from a human MUC1 protein. In one aspect of the
invention, the MUC1 VNTR domain used in a fusion protein of the invention has an
amino acid ce comprising or consisting of an amino acid sequence selected from:
positions 126-145 of SEQ ID NO:11, any consecutive 20 amino acids between ons
61 and 1020 of SEQ ID NO:11 or any consecutive 20 amino acids between positions 126
and 965 of SEQ ID NO:11; SEQ ID NO:12 (including any of the polymorphisms within
SEQ ID NO: 12 as described above), any consecutive 20 amino acids between ons 90
and 130 of SEQ ID NO:14, any consecutive 20 amino acids between ons 60 and 100
of SEQ ID NO:15, a ponding VNTR sequence from a different MUC1 n such
as another human MUC1 protein, or an amino acid sequence that is at least 95% cal,
at least 96% identical, at least 97% identical, at least 98% identical, or at least 99%
identical, to any one of these amino acid sequences.
A MUC1 transmembrane (TM) domain useful in a fusion protein described
above or elsewhere herein can be a TM domain or a portion f that includes at least
one immunogenic domain from any MUC1 protein, and in one aspect, is from a human
MUC1 protein. In one aspect of the invention, the MUC1 TM domain used in a fusion
protein of the invention has an amino acid sequence comprising or consisting of an amino
acid sequence selected from: positions 174-201 of SEQ ID NO:2 or at least one
immunogenic domain thereof, positions 165-192 of SEQ ID NO:4 or at least one
immunogenic domain thereof, positions 165-192 of SEQ ID NO:6 or at least one
immunogenic domain thereof, positions 156-183 of SEQ ID NO:8 or at least one
immunogenic domain thereof, positions 1156-1183 of SEQ ID NOzll or at least one
immunogenic domain thereof, positions 131-158 of SEQ ID NO:14 or at least one
immunogenic domain thereof, positions 101-128 of SEQ ID NO:15 or at least one
immunogenic domain thereof, a ponding sequence from a different MUCl protein
such as another human MUCl protein, or an amino acid sequence that is at least 95%
identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least
99% identical, to any one of these amino acid sequences.
A MUCl cytoplasmic domain (CD) useful in a fusion protein described above
or elsewhere herein can be a CD or a portion thereof that includes at least one
immunogenic domain from any MUCl protein, and in one aspect, is from a human MUCl
protein. In one aspect of the invention, the MUCl CD used in a fusion protein of the
invention has an amino acid ce comprising or consisting of an amino acid sequence
selected from: positions 202—273 of SEQ ID N02 or at least one immunogenic domain
f, positions 193-264 of SEQ ID N024 or at least one immunogenic domain thereof,
positions 193-264 of SEQ ID NO:6 or at least one immunogenic domain thereof, ons
184-255 of SEQ ID NO:8 or at least one immunogenic domain thereof, positions 1184—
1255 of SEQ ID NO: 11 or at least one immunogenic domain thereof, positions 159-230 of
SEQ ID NO:14 or at least one immunogenic domain thereof, positions 129-200 of SEQ ID
NO: 15 or at least one immunogenic domain thereof, positions 7-78 or positions 79-150 or
positions 151-222 of SEQ ID NO:l7 or at least one immunogenic domain thereof;
positions 1—72 or positions 73-144 or positions 145-216 of SEQ ID N0218 or an
immunogenic domain thereof, a corresponding sequence from a different MUCl n
such as another human MUCl n, or an amino acid sequence that is at least 95%
identical, at least 96% identical, at least 97% identical, at least 98% cal, or at least
99% identical, to any one of these amino acid sequences.
In one embodiment of the ion, a fusion protein useful in a based
immunotherapeutic composition of the invention includes the following MUCl antigens,
in the following order from N— to C-terminus: (l) a portion of a MUCl SEA domain and
MUCl extracellular domain (ED) that includes most or all of the MUCl ED; (2) at least
two VNTR domains; (3) a MUCl transmembrane domain; and (4) a MUCl cytoplasmic
domain (CD). In one embodiment, the fusion protein includes the following MUCl
antigens, in the following order from N— to C-terminus: (1) a MUCl signal sequence; (2)
a portion of a MUCl SEA domain and MUCl extracellular domain (ED) that includes
most or all of the MUCl ED; (3) at least two VNTR domains; (4) a MUCl transmembrane
domain; and (5) a MUCl asmic domain (CD). onal or alternate elements to
be included in a fusion protein of the invention may include N—terminal and/or C-terminal
peptides that improve or assist with the sion or stability of, and/or allow for
identification and/or ation of, the fusion protein, and/or short intervening linker
sequences (e.g., l, 2, 3, 4, or 5 amino acid peptides) between segments of the fusion
protein which can be useful for the introduction of restriction enzyme sites to facilitate
cloning, as cleavage sites for host phagosomal proteases, to accelerate protein or antigen
processing, and for future manipulation of the constructs. Such elements are described in
detail below.
One e of such a fusion protein that is useful in a yeast—based
immunotherapeutic composition of the invention comprises or includes the following
MUCl antigens, in the following order from N— to C-terminus:
(1) a MUCl extracellular domain (ED) that may be appended at the inus
by one, two, three, four, five or more flanking amino acids from the non-ED portion
of the SEA domain that reside upstream of the ED in the wild-type protein, wherein
the ED segment comprises or consists of an amino acid sequence selected from:
positions 116-173 of SEQ ID N02; or positions 107-164 of SEQ ID NO:4;
ons 107-164 of SEQ ID N026; positions 98-155 of SEQ ID N028; positions
1098-1155 of SEQ ID NO:1 1; positions 32-89 of SEQ ID NO:l4; positions 2-59 of
SEQ ID NO:15; a corresponding sequence from a different MUC] protein such as
another human MUCl n; or an amino acid sequence that is at least 95%
identical, at least 96% cal, at least 97% identical, at least 98% identical, or at
least 99% identical, to any one of these amino acid sequences;
(2) at least two VNTR domains, wherein each of the VNTR domains comprise
or consist of an amino acid sequence selected from: ons 126-145 of SEQ ID
NO:11, any consecutive 20 amino acids n positions 61 and 1020 of SEQ ID
NO: 11 or any consecutive 20 amino acids between positions 126 and 965 of SEQ ID
NO:1 l; SEQ ID NO:l2 (including any of the polymorphisms within SEQ ID NO:l2
as described above), any consecutive 20 amino acids between positions 90 and 130
of SEQ ID NO:14, any consecutive 20 amino acids between positions 60 and 100 of
SEQ ID NO:15, a corresponding VNTR ce from a different MUCl protein
such as another human MUCl protein, or an amino acid sequence that is at least
95% identical, at least 96% identical, at least 97% identical, at least 98% identical,
or at least 99% identical, to any one of these amino acid sequences;
(3) a MUCl transmembrane (TM) domain, wherein the TM domain comprises
or ts of an amino acid sequence ed from: positions 174-201 of SEQ ID
N02 165-192 of SEQ ID NO:4, ons 165-192 of SEQ ID NO:6,
, positions
positions 156-183 of SEQ ID NO:8, positions 1156-1183 of SEQ ID NO:11,
ons 131—158 of SEQ ID NO:14, ons 101-128 of SEQ ID NO:15, a
corresponding sequence from a different MUCl protein such as another human
MUCl protein, or an amino acid sequence that is at least 95% identical, at least 96%
identical, at least 97% identical, at least 98% identical, or at least 99% identical, to
any one of these amino acid sequences; and
(4) a MUCl cytoplasmic domain (CD), wherein the CD comprises or consists
of an amino acid sequence selected from: positions 202—273 of SEQ ID NO:2,
positions 193-264 of SEQ ID NO:4, positions 193-264 of SEQ ID N026, positions
184-255 of SEQ ID NO:8, positions 1184-1255 of SEQ ID NO:11, positions 159-
230 of SEQ ID NO:14, positions 129-200 of SEQ ID NO:15, ons 7-78 or
positions 79-150 or positions 151-222 of SEQ ID NO:17; positions 1-72 or positions
73-144 or ons 145-216 of SEQ ID NO:18, a corresponding sequence from a
different MUCl protein such as another human MUCl protein, or an amino acid
sequence that is at least 95% identical, at least 96% identical, at least 97% identical,
at least 98% identical, or at least 99% identical, to any one of these amino acid
sequences.
In one aspect of this embodiment, a fusion protein that is useful in a yeast-
based immunotherapeutic composition of the invention comprises or consists of the amino
acid sequence of SEQ ID NO:14 or SEQ ID NO:15. SEQ ID NO:14 es the
ing MUCl antigens, in the following order from N— to C—terminus: (l) a MUCl
signal sequence (positions 1-30 of SEQ ID NO:14); (2) a MUCl SEA/ED segment
(positions 31-89 of SEQ ID NO:14); (3) a VNTR segment comprising two VNTR
domains (positions 90-130 of SEQ ID NO:14); (4) a MUCl TM domain (positions 131-
158 of SEQ ID NO:14); (5) a MUCl CD (positions 159-230 of SEQ ID NO:14); and (6) a
ptide histidine tag (positions 231-236 of SEQ ID . SEQ ID NO:14 is
encoded by the nucleotide sequence represented by SEQ ID NO:13. SEQ ID NO:15
includes the following MUCl ns, in the following order from N— to C-terminus: (l)
a MUCl SEA/ED segment (positions 1—59 of SEQ ID NO:15); (2) a VNTR segment
comprising two VNTR domains (positions 60—100 of SEQ ID NO:15); (3) a MUCl TM
domain (positions 101-128 of SEQ ID NO:15); and (4) a MUCl CD ions 0 of
SEQ ID NO:15). Optionally, the fusion protein of SEQ ID NO:14 or SEQ ID NO:15
includes an N—terminal e that is a synthetic N-terminal peptide designed to impart
resistance to proteasomal degradation and stabilize expression represented by SEQ ID
NO:2l, or an N—terminal peptide from a yeast alpha leader sequence such as SEQ ID
NOIl9 or SEQ ID NO:20, or another N—terminal peptide suitable for use with a yeast-
based immunotherapeutic as described herein. Also optionally, one or more linker
peptides of from one, two, three or more amino acids, such as the two amino acid linker of
r, can be inserted between ts of the fiasion n. The stidine tag at
the C-terminus of the fusion protein is also optional.
In one embodiment of the invention, a fusion protein useful in a yeast-based
immunotherapeutic composition of the invention includes the following MUCl ns,
in the following order from N- to C-terminus: (l) at least two VNTR domains; and (2) a
portion of a MUCl SEA domain and MUCl extracellular domain (ED) that includes most
or all of the MUCl ED. Such a fusion protein may include additional portions of the
MUCl-N region flanking the VNTR domains. Such a fusion protein does not include an
entire MUCl-N subunit.
[0090] In another embodiment of the invention, a fusion protein useful in a yeast-
based immunotherapeutic composition of the invention includes the following MUCl
antigens, in the following order from N— to C-terminus: (l) a first MUCl cytoplasmic
domain (CD); (2) a second MUCl cytoplasmic domain (CD); and (3) a third MUCl
cytoplasmic domain (CD). In one embodiment, additional MUCl cytoplasmic domains
can be ed in such a fusion protein. In one embodiment, at least one of the MUCl
CDs is from a different source than one of the other MUCl CDs (e.g., one MUCl CD is
from a first human MUCl protein and one MUCl CD is from a second MUCl protein,
wherein there can be sequence differences between the first and second MUCl CDs). In
one embodiment, this fusion protein is appended at the N-terminus with a MUCl signal
sequence. In r embodiment, this fusion protein may include N-terminal and/or C-
terminal peptides that improve or assist with the expression or stability of, and/or allow for
fication and/or purification of, the fusion protein, and/or short intervening linker
sequences (e.g., l, 2, 3, 4, or 5 amino acid peptides) between segments of the fusion
n which can be useful for the introduction of restriction enzyme sites to facilitate
g, as cleavage sites for host phagosomal proteases, to accelerate protein or antigen
processing, and for future manipulation of the constructs.
One e of such a fusion protein that is usefial in a based
immunotherapeutic composition of the invention comprises or includes the following
MUCl ns, in the following order from N- to C-terminus:
(1) a first MUC1 asmic domain (CD), wherein the CD comprises or
consists of an amino acid sequence selected from: positions 3 of SEQ ID
N0:2, positions 193-264 of SEQ ID NO:4, positions 193-264 of SEQ ID N026,
positions 184-255 of SEQ ID NO:8, ons 1184-1255 of SEQ ID N0:11,
positions 159—230 of SEQ ID N0214, positions 129-200 of SEQ ID N0:15, positions
7-78 or positions 79-150 or positions 151-222 of SEQ ID N0:l7; positions 1-72 or
positions 73-144 or positions 145-216 of SEQ ID N0218, a corresponding sequence
from a different MUC1 protein such as another human MUC1 protein, or an amino
acid sequence that is at least 95% identical, at least 96% identical, at least 97%
identical, at least 98% identical, or at least 99% identical, to any one of these amino
acid sequences;
(2) a second MUC1 cytoplasmic domain (CD), wherein the CD comprises or
consists of an amino acid sequence selected from: positions 202-273 of SEQ ID
N0:2, positions 193-264 of SEQ ID NO:4, positions 193-264 of SEQ ID N026,
positions 5 of SEQ ID NO:8, positions 1184-1255 of SEQ ID N0:11,
positions 159—230 of SEQ ID NO: 14, positions 129-200 of SEQ ID N0:15, positions
7-78 or positions 79-150 or positions 151-222 of SEQ ID N0:l7; positions 1-72 or
positions 73-144 or positions 145-216 of SEQ ID N0218, a corresponding sequence
from a different MUC1 protein such as another human MUC1 protein, or an amino
acid sequence that is at least 95% identical, at least 96% identical, at least 97%
identical, at least 98% identical, or at least 99% identical, to any one of these amino
acid sequences;
(3) a third MUC1 cytoplasmic domain (CD), wherein the CD comprises or
consists of an amino acid sequence selected from: positions 202-273 of SEQ ID
N0:2, positions 193—264 of SEQ ID NO:4, positions 193—264 of SEQ ID N026,
positions 184-255 of SEQ ID NO:8, positions 1184-1255 of SEQ ID N0:11,
positions 0 of SEQ ID N0214, positions 129-200 of SEQ ID N0:15, positions
7-78 or ons 79-150 or positions 151-222 of SEQ ID N0:l7; ons 1-72 or
positions 73-144 or positions 6 of SEQ ID N0218, a corresponding sequence
from a different MUC1 protein such as another human MUC1 protein, or an amino
acid sequence that is at least 95% cal, at least 96% identical, at least 97%
identical, at least 98% identical, or at least 99% identical, to any one of these amino
acid sequences.
In one aspect of this embodiment, a fusion protein that is useful in a yeast-
based immunotherapeutic composition of the invention comprises or ts of the amino
acid sequence of SEQ ID NO:l7 or SEQ ID NO:l8. SEQ ID NO:l7 includes the
following MUCl antigens, in the following order from N— to C-terminus: (I) an synthetic
peptide represented by SEQ ID NO:21 (positions 1—6 of SEQ ID NO:l7); (2) a first MUCl
CD (positions 7-78 of SEQ ID NO:l7); (3) a second MUCl CD (positions 79-150 of SEQ
ID ; (4) a third MUCl CD (positions 151—222 of SEQ ID NO:l7); and (5) a
hexahistidine tag (positions 223-228 of SEQ ID NO:l7). SEQ ID NO:l7 is encoded by
the nucleotide sequence ented by SEQ ID NO:l6. SEQ ID NO:l8 includes the
following MUCl antigens, in the following order from N- to C-terminus: (l) a first
MUCl CD (positions 1-72 of SEQ ID NO:l8); (2) a second MUCl CD (positions 73-144
of SEQ ID NO:l8); (3) a third MUCl CD (positions 145-216 of SEQ ID NO:l8).
Optionally, the fusion protein of SEQ ID NO: 17 or SEQ ID NO:l8 es an N—terminal
peptide that is a synthetic N-terminal peptide designed to impart resistance to proteasomal
degradation and stabilize expression represented by SEQ ID NO:2l, or an N-terminal
peptide from a yeast alpha leader sequence such as SEQ ID NO:l9 or SEQ ID NO:20, or
another N—terminal peptide suitable for use with a yeast-based therapeutic as
bed herein. Also optionally, one or more linker peptides of from one to three or
more amino acids linker sequences of one, two, three or more amino acids, such as the two
amino acid linker of Thr-Ser can be inserted n ts of the fusion n. The
hexahistidine tag at the inus of the fusion n is also optional.
A MUCl antigen useful in the present invention also includes proteins having
an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any of the
MUCl proteins, domains, fusion proteins, or antigens described herein over the fill length
of the protein, or with respect to a defined fragment or domain thereof (e.g, an
logical domain or functional domain (domain with at least one biological
activity)) that forms part of the protein. For example, a domain of the MUCl protein
bed herein includes the signal sequence, a VNTR domain, an SEA domain, the
extracellular domain (ED), an TM domain, and/or a cytoplasmic domain (CD). An
immunological domain has been described in detail above. MUCl fusion proteins
described herein include those represented by SEQ ID NO:l4, SEQ ID NO:lS, SEQ ID
NO:l7 and SEQ ID NO:l8. Accordingly, a MUCl antigen useful in the yeast-based
immunotherapeutic of the invention includes a MUCl antigen comprising or consisting of
any one of SEQ ID NO:l4, SEQ ID NO:15, SEQ ID NO:l7 and SEQ ID NO:18, an amino
acid ce that is at least about 95%, 96%, 97%, 98% or 99% identical to any one of
SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:17 and SEQ ID NO:18, and/or a
corresponding sequence from a different MUCl protein (e.g, a fusion protein where one
or more of the fusion segments are from the corresponding sequences from a different
MUCl protein or from a MUCl protein agonist sequence, such that minor sequence
differences may be present as compared to the sequences presented here).
It is straightforward to use the corresponding portions of any of the MUCl
proteins or domains d or obtained from sequence or sources other than those
exemplified herein, and particularly from sequences or sources within the same animal
species, to create fusion proteins having a similar or the same l structure as the
fusion proteins described herein. By way of example, one can readily identify a
corresponding sequence in given human MUCl protein from any source that corresponds
to positions 1034-1152 of SEQ ID NOzll, using simple sequence ent tools or
processes. Therefore, sequences with minor and/or conservative differences from the
sequences exemplified herein are expressly encompassed by the present invention.
In some aspects of the invention, amino acid insertions, deletions, and/or
substitutions can be made for one, two, three, four, five, six, seven, eight, nine, ten, eleven,
or more amino acids of a wild-type or reference MUCl protein, provided that the resulting
MUCl n, when used as an antigen in a Yeast-MUCl immunotherapeutic
composition of the invention, elicits an immune response t a native MUCl protein
as the wild-type or reference MUCl protein, which may include an enhanced immune
response, a diminished immune response, or a substantially r immune response. For
example, the invention includes the use of MUCl agonist antigens, which may include one
or more T cell es that have been mutated to enhance the T cell response against the
MUCl agonist, such as by improving the avidity or affinity of the epitope for an MHC
molecule or for the T cell receptor that recognizes the epitope in the context of MHC
presentation. MUCl agonists may therefore improve the potency or efficiency of a T cell
response t native MUCl expressed by a tumor cell. A variety of MUCl T cell
epitopes, ing agonist epitopes are bed in US. Patent 6,546,643; US. Patent
No. 7,118,738; US. Patent No. 094; US. Patent No. 7,696,306; and US. Patent
Application ation No. 2008/0063653, and any one or more of these epitopes can be
used in a MUCl antigen of the t invention, including by adding, deleting or
tuting one or more amino acids within a sequence described herein to conform the
sequence to the published epitope sequence at that position(s).
es of MUCl agonist antigens are provided herein (see Examples 3 and
4). In one embodiment, a MUCl agonist antigen suitable for use in the present ion
comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all 11 of the following substitutions, where the
positions of the substitutions are provided with respect to a wild-type MUCl represented
by Accession No. NP_001191214 (although the same or equivalent positions can be
readily identified in any other wild-type MUCl sequence): T93, A161, P162, G169, S170,
T171, A392, C406, T444, D445, or S460. In one embodiment, a MUCl agonist antigen
that is useful in a yeast—based immunotherapeutic ition of the invention comprises
or consists of the amino acid sequence of SEQ ID NO:23 or SEQ ID NO:25. SEQ ID
NO:23 includes the following MUCl antigens, in the following order from N— to C-
terminus: (l) MUCl signal sequence ions 1-30 of SEQ ID NO:23); (2) a MUCl
SEA/ED segment (positions 31-89 of SEQ ID ; (3) a VNTR segment sing
two VNTR domains (positions 90-130 of SEQ ID NO:23); (4) a MUCl TM domain
ions 131-158 of SEQ ID NO:23); (5) a MUCl CD (positions 0 of SEQ ID
NO:23); (6) a MUCl agonist epitope (positions 231-246 of SEQ ID N023) and (7) a
hexapeptide histidine tag (positions 247-252 of SEQ ID . SEQ ID NO:23 is
encoded by the nucleotide sequence represented by SEQ ID NO:22 (codon zed for
yeast expression). The MUCl signal sequence (positions 1-30 of SEQ ID NO:23) could
be substituted with a different N—terminal sequence designed to impart resistance to
proteasomal degradation and/or stabilize expression, such as the peptide represented by
SEQ ID NO:21, or an N-terminal peptide from a yeast alpha leader sequence such as SEQ
ID NO:19 or SEQ ID NO:20. hexahistidine C-terminal tag is optional, and tates
identification and/or purification of the protein. As ed to the MUCl antigen in
SEQ ID NO:14 or SEQ ID NO:15, the SEQ ID NO:23 contains the following amino acid
substitutions to create a variety of agonist epitopes (substitution positions given with
reference to SEQ ID NO:23, with further reference to the location of the substitution in a
wild-type MUCl represented by Accession No. NP_001191214): A96Y (position 161 in
wild-type MUCl), P97L (position 162 in wild-type MUCl), G104V (position 169 in wild-
type MUCl), S105Y (position 170 in wild-type MUCl), T106L (position 171 in wild-type
MUCl), A147Y (position 392 in wild-type MUCl), C161V (position 406 in wild-type
MUCl), Tl99L (position 444 in wild-type MUCl), D200F (position 445 in wild-type
MUC1), S215Y (position 460 in wild-type MUC1), and T239L (position 93 in ype
MUC1).
SEQ ID NO:25 includes the following MUC1 antigens, in the following order
from N— to C-terminus: (1) an alpha factor leader sequence disclosed elsewhere herein by
SEQ ID NO:19 (positions 1-89 of SEQ ID NO:25); (2) a linker sequence of r
(positions 90-91 of SEQ ID ; (3) a fiall-length MUC1 agonist protein
corresponding to a wild-type protein except for the introduction of 11 agonist epitopes
(positions 92-566 of SEQ ID N025) and (7) a hexapeptide histidine tag (positions 567-
572 of SEQ ID NO:25). SEQ ID NO:25 is encoded by the nucleotide sequence
represented by SEQ ID NO:24 (codon zed for yeast expression). The alpha leader
ce (positions 1-89 of SEQ ID NO:25) could be substituted with a different N—
terminal sequence designed to impart resistance to proteasomal degradation and/or
stabilize expression, such as the peptide represented by SEQ ID NO:21, or an N-terminal
peptide from a different yeast alpha leader sequence such as SEQ ID NO:20, or by a
MUC1 signal sequence. The hexahistidine C-terminal tag is optional, and facilitates
identification and/or purification of the n. As compared to the wild—type MUC1
protein used as a template, the sequence in GI-6106 contains the following amino acid
substitutions to create a variety of agonist epitopes (substitution positions given with
reference to SEQ ID NO:25, with further reference to the location of the substitution in a
wild-type MUC1 represented by Accession No. NP_001191214): T184L (position 93 in
wild-type MUC1), A232Y (position 161 in wild-type MUC1), P233L ion 162 in
wild-type MUC1), G240V (position 169 in wild-type MUC1), S241Y (position 170 in
wild-type MUC1), T242L ion 171 in ype MUC1), A483Y (position 392 in
ype MUC1), C497V (position 406 in wild-type MUC1), T535L (position 444 in
wild-type MUC1), D536F (position 445 in wild-type MUC1), and S551Y (position 460 in
wild-type MUC1).
Accordingly, a MUC1 agonist antigen useful in the yeast-based
immunotherapeutic of the invention includes a MUC1 antigen comprising or consisting of
SEQ ID NO:23 or SEQ ID NO:25, or the MUC1—specific sequences within these larger
fusion proteins, or an amino acid sequence that is at least about 95%, 96%, 97%, 98% or
99% identical to any one of SEQ ID NO:23, SEQ ID NO:25, or the MUC1-specific
sequences within these larger fusion proteins, and/or a corresponding ce from a
different MUC1 protein (e.g., a fusion protein where one or more of the fusion segments
are from the corresponding sequences from a different MUCl protein, such that minor
sequence differences may be present as compared to the sequences presented here).
As discussed above, N-terminal expression sequences and the inal tags,
such as those described above with respect to the fusion proteins of SEQ ID NOzl4, SEQ
ID NO:l7, SEQ ID NO:23, or SEQ ID NO:25 are al, but may be selected from
l different sequences described elsewhere herein to improve or assist with
expression, ity, and/or allow for identification and/or purification of the protein.
Also, many different promoters suitable for use in yeast are known in the art. Furthermore,
short intervening linker sequences (e.g, 1, 2, 3, 4, or 5 amino acid peptides) may be
introduced n portions of a fusion protein comprising a MUCl antigen for a variety
of reasons, including the introduction of restriction enzyme sites to facilitate cloning, as
cleavage sites for host phagosomal proteases, to accelerate protein or antigen processing,
and for future manipulation of the constructs.
Optionally, proteins, including fiision proteins, which are used as a component
of the Yeast-MUCl immunotherapeutic composition of the invention are produced using
antigen constructs that are particularly useful for improving or stabilizing the expression
of logous antigens in yeast. In one ment, the desired antigenic protein(s) or
peptide(s) are fused at their amino-terminal end to: (a) a specific synthetic e that
stabilizes the expression of the fusion protein in the yeast e or prevents
posttranslational modification of the expressed fusion protein (such peptides are described
in detail, for example, in US. Patent Publication No. 2004—0156858 Al, published August
12, 2004, incorporated herein by reference in its entirety); (b) at least a portion of an
endogenous yeast protein, wherein either fusion partner provides improved stability of
expression of the protein in the yeast and/or a prevents post—translational modification of
the proteins by the yeast cells (such ns are also described in detail, for example, in
US. Patent Publication No. 2004-0156858 Al, supra); and/or (0) at least a portion of a
yeast protein that causes the fusion protein to be sed on the surface of the yeast (e.g.,
an Aga protein, described in more detail ). In addition, the present invention
optionally includes the use of peptides that are fused to the C-terminus of the antigen—
encoding construct, particularly for use in the selection and identification of the protein.
Such peptides include, but are not limited to, any synthetic or natural peptide, such as a
peptide tag (e.g, 6X His or hexapeptide) or any other short epitope tag. es attached
to the C-terminus of an antigen according to the ion can be used with or t the
addition of the N-terminal peptides discussed above, and vice versa.
] In one embodiment, a synthetic peptide useful in a fusion protein to be
sed in a yeast is linked to the N—terminus of the antigen, the peptide consisting of at
least two amino acid positions that are logous to the antigen, wherein the peptide
stabilizes the expression of the fusion protein in the yeast vehicle or prevents
posttranslational modification of the expressed fusion protein. The synthetic e and
N—terminal portion of the antigen together form a fusion protein that has the following
requirements: (1) the amino acid residue at on one of the fusion protein is a
methionine (z'.e., the first amino acid in the synthetic e is a methionine); (2) the
amino acid residue at position two of the fusion protein is not a glycine or a proline (i.e.,
the second amino acid in the tic peptide is not a glycine or a proline); (3) none of
the amino acid positions at positions 2-6 of the fusion protein is a methionine (126., the
amino acids at positions 2—6, whether part of the synthetic peptide or the protein, if the
synthetic peptide is shorter than 6 amino acids, do not include a methionine); and (4) none
of the amino acids at positions 2-6 of the fusion protein is a lysine or an arginine (i.e., the
amino acids at positions 2-6, whether part of the synthetic peptide or the protein, if the
synthetic peptide is shorter than 5 amino acids, do not include a lysine or an arginine).
The synthetic peptide can be as short as two amino acids, but in one aspect, is 2-6 amino
acids (including 3, 4, 5 amino acids), and can be longer than 6 amino acids, in whole
integers, up to about 200 amino acids, 300 amino acids, 400 amino acids, 500 amino acids,
or more.
In one embodiment, a fusion protein comprises an amino acid sequence of M-
X2-X3-X4-X5-X6, wherein M is methionine; wherein X2 is any amino acid except
glycine, proline, lysine or arginine; wherein X3 is any amino acid except methionine,
lysine or arginine; wherein X4 is any amino acid except methionine, lysine or arginine;
wherein X5 is any amino acid except methionine, lysine or arginine; and wherein X6 is
any amino acid except methionine, lysine or arginine. In one embodiment, the X6 residue
is a e. An exemplary synthetic sequence that enhances the stability of expression of
an antigen in a yeast cell and/or prevents post-translational modification of the protein in
the yeast includes the sequence M-A-D-E-A-P (represented herein by SEQ ID . In
addition to the enhanced stability of the expression t, this fusion partner does not
appear to negatively impact the immune response against the immunizing antigen in the
construct. In on, the tic fusion peptides can be designed to provide an epitope
that can be recognized by a ion agent, such as an antibody.
] In one embodiment, the MUCl antigen is linked at the inus to a yeast
protein, such as an alpha factor prepro sequence (also referred to as the alpha factor signal
leader sequence, the amino acid sequence of which is exemplified herein by SEQ ID
NO:l9 or SEQ ID NO:20 Other sequences for yeast alpha factor prepro sequence are
known in the art and are encompassed for use in the present invention.
In one aspect of the invention, the yeast vehicle is manipulated such that the
antigen is expressed or provided by delivery or translocation of an expressed protein
product, partially or wholly, on the surface of the yeast vehicle cellular expression).
One method for accomplishing this aspect of the invention is to use a spacer arm for
positioning one or more protein(s) on the surface of the yeast vehicle. For example, one
can use a spacer arm to create a fusion protein of the antigen(s) or other n of interest
with a protein that targets the antigen(s) or other protein of interest to the yeast cell wall.
For example, one such n that can be used to target other proteins is a yeast protein
(e.g., cell wall protein 2 (cwp2), Aga2, Pir4 or Flol protein) that enables the antigen(s) or
other n to be targeted to the yeast cell wall such that the n or other protein is
located on the surface of the yeast. Proteins other than yeast proteins may be used for the
spacer arm; however, for any spacer arm protein, it is most desirable to have the
immunogenic response be directed against the target antigen rather than the spacer arm
protein. As such, if other proteins are used for the spacer arm, then the spacer arm protein
that is used should not generate such a large immune response to the spacer arm protein
itself such that the immune response to the target antigen(s) is overwhelmed. One of skill
in the art should aim for a small immune se to the spacer arm protein ve to the
immune response for the target antigen(s). Spacer arms can be constructed to have
ge sites (e.g., protease cleavage sites) that allow the antigen to be readily removed
or processed away from the yeast, if d. Any known method of determining the
magnitude of immune responses can be used (e.g., antibody production, lytic assays, etc.)
and are readily known to one of skill in the art.
Another method for positioning the target antigen(s) or other proteins to be
exposed on the yeast surface is to use signal sequences such as glycosylphosphatidyl
inositol (GPI) to anchor the target to the yeast cell wall. Alternatively, positioning can be
accomplished by appending signal sequences that target the antigen(s) or other proteins of
interest into the ory pathway via translocation into the endoplasmic reticulum (ER)
such that the antigen binds to a protein which is bound to the cell wall (e.g., cwp).
In one aspect, the spacer arm protein is a yeast protein. The yeast protein can
consist of n about two and about 800 amino acids of a yeast protein. In one
embodiment, the yeast protein is about 10 to 700 amino acids. In r embodiment, the
yeast protein is about 40 to 600 amino acids. Other embodiments of the invention include
the yeast n being at least 250 amino acids, at least 300 amino acids, at least 350
amino acids, at least 400 amino acids, at least 450 amino acids, at least 500 amino acids, at
least 550 amino acids, at least 600 amino acids, or at least 650 amino acids. In one
embodiment, the yeast protein is at least 450 amino acids in length. Another consideration
for optimizing antigen surface expression, if that is d, is whether the antigen and
spacer arm combination should be expressed as a monomer or as dimer or as a trimer, or
even more units connected together. This use of monomers, dimers, trimers, etc. allows
for appropriate spacing or folding of the antigen such that some part, if not all, of the
antigen is displayed on the surface of the yeast vehicle in a manner that makes it more
immunogenic.
[00107] Use of yeast ns can stabilize the sion of fiision proteins in the
yeast vehicle, prevents posttranslational modification of the expressed fusion n,
and/or targets the fusion protein to a particular compartment in the yeast (e.g., to be
expressed on the yeast cell surface). For ry into the yeast secretory pathway,
exemplary yeast proteins to use include, but are not limited to: Aga (including, but not
limited to, Agal and/or Aga2); SUC2 (yeast invertase); alpha factor signal leader
sequence; CPY; pr2p for its localization and retention in the cell wall; BUD genes for
localization at the yeast cell bud during the initial phase of daughter cell ion; Flolp;
Pir2p; and Pir4p.
Other sequences can be used to target, retain and/or stabilize the protein to
other parts of the yeast vehicle, for example, in the cytosol or the mitochondria or the
endoplasmic reticulum or the nucleus. Examples of suitable yeast n that can be used
for any of the embodiments above include, but are not limited to, TK, AF, SEC7;
oenolpyruvate carboxykinase PCKl, phosphoglycerokinase PGK and triose
phosphate isomerase TPI gene products for their repressible expression in glucose and
cytosolic localization; the heat shock proteins SSAl, SSA3, SSA4, SSCl, whose
expression is d and whose proteins are more thermostable upon exposure of cells to
heat treatment; the mitochondrial protein CYCl for import into mitochondria; ACTl.
] Methods of producing yeast vehicles and expressing, combining and/or
associating yeast es with antigens and/or other proteins and/or agents of interest to
produce yeast-based immunotherapy compositions are contemplated by the invention.
According to the present invention, the term "yeast vehicle-antigen complex"
or "yeast-antigen complex" is used generically to describe any association of a yeast
vehicle with ‘
an antigen, and can be used interchangeably with ‘yeast-based
immunotherapy composition” when such composition is used to elicit an immune response
as described above. Such association includes sion of the n by the yeast (a
recombinant yeast), introduction of an antigen into a yeast, physical attachment of the
antigen to the yeast, and mixing of the yeast and antigen together, such as in a buffer or
other solution or formulation. These types of xes are described in detail below.
In one embodiment, a yeast cell used to prepare the yeast vehicle is transfected
with a heterologous c acid molecule encoding a protein (e.g, the antigen) such that
the protein is expressed by the yeast cell. Such a yeast is also referred to herein as a
recombinant yeast or a recombinant yeast vehicle. The yeast cell can then be formulated
with a pharmaceutically acceptable excipient and administered directly to a patient, stored
for later administration, or loaded into a dendritic cell as an intact cell. The yeast cell can
also be killed, or it can be tized such as by formation of yeast spheroplasts,
cytoplasts, , or subcellular particles, any of which may be followed by storing,
administering, or loading of the derivative into the dendritic cell. Yeast plasts can
also be directly transfected with a recombinant nucleic acid molecule (e.g., the spheroplast
is produced from a whole yeast, and then transfected) in order to produce a recombinant
spheroplast that expresses the antigen. Yeast cells or yeast spheroplasts that
recombinantly express the antigen(s) may be used to produce a yeast vehicle comprising a
yeast cytoplast, a yeast ghost, or a yeast membrane particle or yeast cell wall particle, or
on thereof.
In general, the yeast e and antigen(s) and/or other agents can be
ated by any technique described herein. In one aspect, the yeast vehicle was loaded
intracellularly with the antigen(s) and/or s). In another aspect, the n(s) and/or
agent(s) was covalently or non-covalently attached to the yeast vehicle. In yet another
, the yeast vehicle and the antigen(s) and/or agent(s) were associated by mixing. In
another aspect, and in one embodiment, the n(s) and/or agent(s) are expressed
recombinantly by the yeast vehicle or by the yeast cell or yeast spheroplast from which the
yeast vehicle was derived.
A number of ns and/or other proteins to be ed by a yeast vehicle
of the present invention is any number of antigens and/or other proteins that can be
reasonably produced by a yeast e, and typically ranges from at least one to at least
about 6 or more, including from about 2 to about 6 antigens and or other proteins.
Expression of an antigen or other protein in a yeast e of the present
ion is accomplished using techniques known to those d in the art. Briefly, a
nucleic acid molecule encoding at least one desired n or other protein is inserted into
an expression vector in such a manner that the nucleic acid molecule is operatively linked
to a transcription control sequence in order to be capable of effecting either constitutive or
regulated expression of the c acid molecule when transformed into a host yeast cell.
Nucleic acid molecules encoding one or more ns and/or other proteins can be on one
or more expression vectors operatively linked to one or more expression control sequences.
Particularly important expression l sequences are those which control transcription
initiation, such as promoter and upstream activation sequences. Any suitable yeast
promoter can be used in the present invention and a variety of such promoters are known
to those skilled in the art. Promoters for expression in Saccharomyces cerevisiae include,
but are not limited to, promoters of genes encoding the following yeast proteins: alcohol
dehydrogenase I (ADHl) or II (ADH2), CUPl, phosphoglycerate kinase (PGK), triose
phosphate ase (TPI), translational tion factor EF—l alpha (TEFZ),
glyceraldehydephosphate dehydrogenase ; also referred to as TDH3, for triose
phosphate dehydrogenase), galactokinase (GALl), galactose—l-phosphate uridyl-
transferase (GAL7), UDP-galactose epimerase (GALlO), cytochrome cl , Sec7
protein (SEC7) and acid phosphatase (PHOS), including hybrid promoters such as
ADH2/GAPDH and CYCI/GALI0 promoters, and including the ADH2/GAPDH promoter,
which is induced when glucose concentrations in the cell are low (e.g., about 0.1 to about
0.2 t), as well as the CUPI promoter and the TEF2 promoter. Likewise, a number
of upstream activation sequences (UASs), also referred to as enhancers, are known.
Upstream activation sequences for expression in Saccharomyces cerevisiae include, but
are not limited to, the UASs of genes encoding the following proteins: PCKl, TPI, TDH3,
CYCl, ADHl, ADH2, SUC2, GALl, GAL7 and GALIO, as well as other UASs activated
by the GAL4 gene product, with the ADH2 UAS being used in one aspect. Since the
ADH2 UAS is activated by the ADRl gene product, it may be preferable to overexpress
the ADRl gene when a heterologous gene is operatively linked to the ADH2 UAS.
ription termination sequences for expression in Saccharomyces cerevisiae include
the termination sequences of the (X-faCtOI‘, GAPDH, and CYCl genes.
Transcription l sequences to express genes in methyltrophic yeast
include the transcription control regions of the genes ng alcohol oxidase and
formate dehydrogenase.
ection of a nucleic acid molecule into a yeast cell according to the
present invention can be accomplished by any method by which a nucleic acid molecule
can be introduced into the cell and includes, but is not limited to, diffiision, active
transport, bath sonication, electroporation, microinjection, lipofection, adsorption, and
protoplast fusion. Transfected nucleic acid molecules can be integrated into a yeast
chromosome or maintained on extrachromosomal vectors using techniques known to those
skilled in the art. Examples of yeast vehicles carrying such nucleic acid molecules are
disclosed in detail herein. As discussed above, yeast cytoplast, yeast ghost, and yeast
membrane particles or cell wall ations can also be produced recombinantly by
transfecting intact yeast microorganisms or yeast spheroplasts with desired nucleic acid
les, ing the antigen therein, and then further manipulating the
microorganisms or spheroplasts using techniques known to those skilled in the art to
produce ast, ghost or subcellular yeast membrane extract or ons thereof
containing desired antigens or other proteins.
[00117] Effective conditions for the production of recombinant yeast vehicles and
expression of the n and/or other protein by the yeast vehicle include an effective
medium in which a yeast strain can be cultured. An effective medium is typically an
aqueous medium comprising assimilable carbohydrate, nitrogen and phosphate sources, as
well as appropriate salts, ls, metals and other nutrients, such as vitamins and growth
factors. The medium may comprise complex nutrients or may be a defined minimal
medium. Yeast s of the present invention can be cultured in a variety of ners,
including, but not d to, bioreactors, Erlenmeyer flasks, test tubes, microtiter dishes,
and Petri plates. Culturing is carried out at a temperature, pH and oxygen content
appropriate for the yeast strain. Such culturing conditions are well within the expertise of
one of ordinary skill in the art (see, for example, e et al. (eds), 1991, Methods in
Enzymology, vol. 194, Academic Press, San Diego). For example, under one protocol,
liquid cultures containing a suitable medium can be inoculated using cultures ed
from starter plates and/or r cultures of Yeast-MUCl immunotherapy compositions,
and are grown for approximately 20h at 30°C, with agitation at 250 rpm. Primary cultures
can then be expanded into larger cultures as desired. Protein expression from vectors with
which the yeast were transformed (e.g, MUCl expression) may be constitutive if the
er utilized is a constitutive promoter, or may be induced by addition of the
appropriate induction ions for the promoter if the promoter utilized is an ble
promoter (e.g., copper sulfate in the case of the CUP] promoter). In the case of an
inducible promoter, induction of protein expression may be initiated after the culture has
grown to a suitable cell density, which may be at about 0.2 Y.U./ml or higher densities.
One miting example of a medium suitable for the culture of a Yeast-
MUCl immunotherapy ition of the invention is U2 medium. U2 medium
comprises the following components: 15g/L of glucose, 6.7 g/L of Yeast nitrogen base
containing ammonium sulfate, and_0.04 mg/mL each of histidine, tryptophan, and adenine,
and 0.06 mg/ml of leucine. Another non-limiting example of a medium suitable for the
culture of Yeast-MUCl immunotherapy composition of the invention is UL2 medium.
UL2 medium comprises the following components: 15g/L of glucose, 6.7 g/L of Yeast
nitrogen base containing ammonium e, and 0.04 mg/mL each of histidine, tryptophan,
and e.
In some embodiments of the invention, the yeast are grown under neutral pH
conditions. As used herein, the general use of the term “neutral pH” refers to a pH range
between about pH 5.5 and about pH 8, and in one aspect, between about pH 6 and about 8.
One of skill the art will appreciate that minor fluctuations (e.g., tenths or hundredths) can
occur when measuring with a pH meter. As such, the use of neutral pH to grow yeast cells
means that the yeast cells are grown in neutral pH for the majority of the time that they are
in culture. In one embodiment, yeast are grown in a medium maintained at a pH level of
at least 5.5 (i.e., the pH of the e medium is not allowed to drop below pH 5.5). In
another aspect, yeast are grown at a pH level maintained at about 6, 6.5, 7, 7.5 or 8. In one
aspect, neutral pH is ined by using a suitable buffer to create a ed culture or
growth . The use of a neutral pH in culturing yeast promotes several biological
effects that are desirable characteristics for using the yeast as vehicles for
immunomodulation. For example, culturing the yeast in neutral pH allows for good
growth of the yeast without negative effect on the cell generation time (e.g, g of
doubling time). The yeast can continue to grow to high densities without losing their cell
wall lity. The use of a neutral pH allows for the production of yeast with pliable cell
walls and/or yeast that are more sensitive to cell wall digesting enzymes (e.g, glucanase)
at all harvest densities. This trait is desirable because yeast with flexible cell walls can
induce different or improved immune responses as compared to yeast grown under more
acidic conditions, e.g., by ing the secretion of cytokines by antigen presenting cells
that have ytosed the yeast (e.g., THl-type cytokines including, but not limited to,
IFN—y, interleukin-12 (IL-12), and IL-2, as well as proinflammatory cytokines such as IL-
6). In addition, greater accessibility to the antigens located in the cell wall is afforded by
such culture methods. In another aspect, the use of neutral pH for some antigens allows
for release of the di—sulfide bonded antigen by ent with dithiothreitol (DTT) that is
not possible when such an antigen-expressing yeast is cultured in media at lower pH (e.g,
pH 5). In one non-limiting example of the use of neutral pH conditions to culture yeast for
use in the present invention, UL2 medium described above is buffered using, for example,
4.2g/L of Bis-Tris.
The ors demonstrate herein that yeast-MUCl immunotherapeutic
compositions of the ion grown using l pH conditions are more potent
activators of dendritic cells and activate MUC-l-specific T cells to produce higher levels
of IFN-y than the same yeast-MUCl immunotherapeutic compositions grown under
standard conditions (where neutral pH is not maintained) (see Examples).
In one embodiment, control of the amount of yeast glycosylation is used to
control the expression of antigens by the yeast, particularly on the surface. The amount of
yeast ylation can affect the immunogenicity and nicity of the antigen,
particularly one expressed on the surface, since sugar moieties tend to be bulky. As such,
the existence of sugar moieties on the surface of yeast and its impact on the three-
dimensional space around the target n(s) should be considered in the modulation of
yeast according to the ion. Any method can be used to reduce or increase the
amount of glycosylation of the yeast, if desired. For example, one could use a yeast
mutant strain that has been selected to have low glycosylation (e.g. mnnl, ochl and mnn9
mutants), or one could eliminate by mutation the glycosylation acceptor sequences on the
target antigen. Alternatively, one could use yeast with abbreviated ylation patterns,
e.g., Pichia. One can also treat the yeast using methods that reduce or alter the
glycosylation.
[00122] In one embodiment of the present invention, as an alternative to expression of
an n or other protein recombinantly in the yeast vehicle, a yeast vehicle is loaded
intracellularly with the protein or peptide, or with ydrates or other molecules that
serve as an antigen and/or are useful as immunomodulatory agents or biological response
modifiers according to the invention. Subsequently, the yeast vehicle, which now contains
the n and/or other proteins intracellularly, can be administered to an individual or
loaded into a carrier such as a dendritic cell. Peptides and proteins can be inserted directly
into yeast vehicles of the present ion by techniques known to those skilled in the art,
such as by diffusion, active transport, liposome fusion, electroporation, phagocytosis,
freeze—thaw cycles and bath sonication. Yeast es that can be directly loaded with
peptides, proteins, carbohydrates, or other molecules include intact yeast, as well as
spheroplasts, ghosts or cytoplasts, which can be loaded with antigens and other agents
after production. Alternatively, intact yeast can be loaded with the antigen and/or agent,
and then plasts, ghosts, cytoplasts, or lular les can be prepared
therefrom. Any number of antigens and/or other agents can be loaded into a yeast vehicle
in this embodiment, from at least 1, 2, 3, 4 or any whole integer up to hundreds or
thousands of antigens and/or other agents, such as would be provided by the loading of a
rganism or portions thereof, for example.
In r embodiment of the present invention, an antigen and/or other agent
is ally ed to the yeast vehicle. Physical attachment of the antigen and/or other
agent to the yeast vehicle can be accomplished by any method suitable in the art, including
covalent and non-covalent association methods which include, but are not limited to,
chemically inking the antigen and/or other agent to the outer surface of the yeast
vehicle or biologically linking the antigen and/or other agent to the outer surface of the
yeast vehicle, such as by using an antibody or other binding partner. Chemical cross—
linking can be achieved, for example, by methods including glutaraldehyde e,
photoaffinity labeling, treatment with carbodiimides, treatment with chemicals capable of
linking di-sulfide bonds, and treatment with other cross-linking chemicals standard in the
art. Alternatively, a chemical can be contacted with the yeast vehicle that alters the charge
of the lipid bilayer of yeast membrane or the composition of the cell wall so that the outer
surface of the yeast is more likely to fuse or bind to antigens and/or other agent having
particular charge characteristics. Targeting agents such as antibodies, binding peptides,
soluble receptors, and other ligands may also be incorporated into an antigen as a fusion
protein or otherwise ated with an antigen for binding of the antigen to the yeast
vehicle.
When the antigen or other protein is expressed on or physically attached to the
surface of the yeast, spacer arms may, in one aspect, be carefully selected to optimize
antigen or other protein expression or t on the surface. The size of the spacer arm(s)
can affect how much of the antigen or other protein is exposed for g on the surface
of the yeast. Thus, depending on which antigen(s) or other protein(s) are being used, one
of skill in the art will select a spacer arm that effectuates appropriate spacing for the
antigen or other protein on the yeast surface. In one embodiment, the spacer arm is a yeast
protein of at least 450 amino acids. Spacer arms have been discussed in detail above.
In yet another embodiment, the yeast vehicle and the antigen or other protein
are associated with each other by a more passive, non-specific or non—covalent binding
mechanism, such as by gently mixing the yeast vehicle and the antigen or other protein
er in a buffer or other suitable formulation (e. g., admixture).
In one embodiment, intact yeast (with or without sion of heterologous
antigens or other proteins) can be ground up or processed in a manner to e yeast
cell wall preparations, yeast membrane particles or yeast nts (i.e., not intact) and
the yeast fragments can, in some ments, be provided with or administered with
other compositions that include antigens (e.g, DNA vaccines, n subunit vaccines,
killed or inactivated pathogens, viral vector vaccines) to enhance immune responses. For
example, enzymatic ent, chemical treatment or physical force (e.g., mechanical
shearing or sonication) can be used to break up the yeast into parts that are used as an
adjuvant.
] In one embodiment of the ion, yeast vehicles useful in the invention
include yeast vehicles that have been killed or inactivated. Killing or inactivating of yeast
can be accomplished by any of a variety of le methods known in the art. For
example, heat inactivation of yeast is a standard way of inactivating yeast, and one of skill
in the art can monitor the structural changes of the target antigen, if desired, by standard
s known in the art. Alternatively, other methods of inactivating the yeast can be
used, such as chemical, electrical, ctive or UV methods. See, for example, the
methodology disclosed in standard yeast culturing textbooks such as Methods of
Enzymology, Vol. 194, Cold Spring Harbor Publishing (1990). Any of the inactivation
strategies used should take the ary, tertiary or quaternary structure of the target
antigen into consideration and ve such structure as to optimize its immunogenicity.
Yeast vehicles can be formulated into yeast-based immunotherapy
compositions or products of the present invention using a number of techniques known to
those skilled in the art. For example, yeast vehicles can be dried by lyophilization.
Formulations comprising yeast vehicles can also be prepared by packing yeast in a cake or
a tablet, such as is done for yeast used in baking or brewing ions. In addition, yeast
vehicles can be mixed with a pharmaceutically acceptable excipient, such as an isotonic
buffer that is ted by a host or host cell. Examples of such excipients include water,
saline, Ringer's solution, dextrose solution, Hank's solution, and other s
physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame
oil, ethyl oleate, or cerides may also be used. Other useful formulations include
suspensions ning viscosity—enhancing agents, such as sodium
ymethylcellulose, sorbitol, glycerol or dextran. Excipients can also contain minor
amounts of additives, such as substances that enhance icity and chemical stability.
Examples of buffers include phosphate , bicarbonate buffer and Tris buffer, while
examples of preservatives include thimerosal, m- or ol, formalin and benzyl alcohol.
Standard formulations can either be liquid injectables or solids which can be taken up in a
suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation,
the excipient can comprise, for example, dextrose, human serum n, and/or
preservatives to which sterile water or saline can be added prior to administration.
In one embodiment of the t invention, a composition can include
additional agents, which may also be referred to as biological response modifier
compounds, or the ability to produce such agents/modifiers. For example, a yeast vehicle
can be transfected with or loaded with at least one antigen and at least one agent/biological
response modifier compound, or a composition of the invention can be administered in
conjunction with at least one agent/biological response modifier. Biological response
modifiers include adjuvants and other compounds that can modulate immune ses,
which may be referred to as modulatory nds, as well as compounds that
modify the biological activity of another compound or agent, such as a yeast-based
immunotherapeutic, such biological activity not being limited to immune system effects.
Certain immunomodulatory compounds can stimulate a protective immune response
whereas others can suppress a harmful immune response, and whether an
immunomodulatory is useful in combination with a given based immunotherapeutic
may depend, at least in part, on the disease state or condition to be treated or prevented,
and/or on the individual who is to be treated. Certain biological response modifiers
preferentially enhance a cell-mediated immune response whereas others entially
enhance a l immune response (z'.e., can stimulate an immune response in which
there is an increased level of cell-mediated compared to humoral immunity, or vice versa.).
Certain biological se modifiers have one or more properties in common with the
biological properties of yeast-based immunotherapeutics or enhance or complement the
biological properties of based immunotherapeutics. There are a number of
techniques known to those skilled in the art to measure stimulation or suppression of
immune responses, as well as to differentiate cell-mediated immune responses from
humoral immune responses, and to differentiate one type of cell-mediated response from
another (e.g, a THl7 response versus a THl response).
Agents/biological response modifiers useful in the invention may include, but
are not limited to, cytokines, chemokines, hormones, c derivatives, peptides, proteins,
polysaccharides, small molecule drugs, antibodies and antigen binding nts thereof
(including, but not limited to, anti-cytokine antibodies, anti—cytokine receptor antibodies,
anti—chemokine antibodies), Vitamins, polynucleotides, nucleic acid binding moieties,
aptamers, and growth modulators. Some suitable agents e, but are not limited to,
IL-1 or agonists of IL—1 or of IL-lR, anti-IL-l or other IL—l antagonists; IL-6 or agonists
of IL-6 or of IL-6R, anti-IL-6 or other IL-6 antagonists; IL-12 or agonists of IL-12 or of
IL-12R, anti-IL-12 or other IL-12 antagonists; IL—17 or agonists of IL-17 or of IL-l7R,
anti-IL-l7 or other IL-l7 antagonists; IL-Zl or agonists of IL-2l or of IL-ZlR, anti-IL-21
or other IL-21 nists; IL-22 or agonists of IL-22 or of IL-22R, anti-IL-22 or other IL-
22 antagonists; IL-23 or agonists of IL—23 or of IL-23R, L-23 or other IL-23
antagonists; IL-25 or agonists of IL-25 or of IL-25R, L-ZS or other IL-25
antagonists; IL—27 or agonists of IL—27 or of IL—27R, anti-IL—27 or other IL-27
antagonists; type I eron (including ) or agonists or antagonists of type I
eron or a receptor thereof; type II interferon (including IFN—y) or agonists or
antagonists of type II interferon or a receptor thereof; anti-CD40, CD40L, lymphocyte-
tion gene 3 (LAG3) protein and/or IMP32l (T-cell immunostimulatory factor
derived from the soluble form of LAG3), TLA-4 dy (e. g., to release anergic T
cells); T cell co-stimulators (e.g., anti-CD137, D28, D40); alemtuzumab (e.g.,
CamPath®), denileukin diftitox (e.g., ONTAK®); anti-CD4; D25; anti-PD-l, anti—
PD-Ll, anti-PD-L2; agents that block FOXP3 (e.g., to abrogate the activity/kill
CD4+/CD25+ T regulatory cells); Flt3 ligand, imiquimod (AldaraTM), granulocyte—
macrophage colony stimulating factor (GM-CSF); granulocyte-colony stimulating factor
(G-CSF), mostim (Leukine®); hormones including without limitation prolactin and
growth hormone; Toll-like receptor (TLR) agonists, including but not limited to TLR-2
agonists, TLR-4 agonists, TLR-7 agonists, and TLR-9 agonists; TLR antagonists,
ing but not limited to TLR-2 antagonists, TLR-4 antagonists, TLR-7 antagonists,
and TLR-9 antagonists; anti-inflammatory agents and immunomodulators, including but
not limited to, COX-2 inhibitors (e.g., Celecoxib, NSAIDS), glucocorticoids, statins, and
thalidomide and analogues f including IMiDTMs (which are structural and functional
analogues of thalidomide (e.g., REVLIMID® (lenalidomide), ACTIMID®
(pomalidomide)); proinflammatory agents, such as fungal or bacterial components or any
proinflammatory cytokine or chemokine; immunotherapeutic vaccines including, but not
limited to, Virus—based vaccines, bacteria—based vaccines, or antibody—based vaccines; and
any other immunomodulators, immunopotentiators, anti-inflammatory agents, pro-
inflammatory agents, and any agents that modulate the number of, modulate the activation
state of, and/or modulate the survival of antigen-presenting cells or of THl7, THl, and/or
Treg cells. Any ation of such agents is plated by the invention, and any of
such agents combined with or administered in a protocol with (e.g., concurrently,
sequentially, or in other s with) a yeast-based therapeutic is a composition
encompassed by the invention. Such agents are well known in the art. These agents may
be used alone or in combination with other agents described herein.
Agents can include agonists and antagonists of a given protein or peptide or
domain thereof. As used , an “agonist” is any compound or agent, including without
limitation small molecules, proteins, peptides, antibodies, nucleic acid binding agents, etc.,
that binds to a or or ligand and produces or triggers a response, which may include
agents that mimic or enhance the action of a naturally occurring substance that binds to the
receptor or ligand. An “antagonist” is any compound or agent, ing t
limitation small molecules, proteins, peptides, antibodies, nucleic acid binding agents, etc.,
that blocks or inhibits or reduces the action of an agonist.
Compositions of the invention can further include or can be administered with
(concurrently, sequentially, or intermittently with) any other agents or compositions or
protocols that are useful for preventing or treating cancer or any compounds that treat or
ameliorate any symptom of cancer, and particularly cancers associated with MUCl
expression or overexpression. In addition, compositions of the invention can be used
together with other therapeutic compositions, including prophylactic and/or
therapeutic immunotherapy. Additional agents, itions or protocols (e.g.,
therapeutic protocols) that are useful for the treatment of cancer e, but are not
limited to, chemotherapy, surgical resection of a tumor, radiation therapy, neic or
gous stem cell transplantation, T cell adoptive transfer, other types of
immunotherapy, including viral vector-based immunotherapy and dendritic umor
fusion immunotherapy, and/or targeted cancer therapies (e.g., small molecule drugs,
biologics, or monoclonal antibody ies that specifically target molecules involved in
tumor growth and progression, including, but not limited to, selective estrogen receptor
modulators (SERMs), aromatase tors, tyrosine kinase inhibitors, serine/threonine
kinase inhibitors, histone deacetylase (HDAC) inhibitors, retinoid receptor activators,
sis stimulators, angiogenesis inhibitors, poly ibose) polymerase (PARP)
inhibitors, or stimulators). Any of these onal therapeutic agents and/or
therapeutic ols may be administered before, concurrently with, ating with, or
after the immunotherapy compositions of the invention, or at different time points. For
example, when given to an individual in conjunction with chemotherapy or a targeted
cancer therapy, it may be ble to administer the yeast-MUCl immunotherapy
compositions during the “holiday” between doses of chemotherapy or ed cancer
therapy, in order to maximize the efficacy of the immunotherapy compositions. Surgical
resection of a tumor may frequently precede administration of a yeast—MUCl
immunotherapy composition, but additional or primary surgery may occur during or after
administration of a yeast-MUCl immunotherapy composition.
] The invention also includes a kit comprising any of the compositions
described herein, or any of the individual components of the compositions described
herein. Kits may include additional reagents and written instructions or directions for
using any of the compositions of the invention to prevent or treat cancer associated with or
characterized by MUCl expression or overexpression.
Methods for Administration or Use 01 Comgositions oi the Invention
Yeast-MUCl immunotherapeutic compositions of the invention are ed
for use to prevent or treat cancers that are associated with or characterized by MUCl
expression or overexpression, including by preventing emergence of such cancers,
arresting progression of such cancers or eliminating such cancers. More particularly,
yeast-MUCl immunotherapeutic compositions can be used to t, inhibit or delay the
development of MUCl-expressing tumors, and/or to prevent, inhibit or delay tumor
migration and/or tumor invasion of other tissues (metastases) and/or to generally t
or inhibit progression of cancer in an individual. Yeast-MUCl immunotherapeutic
compositions can also be used to rate at least one symptom of the cancer, such as by
reducing tumor burden in the individual; inhibiting tumor growth in the individual;
increasing al of the individual; and/or preventing, inhibiting, reversing or delaying
progression of the cancer in the individual.
Cancers that are relevant to the compositions and methods of the invention are
any cancer that expresses, or may express, MUCl, or cancers in ity to cancers that
s or may express MUCl, including cancers of epithelial tissues, and include, but are
not limited to, cancer of the , small intestine, stomach, kidney, bladder, uterus, ovary,
testes, lung, colon, pancreas, prostate, testes, and metastatic cancers thereof. In addition,
MUCl is or may be expressed in hematological cancers, such as lymphomas, leukemias
and myelomas, including, but not limited to, c lymphocytic leukemia (CLL),
le myelogenous lymphoma (MML), acute myeloid leukemia (AML), Epstein-Barr
virus (EBV) transformed B cells, Burkitt’s and Hodgkin’s lymphomas.
In one aspect, MUCl is not detected in the individual’s cancer at the time the
composition is first administered. When MUCl is not ed in the individual’s cancer,
the individual may have an earlier stage cancer in which MUCl expression has not yet
manifested (e.g, stage I or stage II), or in which MUCl expression is not yet detectable in
any event (i.e., MUCl may or may not be expressed at a low level or in a small number of
tumor cells, but is not yet readily detectable using standard ion methods).
Alternatively, the individual may have precancerous lesions or tumors, or may be known
to be posed to developing cancer (e.g., by knowledge of family history, genetic
markers, etc.). In these aspects of the invention, the development of MUCl-expressing
tumor cells is prevented, delayed or inhibited by use of the Yeast-MUCl
therapeutic ition.
In another aspect, MUCl expression is or can be detected in the dual’s
cancer at the time the composition is first administered. The individual may have stage 1,
stage II, stage III, or stage IV cancer in this aspect of the invention. In this aspect, use of
the Yeast-MUCl immunotherapeutic composition reduces, eliminates or slows or arrests
the growth of tumors expressing MUCl, which can result in reduction in tumor burden in
the individual, tion of MUCl-expressing tumor , and/or increased survival of
the individual.
Another embodiment of the invention s to a method to treat cancer, and
particularly, a MUCl-expressing cancer. The method includes administering to an
individual who has a MUCl-expressing cancer a Yeast-MUCl immunotherapeutic
composition described herein, which can include a ition comprising: (a) a yeast
e; and (b) a cancer antigen comprising at least one MUCl antigen. In one aspect,
the method reduces tumor burden in the patient. In one aspect, the method increases
survival of the patient. In one aspect, the method inhibits tumor growth in the individual.
In one aspect, the individual is additionally treated with at least one other
therapeutic compound or therapeutic protocol useful for the treatment of cancer. Such
therapeutic agents and protocols have been sed in detail elsewhere herein. For
example, in any of the embodiments regarding methods of the invention bed herein,
in one aspect, when the dual has cancer (regardless of the status of detectable MUCl
expression in tumor cells) the individual is being d or has been treated with another
therapy for cancer. Such therapy can include any of the therapeutic protocols or use of
any therapeutic compound or agent described previously herein, including, but not limited
to, chemotherapy, radiation therapy, targeted cancer therapy, surgical resection of a tumor,
stem cell transfer, cytokine therapy, adoptive T cell transfer, and/or administration of a
second immunotherapeutic composition. In the case of administration of a second
immunotherapeutic composition, such compositions may include, but are not limited to,
additional yeast-based immunotherapy, recombinant Virus-based immunotherapy (Viral
vectors, e.g., see PCT Publication No. WO/00/34494), cytokine therapy, immunostimulant
therapy (including chemotherapy with immunostimulating properties), DNA vaccines,
dendritic cell/tumor fusion immunotherapy (e.g., see PCT Publication No.
WO/2009/062001), and other therapy itions.
In one , the second immunotherapeutic ition includes a second
cancer antigen that is not a MUCl antigen. For example, a second immunotherapeutic
composition useful in combination with a Yeast-MUCl immunotherapeutic composition is
a immunotherapeutic composition comprising another cancer antigen that is
sed by the same tumor type, or by other tumors the individual to be d has or
may develop. Such cancer antigens include, but are not limited to, any one or more of
carcinoembryonic antigen (CEA), point mutated Ras oncoprotein, Brachyury, EGFR,
BCR—Abl, MART-l, MAGE—l, MAGE-3, GAGE, GP-lOO, MUC—2, normal and point
mutated p53 oncoproteins, PSMA, tyrosinase, TRP-l (gp75), NY-ESO-l, TRP-2, TAG72,
KSA, CA-l25, PSA, HER-2/neu/c-erb/B2, hTERT, p73, B-RAF, adenomatous sis
coli (APC), Myc, von Hippel-Lindau protein (VHL), Rb-l, Rb-2, androgen receptor (AR),
Smad4, MDRl, Flt-3, BRCA-l, BRCA-Z, pax3—fl<hr, ews-fli—l, HERV—H, HERV-K,
TWIST, Mesothelin, NGEP, modifications of such antigens, splice variants of such
ns, and epitope agonists of such ns, as well as combinations of such antigens,
and/or immunogenic domains thereof, modifications f, variants thereof, and/or
epitope agonists thereof.
As used herein, to “treat” a cancer, or any permutation thereof (e.g, “treated
for cancer”, etc.) generally refers to administering a composition of the invention once the
cancer has occurred (e.g., once the cancer has been sed or detected in an individual),
with at least one therapeutic goal of the ent (as compared to in the absence of this
treatment) including: reduction in tumor burden; inhibition of tumor ; se in
al of the individual; delaying, inhibiting, arresting or preventing the onset or
development of metastatic cancer (such as by delaying, inhibiting, arresting or preventing
the onset of development of tumor migration and/or tumor invasion of tissues outside of
primary cancer and/or other processes associated with metastatic progression of cancer);
delaying or arresting primary cancer progression; improvement of immune responses
against the tumor; improvement of long term memory immune responses t the
tumor antigens,; and/or improved l health of the individual. To “prevent” or
“protect” from a cancer, or any permutation thereof (e.g., “prevention of cancer”, etc.),
generally refers to administering a composition of the invention before a cancer has
occurred, when pre-cancerous cells are detected, or before a specific stage of cancer or
tumor n expression in a cancer has occurred (e.g, before MUCl expression is
detected in the cancer), with at least one goal of the treatment (as compared to in the
absence of this treatment) including: preventing or ng the onset or development of a
cancer, or, should the cancer occur after the treatment, at least reducing the severity of the
cancer (e.g., reducing the level of tumor growth, arresting cancer progression, improving
the immune response against the cancer, ting metastatic processes, etc.) or
improving outcomes in the individual (e.g., improving survival).
[00142] The present invention es the delivery (administration, zation,
vaccination) of a Yeast-MUCl immunotherapeutic composition of the invention to a
subject or dual. The administration process can be performed ex viva or in viva, but
is typically performed in viva. Ex viva administration refers to ming part of the
regulatory step outside of the patient, such as administering a composition of the present
invention to a population of cells (dendritic cells) removed from a patient under conditions
such that a yeast vehicle, antigen(s) and any other agents or compositions are loaded into
the cell, and returning the cells to the patient. The eutic composition of the present
invention can then be returned to a patient, or administered to a patient, by any suitable
mode of administration.
[00143] stration of a composition can be systemic, mucosal and/or proximal to
the location of the target site (e.g, near a site of a tumor). Suitable routes of
administration will be apparent to those of skill in the art, depending on the type of cancer
to be prevented or treated and/or the target cell population or tissue. Various acceptable
methods of administration include, but are not limited to, intravenous administration,
intraperitoneal administration, intramuscular administration, intranodal administration,
oronary stration, intraarterial administration (e. g., into a carotid ),
subcutaneous administration, transdermal delivery, intratracheal administration,
intraarticular administration, intraventricular administration, inhalation (e.g., aerosol),
intracranial, intraspinal, intraocular, aural, intranasal, oral, pulmonary administration,
impregnation of a catheter, and direct injection into a . In one aspect, routes of
administration e: intravenous, intraperitoneal, subcutaneous, intradermal, intranodal,
intramuscular, transdermal, inhaled, intranasal, oral, intraocular, intraarticular, intracranial,
and intraspinal. eral delivery can e intradermal, intramuscular, eritoneal,
intrapleural, intrapulmonary, intravenous, subcutaneous, atrial catheter and venal catheter
routes. Aural delivery can include ear drops, intranasal delivery can include nose drops or
intranasal injection, and intraocular delivery can include eye drops. Aerosol (inhalation)
delivery can also be med using methods standard in the art (see, for example,
Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992). In one aspect, a
MUCl immunotherapeutic composition of the invention is administered
subcutaneously. In one aspect, the Yeast-MUCl immunotherapeutic composition is
administered directly into a tumor milieu.
In general, a le single dose of a Yeast-MUCl immunotherapeutic
composition is a dose that is e of effectively providing a yeast vehicle and the
MUCl antigen to a given cell type, tissue, or region of the patient body in an amount
effective to elicit an antigen-specific immune response against one or more MUCl
antigens or epitopes, when administered one or more times over a suitable time period.
For example, in one embodiment, a single dose of a Yeast—MUCI of the present invention
is from about I x 105 to about 5 x 107 yeast cell equivalents per kilogram body weight of
the organism being administered the composition. One Yeast Unit (Y.U.) is l x 107 yeast
cells or yeast cell equivalents. In one aspect, a single dose of a yeast vehicle of the present
invention is from about 0.1 Y.U. (1 x 106 yeast cells or yeast cell equivalents) to about 100
Y.U. (l x 109 cells) per dose (i.e., per organism), including any m dose, in ents
of 0.1 x 106 cells (i.e., 1.1 x 106, 1.2 x 106, 1.3 x 106...). In one embodiment, a suitable
dose includes doses between 1 Y.U. and 40 Y.U. and in one aspect, between 10 Y.U. and
40 Y.U. or between 10 Y.U. and 80 Y.U. In one embodiment, the doses are administered
at different sites on the individual but during the same dosing period. For example, a 40
Y.U. dose may be stered by injecting 10 Y.U. doses to four different sites on the
individual during one dosing . The invention includes administration of an amount
of the Yeast-MUCl immunotherapy composition (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 10, 11, 12,
13, 14,15, 16,17, 18,19, 20 Y.U. or more) at 1, 2, 3, 4, 5, 6, 7, 8, 9,10, or more different
sites on an individual to form a single dose.
"Boosters" or "boosts" of a therapeutic composition are administered, for
example, when the immune response against the antigen has waned or as needed to
provide an immune response or induce a memory response against a particular antigen or
antigen(s). Boosters can be administered about 1, 2, 3, 4, 5, 6, 7, or 8 weeks apart, or
monthly, bimonthly, quarterly, annually, and/or in a few or several year increments after
the original administration, ing on the status of the individual being treated and the
goal of the therapy at the time of stration (e.g, prophylactic, active treatment,
maintenance). In one embodiment, an administration schedule is one in which doses of
Yeast-MUCl immunotherapeutic composition is stered at least 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, or more times over a time period of from weeks, to , to years. In one
embodiment, the doses are administered weekly or biweekly for l, 2, 3, 4, 5, 6, 7, 8, 9, 10
or more doses, followed by biweekly or monthly doses as needed to e the desired
preventative or therapeutic treatment for cancer. Additional boosters can then be given at
similar or longer intervals (months or years) as a maintenance or ion therapy, if
desired.
In one aspect of the invention, one or more additional therapeutic agents or
therapeutic protocols are administered or med sequentially and/or concurrently with
the administration of the Yeast-MUCl immunotherapy composition, e.g., surgical
resection of the tumor, administration of chemotherapy, administration of radiation
therapy, administration of another immunotherapy composition or ol including viral
vector therapy and dendritic cell/tumor fusion therapy, cytokine therapy, adoptive T cell
transfer (including adoptive transfer of T cells that have been stimulated ex vivo by an
antigen and/or immunotherapy composition), or stem cell transplantation. In one example,
yeast-MUCl immunotherapy is administered in conjunction with a y utilizing viral
vector-based immunotherapy, such as that described in PCT Publication No.
WO/00/34494. In another example, yeast-MUCl therapy is administered in
conjunction with dendritic cell/tumor cell fiasion therapy or immune system cells (e.g., T
cells) ated with such dendritic cell/tumor cell fusions, such as that described in PCT
Publication No. WO/2009062001. In such embodiments, the non-yeast-based
immunotherapy may target the MUCl or a different tumor antigen, and such therapies
may include the additional administration of other agents, such as cytokines, antibodies, or
other agents.
In one aspect, one or more therapies for cancer ding any therapies
described herein or otherwise known in the art) can be administered or performed prior to
the first dose of Yeast—MUCI immunotherapy ition or after the first dose is
stered. In one embodiment, one or more therapies can be administered or
performed in an alternating manner with the dosing of Yeast-MUCl immunotherapy
composition, such as in a ol in which the Yeast-MUCl composition is stered
at prescribed intervals in between one or more consecutive doses of chemotherapy or other
therapy. In one embodiment, the Yeast-MUCl immunotherapy composition is
stered in one or more doses over a period of time prior to commencing additional
therapies. In other words, the Yeast—MUCl immunotherapeutic composition is
administered as a monotherapy for a period of time, and then an additional therapy is
added (e.g, herapy), either concurrently with new doses of Yeast-MUCl
immunotherapy, or in an alternating fashion with Yeast-MUCl immunotherapy.
Alternatively or in addition, another therapy may be administered for a period of time
prior to beginning administration of the Yeast-MUCl immunotherapy ition, and
the concepts may be combined (e.g., surgical resection of a tumor, followed by
monotherapy with Yeast-MUCl immunotherapy for several weeks, followed by
alternating doses of chemotherapy and Yeast—MUCl immunotherapy for weeks or months,
optionally followed by monotherapy using Yeast-MUCl immunotherapy and/or another
therapy, or by a new protocol of ations of therapy provided tially,
concurrently, or in alternating fashion). Various ols for the treatment of cancer
using Yeast-MUCl immunotherapy are contemplated by the invention, and these
examples should be considered to be non—limiting examples of various le protocols.
A virus-based immunotherapy composition typically comprises a viral vector
comprising a virus genome or portions thereof (e.g, a recombinant virus) and a nucleic
acid ce encoding at least one antigen(s) from a disease causing agent or disease
state (e.g, a cancer antigen(s), infectious disease antigen(s), and/or at least one
immunogenic domain thereof). In some ments, a virus-based immunotherapy
composition further es at least one viral vector comprising one or more nucleic acid
sequences encoding one or more immunostimulatory molecule(s). In some embodiments,
the genes encoding immunostimulatory molecules and antigens are inserted into the same
Viral vector (the same recombinant Virus).
Dendritic cell/tumor cell fusion immunotherapy compositions typically are
hybrid cells generated by the fusion between dendritic cells and non-dendritic cells that
express tumor antigens, including tumor cells, using fusion methods that are known in the
art. The fused cells have dendritic cell characteristics and also express and t tumor
ns from the tumor cell. The compositions may be administered to an individual, or
used to stimulate T cells ex viva for T cell transfer methods.
In one aspect of the invention, onal antigens other than MUCl are also
targeted using based immunotherapy, in on to targeting MUCl. Such
additional target antigens can be included within the same yeast—vehicle as the MUCl
antigens, or additional yeast-based immunotherapy compositions targeting different
antigens can be produced and then combined as desired depending on the individual to be
treated, the antigens expressed by the type of cancer or by the individual’s particular tumor,
and/or ing on the stage of cancer in the individual, or the stage of treatment of the
individual. For es a combination of antigens may be selected that cover: (1)
antigens involved in seminal events in cancer development, such as mutated Ras, (2)
antigens involved in or associated with dysregulation of cellular processes, such as CEA
or MUCl, and (3) Brachyury, which is involved in metastatic processes. For example,
one or more other yeast-based immunotherapy compositions may express one or more
antigens including, but not d to, carcinoembryonic antigen (CEA), point mutated Ras
oncoprotein, Brachyury, EGFR, BCR-Abl, , MAGE—l, MAGE-3, GAGE, GP—
100, MUC—2, normal and point d p53 oncoproteins, PSMA, tyrosinase, TRP-l
(gp75), NY—ESO-l, TRP-2, TAG72, KSA, CA-125, PSA, HER—2/neu/c—erb/B2, hTERT,
p73, B—RAF, adenomatous polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL),
Rb-l, Rb-2, androgen receptor (AR), Smad4, MDRl, Flt-3, BRCA-l, BRCA-2, pax3-fl<hr,
ews—fli-l, HERV—H, HERV-K, TWIST, Mesothelin, NGEP, modifications of such
antigens, splice variants of such antigens, and epitope agonists of such antigens, as well as
combinations of such antigens, and/or immunogenic domains thereof, modifications
thereof, variants thereof, and/0r epitope ts thereof. One, two, three, or more of these
yeast-based immunotherapy compositions may be administered to an individual prior to,
concurrently or alternating with, and/or after administration of a Yeast-MUCI
immunotherapy ition, in order to optimize targeting of ns in the individual’s
tumor. As above, additional therapies can also be used in such protocols (e.g., surgical
resection of tumor, chemotherapy, targeted cancer therapy, ion therapy, etc.).
In one embodiment of the invention, a method to treat cancer is provided. The
method includes the steps of: (a) administering to an individual who has cancer or pre—
cancerous tumor, a first immunotherapeutic composition comprising a yeast vehicle and a
MUCl antigen as described herein; and (b) administering to the individual, prior to,
concurrently with, or subsequent to, administration of the first immunotherapeutic
composition one or more additional immunotherapeutic compositions, each comprising a
yeast vehicle and each comprising a different cancer antigen that is not a MUC1 antigen.
The additional cancer antigen can be any of those known in the art or described herein,
including, but not limited to, mutated Ras, carcinoembryonic antigen (CEA), ury,
EGFR, etc. Steps may be repeated as needed to treat a particular individual’s cancer, and
the cancer antigens can be modified before or during treatment to specifically address the
particular individual’s cancer.
In the method of the present ion, compositions and therapeutic
compositions can be administered to any animal, including any vertebrate, and particularly
to any member of the Vertebrate class, Mammalia, including, without limitation, primates,
rodents, livestock and domestic pets. Livestock include mammals to be ed or that
e useful products (e.g., sheep for wool production). Mammals to treat or protect
utilizing the invention e humans, non-human primates, dogs, cats, mice, rats, goats,
sheep, cattle, horses and pigs.
[00153] An “individual” is a vertebrate, such as a mammal, ing without
limitation a human. Mammals e, but are not limited to, farm animals, sport animals,
pets, primates, mice and rats. The term “individual” can be used hangeably with the
term “animal”, ct” or nt”.
General Techniques Useful in the Invention
[00154] The practice of the present ion will employ, unless otherwise indicated,
conventional techniques of molecular biology (including recombinant techniques),
microbiology, cell biology, biochemistry, nucleic acid chemistry, and immunology, which
are well known to those skilled in the art. Such techniques are explained fully in the
literature, such as, s of Enzymology, Vol. 194, Guthrie et al., eds., Cold Spring
Harbor Laboratory Press (1990); Biology and activities of yeasts, Skinner, et al., eds.,
Academic Press (1980); Methods in yeast genetics : a laboratog course manual, Rose et
al., Cold Spring Harbor Laboratory Press (1990); The Yeast Saccharomyces: Cell Cycle
and Cell Biology, Pringle et al., eds., Cold Spring Harbor Laboratory Press (1997); T_he
Yeast romyces: Gene Expression, Jones et al., eds., Cold Spring Harbor Laboratory
Press (1993); The Yeast Saccharomyces: Genome Dflamics, Protein Synthesis, and
tics, Broach et al., eds., Cold Spring Harbor Laboratory Press (1992); Molecular
Cloning: A togy Manual, second edition (Sambrook et al., 1989) and lar
Cloning: A Laboratog Manual, third edition (Sambrook and Russel, 2001), (jointly
referred to herein as “Sambrook”); Current Protocols in Molecular y (F.M. Ausubel
et al., eds., 1987, including supplements through 2001); PCR: The Polymerase Chain
Reaction, (Mullis et al., eds., 1994); Harlow and Lane (1988), Antibodies, A Laboratog
Manual, Cold Spring Harbor Publications, New York; Harlow and Lane (1999) M
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY (jointly referred to herein as “Harlow and , Beaucage et al. eds.,
Current Protocols in Nucleic Acid Chemistry, John Wiley & Sons, Inc., New York, 2000);
Casarett and Doull’s Toxicology The Basic Science of Poisons, C. Klaassen, ed., 6th
edition (2001), and Vaccines, S. Plotkin, W. Orenstein, and P. Offit, eds., Fifth Edition
(2008).
General Definitions
A “TARMOGEN®” (GlobeImmune, Inc., ille, Colorado) generally
refers to a yeast vehicle expressing one or more heterologous antigens ellularly (on
its surface), intracellularly (internally or cytosolically) or both extracellularly and
intracellularly. TARMOGEN®s have been generally described (see, e.g, US. Patent No.
5,830,463). Certain yeast-based immunotherapy compositions, and methods of making
and generally using the same, are also described in detail, for example, in US. Patent No.
,830,463, US. Patent No. 7,083,787, US. Patent No. 642, Stubbs et al., Nat. Med.
7:625-629 (2001), Lu et al., Cancer Research 64:5084—5088 (2004), and in Bernstein et al.,
Vaccine 2008 Jan 24;26(4):509-21, each of which is incorporated herein by reference in its
entirety.
As used herein, the term "analog" refers to a chemical compound that is
structurally similar to another nd but differs slightly in composition (as in the
replacement of one atom by an atom of a different element or in the presence of a
particular functional group, or the ement of one functional group by another
onal . Thus, an analog is a compound that is similar or comparable in function
and appearance, but has a different structure or origin with respect to the reference
compound.
The terms "substituted", "substituted derivative" and "derivative", when used
to describe a compound, means that at least one hydrogen bound to the unsubstituted
compound is replaced with a different atom or a chemical moiety.
Although a derivative has a similar physical structure to the parent nd,
the derivative may have ent chemical and/or biological properties than the parent
compound. Such properties can include, but are not d to, sed or decreased
activity of the parent compound, new activity as compared to the parent compound,
enhanced or decreased bioavailability, enhanced or decreased efficacy, enhanced or
sed stability in vitro and/or in viva, and/or enhanced or decreased absorption
properties.
In general, the term gically active" indicates that a compound (including
a protein or peptide) has at least one detectable activity that has an effect on the metabolic,
physiological, chemical, or other processes of a cell, a tissue, or an organism, as measured
or observed in viva (i.e., in a natural logical nment) or in vitro (2'.e., under
tory conditions).
] According to the present invention, the term “modulate” can be used
hangeably with “regulate” and refers generally to upregulation or downregulation of
a particular activity. As used herein, the term “upregulate” can be used generally to
describe any of: elicitation, initiation, increasing, augmenting, boosting, improving,
enhancing, amplifying, promoting, or providing, with respect to a particular activity.
Similarly, the term “downregulate” can be used generally to describe any of: decreasing,
reducing, inhibiting, ameliorating, diminishing, lessening, blocking, or preventing, with
respect to a ular activity.
In one embodiment of the present invention, any of the amino acid sequences
described herein can be produced with from at least one, and up to about 20, additional
heterologous amino acids flanking each of the C- and/or N—terminal ends of the ed
amino acid sequence. The resulting protein or polypeptide can be referred to as
"consisting essentially of‘ the specified amino acid ce. According to the present
invention, the heterologous amino acids are a sequence of amino acids that are not
naturally found (z'.e., not found in nature, in vivo) flanking the specified amino acid
sequence, or that are not related to the function of the specified amino acid sequence, or
that would not be encoded by the nucleotides that flank the naturally occurring nucleic
acid sequence ng the specified amino acid ce as it occurs in the gene, if such
nucleotides in the naturally occurring sequence were translated using standard codon
usage for the organism from which the given amino acid sequence is derived. rly,
the phrase "consisting essentially of', when used with reference to a nucleic acid sequence
herein, refers to a nucleic acid sequence encoding a specified amino acid sequence that can
be flanked by from at least one, and up to as many as about 60, additional logous
tides at each of the 5' and/or the 3' end of the nucleic acid sequence encoding the
specified amino acid sequence. The heterologous nucleotides are not naturally found (i.e.,
not found in nature, in viva) flanking the nucleic acid sequence encoding the specified
amino acid sequence as it occurs in the natural gene or do not encode a protein that
imparts any additional function to the protein or changes the function of the protein having
the specified amino acid sequence.
According to the t invention, the phrase "selectively binds to" refers to
the y of an antibody, antigen-binding nt or binding partner of the present
ion to preferentially bind to specified proteins. More specifically, the phrase
tively binds" refers to the specific binding of one protein to another (e.g., an
antibody, fragment thereof, or binding partner to an antigen), wherein the level of g,
as measured by any standard assay (e.g., an immunoassay), is statistically significantly
higher than the background control for the assay. For example, when performing an
immunoassay, controls typically include a reaction well/tube that contain antibody or
antigen binding fragment alone (i.e., in the absence of antigen), wherein an amount of
reactivity (e.g., non-specific binding to the well) by the antibody or antigen-binding
fragment thereof in the absence of the antigen is ered to be background. Binding
can be measured using a variety of methods standard in the art including enzyme
immunoassays (e.g., ELISA, immunoblot assays, etc.).
General nce to a protein or polypeptide used in the present invention
es full-length proteins, or any fragment, domain (structural, functional, or
immunogenic), mational epitope, or a gue or variant of a given protein. A
fusion protein may also be generally referred to as a protein or polypeptide. An isolated
protein, according to the present invention, is a protein (including a polypeptide or
peptide) that has been removed from its l milieu (z'.e., that has been subject to human
manipulation) and can include purified proteins, partially purified proteins, recombinantly
produced proteins, and synthetically produced ns, for example. As such, ted"
does not reflect the extent to which the protein has been purified. Preferably, an isolated
protein of the present invention is produced recombinantly. According to the present
invention, the terms "modification" and mutation" can be used interchangeably,
particularly with regard to the modifications/mutations to the amino acid sequence of
proteins or ns thereof (or nucleic acid sequences) described herein.
As used herein, the term ogue" or nt” is used to refer to a protein
or peptide which differs from a reference n or peptide (i.e., the "prototype" or "wild-
type" protein) by minor modifications to the reference protein or peptide, but which
maintains the basic protein and side chain structure of the naturally occurring form. Such
changes include, but are not limited to: changes in one or a few amino acid side chains;
changes one or a few amino acids, including deletions (e.g., a truncated version of the
protein or peptide) insertions and/or tutions; changes in stereochemistry of one or a
few atoms; and/or minor tizations, including but not limited to: methylation,
glycosylation, phosphorylation, acetylation, myristoylation, prenylation, ation,
amidation and/or addition of glycosylphosphatidyl inositol. A homologue or variant can
have enhanced, sed, or substantially similar properties as compared to the reference
protein or peptide. A homologue or t can include an agonist of a protein or an
antagonist of a protein. Homologues or variants can be produced using techniques known
in the art for the production of proteins including, but not limited to, direct modifications
to the isolated reference protein, direct protein synthesis, or modifications to the nucleic
acid sequence encoding the protein using, for example, classic or inant DNA
techniques to effect random or targeted mutagenesis, resulting in the encoding of a protein
variant. In addition, naturally occurring variants of a reference protein may exist (e.g.,
isoforms, allelic variants, or other natural variants that may occur from individual to
individual) and may be isolated, ed and/or utilized in the invention.
A homologue or variant of a given n may comprise, consist essentially
of, or consist of, an amino acid ce that is at least about 45%, or at least about 50%,
or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%,
or at least about 75%, or at least about 80%, or at least about 85%, or at least about 86%
identical, or at least about 87% identical, or at least about 88% identical, or at least about
89% identical, or at least about 90%, or at least about 91% cal, or at least about 92%
cal, or at least about 93% identical, or at least about 94% cal, or at least about
95% identical, or at least about 96% identical, or at least about 97% identical, or at least
about 98% identical, or at least about 99% identical (or any percent identity between 45%
and 99%, in whole integer increments), to the amino acid sequence of the reference
protein (e.g, an amino acid sequence specified herein, or the amino acid sequence of a
specified protein). In one embodiment, the homologue or variant comprises, consists
ially of, or consists of, an amino acid sequence that is less than 100% identical, less
than about 99% identical, less than about 98% identical, less than about 97% identical, less
than about 96% identical, less than about 95% identical, and so on, in increments of l%, to
less than about 70% identical to the amino acid sequence of the reference protein.
As used herein, unless otherwise specified, reference to a t (%) ty
refers to an evaluation of homology which is med using: (1) a Basic Local
Alignment Search Tool ) basic homology search using blastp for amino acid
searches and blastn for nucleic acid es with standard default parameters, n the
query sequence is filtered for low complexity regions by default (such as bed in
Altschul, S.F., Madden, T.L., Schaaffer, A.A., Zhang, J., Zhang, Z., Miller, W. & Lipman,
DJ. (1997) "Gapped BLAST and PSI—BLAST: a new generation of protein database
search programs." c Acids Res. 25:3389-3402, incorporated herein by reference in
its entirety); (2) a BLAST alignment of two sequences (e.g., using the parameters
described below); (3) and/or PSI-BLAST with the rd default parameters (Position-
Specific ed BLAST. It is noted that due to some differences in the standard
parameters between Basic BLAST and BLAST for two sequences, two specific sequences
might be recognized as having significant homology using the BLAST program, whereas a
search performed in Basic BLAST using one of the sequences as the query sequence may
not identify the second sequence in the top matches. In addition, PSI-BLAST provides an
automated, o-use version of a "profile" search, which is a sensitive way to look for
sequence homologues. The m first performs a gapped BLAST database search. The
PSI—BLAST program uses the information from any significant alignments returned to
construct a position-specific score matrix, which replaces the query sequence for the next
round of database searching. Therefore, it is to be understood that percent identity can be
determined by using any one of these programs.
Two specific sequences can be aligned to one another using BLAST as
described in Tatusova and Madden, (1999), "Blast 2 sequences - a new tool for comparing
protein and nucleotide sequences", FEMS Microbiol Lett. 174:247-250, incorporated
herein by reference in its entirety. Such a sequence ent is performed in blastp or
blastn using the BLAST 2.0 algorithm to perform a Gapped BLAST search (BLAST 2.0)
between the two sequences allowing for the introduction of gaps (deletions and insertions)
in the ing alignment. For purposes of clarity herein, a BLAST sequence alignment
for two sequences is med using the standard default parameters as follows.
For blastn, using 0 BLOSUM62 matrix:
Reward for match = 1
Penalty for mismatch = -2
Open gap (5) and extension gap (2) penalties
gap x_dropoff (50) expect (10) word size (11) filter (on)
For blastp, using 0 BLOSUM62 matrix:
Open gap (11) and extension gap (1) penalties
gap x_dropoff (50)m (10) word size (3) filter (on).
[00168] An isolated nucleic acid molecule is a nucleic acid molecule that has been
removed from its natural milieu (z'.e., that has been subject to human manipulation), its
natural milieu being the genome or chromosome in which the nucleic acid molecule is
found in nature. As such, "isolated" does not necessarily reflect the extent to which the
nucleic acid molecule has been purified, but indicates that the molecule does not include
an entire genome or an entire chromosome or a segment of the genome containing more
than one gene, in which the c acid molecule is found in nature. An isolated nucleic
acid molecule can include a complete gene. An isolated nucleic acid molecule that
includes a gene is not a nt of a chromosome that es such gene, but rather
includes the coding region and regulatory regions ated with the gene, but no
additional genes that are naturally found on the same chromosome. An isolated nucleic
acid molecule may also include portions of a gene. An isolated nucleic acid molecule can
also include a specified nucleic acid sequence flanked by (z'.e., at the 5' and/or the 3' end of
the ce) additional nucleic acids that do not ly flank the ed nucleic acid
sequence in nature (i.e., logous sequences). ed nucleic acid le can
include DNA, RNA (e. g., mRNA), or derivatives of either DNA or RNA (e. g., cDNA).
Although the phrase "nucleic acid molecule" primarily refers to the al nucleic acid
molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of
nucleotides on the nucleic acid molecule, the two phrases can be used hangeably,
especially with respect to a nucleic acid le, or a nucleic acid sequence, being
capable of encoding a protein or domain of a protein.
A recombinant nucleic acid molecule is a molecule that can include at least
one of any nucleic acid sequence encoding any one or more proteins described herein
ively linked to at least one of any transcription control sequence capable of
effectively regulating expression of the nucleic acid molecule(s) in the cell to be
transfected. Although the phrase "nucleic acid molecule" primarily refers to the physical
nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the
sequence of nucleotides on the nucleic acid molecule, the two phrases can be used
interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid
sequence, being capable of encoding a protein. In on, the phrase "recombinant
molecule" primarily refers to a nucleic acid molecule operatively linked to a ription
l sequence, but can be used interchangeably with the phrase "nucleic acid molecule"
which is administered to an animal.
A inant nucleic acid molecule includes a recombinant vector, which is
any nucleic acid sequence, typically a heterologous sequence, which is operatively linked
to the isolated nucleic acid molecule ng a fusion protein of the present invention,
which is capable of enabling recombinant production of the fusion protein, and which is
capable of ring the nucleic acid molecule into a host cell according to the present
invention. Such a vector can contain nucleic acid sequences that are not naturally found
adjacent to the isolated nucleic acid molecules to be inserted into the vector. The vector
can be either RNA or DNA, either yotic or eukaryotic, and preferably in the present
invention, is a plasmid useful for transfecting yeast. Recombinant vectors can be used in
the cloning, sequencing, and/or otherwise manipulating of c acid molecules, and can
be used in delivery of such molecules (e.g., as in a DNA composition or a viral vector—
based composition). Recombinant vectors are preferably used in the expression of nucleic
acid molecules, and can also be referred to as expression vectors. Preferred recombinant
vectors are capable of being expressed in a transfected host cell, such as a yeast.
] In a recombinant molecule of the present invention, nucleic acid molecules are
operatively linked to expression vectors containing regulatory sequences such as
ription l sequences, translation control sequences, origins of replication, and
other regulatory sequences that are compatible with the host cell and that control the
expression of nucleic acid molecules of the present ion. In particular, recombinant
molecules of the present invention include c acid molecules that are operatively
linked to one or more expression control sequences. The phrase "operatively linked"
refers to g a nucleic acid molecule to an expression control sequence in a manner
such that the le is expressed when transfected (i.e., transformed, transduced or
transfected) into a host cell.
[00172] According to the present invention, the term fection” is used to refer to
any method by which an exogenous nucleic acid molecule (i.e., a recombinant nucleic acid
molecule) can be inserted into a cell. The term "transformation" can be used
interchangeably with the term "transfection" when such term is used to refer to the
introduction of nucleic acid molecules into microbial cells, such as algae, bacteria and
yeast. In microbial s, the term "transformation" is used to describe an inherited
change due to the ition of exogenous nucleic acids by the microorganism and is
essentially synonymous with the term "transfection. H Therefore, transfection techniques
include, but are not limited to, ormation, chemical treatment of cells, particle
dment, electroporation, microinjection, lipofection, adsorption, infection and
protoplast fusion.
The following experimental results are provided for purposes of illustration
and are not intended to limit the scope of the invention.
EXAMPLES
Example 1
The following example describes the production of a Yeast-MUCl
immunotherapeutic composition known as GI—6lOl.
In this ment, yeast (Saccharomyces cerevisiae) were engineered to
express a human MUCl n under the control of the copper-inducible promoter,
CUP], or the constitutive er, TEF2, producing yeast-MUCl immunotherapy
compositions. In each case, a fusion protein comprising a MUCl antigen was produced as
a single polypeptide with the following sequence elements fused in frame from N— to C-
terminus, represented by SEQ ID NO:15: (1) a MUCl SEA/ED segment (positions 1-59
of SEQ ID NO:15); (2) a VNTR segment comprising two VNTR domains (positions 60-
100 of SEQ ID NO:15); (3) a MUCl TM domain (positions 101—128 of SEQ ID NO:15);
and (4) a MUCl CD (positions 129-200 of SEQ ID NO:15). This fusion protein further
included a MUCl signal sequence ions l-30 of SEQ ID NO:14) that could be
tuted with a different inal sequence designed to impart resistance to
proteasomal degradation and/or stabilize expression, such as the peptide represented by
SEQ ID NO:21, or an N-terminal peptide from a yeast alpha leader sequence such as SEQ
ID NO:19 or SEQ ID NO:20. The complete fusion protein including the N-terminal
MUCl signal sequence and a hexahistidine C-terminal tag to facilitate identification
and/or purification of the protein is a single polypeptide with the following sequence
elements fused in frame from N— to C-terminus, represented by SEQ ID NO:14: (l)
MUCl signal sequence (positions l—30 of SEQ ID NO:14); (2) a MUCl SEA/ED segment
(positions 31-89 of SEQ ID NO:14); (3) a VNTR segment comprising two VNTR
domains (positions 90-130 of SEQ ID ; (4) a MUCl TM domain (positions 131-
158 of SEQ ID ; (5) a MUCl CD (positions 159-230 of SEQ ID NO:14); and (6) a
hexapeptide histidine tag (positions 231—236 of SEQ ID NO:14). SEQ ID NO:14 is
encoded by the nucleotide sequence represented by SEQ ID NO:13 (codon optimized for
yeast expression).
Briefly, DNA encoding the MUCl antigens were synthesized, and then
inserted at EcoRI and Not] g sites behind the CUP] promoter (vector pGI-100) or
the TEF2 promoter (vector plu011) in yeast 2 um expression vectors. Nucleotide
sequences ng a C-terminal hexahistidine peptide were added to the plasmid vector
to encode the complete fusion protein ented by SEQ ID NO:14. The resulting
plasmids were transformed into DHSa for d storage, and into Saccharomyces
cerevisiae W3030t for production of the yeast-MUCl immunotherapeutic compositions.
[00177] ormation into Saccharomyces cerevisiae was performed by lithium
acetate/polyethylene glycol transfection, and primary ectants were selected on solid
minimal plates lacking Uracil (UDM; uridine dropout medium). es were selected
by growing in U2 ne dropout medium) or UL2 (uridine and leucine dropout medium)
medium at 30° C.
[00178] The yeast-MUCl immunotherapy composition comprising a polynucleotide
encoding the human MUCl fusion protein represented by SEQ ID NO:14 under the
control of the TEF2 promoter is also referred to herein as GI-6101.
Liquid cultures lacking uridine (U2) or lacking uridine and leucine (UL2)
were inoculated using the plates and r cultures described above, and were grown for
about 24h at 30°C, 250 rpm. pH buffered UL2 medium containing 4.2g/L of is
(BT-UL2) was also inoculated from frozen yeast banks to evaluate yeast-MUCl
immunotherapeutics produced under neutral pH manufacturing conditions (data not
shown). Culturing in pH buffered UL2 medium exposes B-glucans on the yeast cell wall
and is believed to modify the cellular immune responses d by the yeast as a result of
modifying the interactions with dectin receptors on antigen presenting cells. The
remaining culture conditions were the same whether U2, UL2 or BT-UL2 was used.
Primary cultures were used to inoculate final cultures of the same formulation.
Recipe for U2 liguid media:
15g/L of glucose
6.7 g/L of Yeast nitrogen base ning ammonium sulfate
0.04 g/L each of histidine, tryptophan, adenine and 0.06 g/L of leucine
Recipe for UL2 liguid media:
15g/L of e
6.7 g/L of Yeast nitrogen base containing ammonium sulfate
0.04 g/L each of histidine, tryptophan, and adenine
In initial experiments comparing yeast-MUCl immunotherapeutic
compositions under the control of different promoters, CUPI-driven (inducible
expression) yeast-MUCl sion was produced in a 2-step or 3-step culture; after
starter or intermediate culture reaches mid-log (1.5-4 Y.U./ml), the expression was
initiated by the addition of 0.375 mM copper e to final the culture diluted to 0.1 or
0.2 Y.U./mL from intermediate culture and was ued until the culture d a
density of 1.5-3 Y.U. TEFZ-driven yeast- MUCl sion is constitutive, and growth of
these cells was continued until the cultures reached a y of between 1.1 to 4.0
l. The cells from each culture were then harvested, washed and heat-killed at 56°C
for 1 hour in PBS.
After heat-kill of the cultures, the cells were washed three times in PBS. Total
protein expression was ed by a TCA precipitation/nitrocellulose binding assay and
by Western blot using an anti-his tag monoclonal antibody and an anti-MUCl (VNTR)
antibody (SC-7313, Santa Cruz). Protein content was quantified using semi-quantitative
digital g methods. GI-6101 was expected to express the MUCl fusion protein as a
membrane associated protein of about 25 kDa.
] Fig. 2A shows expression of the MUCl antigen in GI-6101 using anti-MUCl
(VNTR) and anti-His antibodies for detection. These s showed good expression of
the MUCl protein. Fig. 2B shows the MUCl antigen of GI-6101 after deglycosylation
with either EdoH or PNGaseF. This figure shows that the l fusion protein is
expressed as a glycosylated product, since the size of the fusion protein is larger than
estimated prior to deglycosylation, but reduces to the expected size (25 kDa) after
deglycosylation by EdoH or PNGaseF.
[00183] Quantification of antigen expression in GI-6lOl that was grown under
standard culture conditions was compared to GI-6101 grown under neutral pH conditions,
as described above. The levels of antigen expression were approximately the same using
either process (data not shown), demonstrating that the neutral pH process does not alter
the level of MUCl antigen sion by the yeast.
e 2
The following example described the production of a yeast-MUCl
immunotherapeutic composition known as GI—6lO4.
In this experiment, yeast (Saccharomyces cerevisiae) were engineered to
express a human MUCl antigen under the l of the copper-inducible promoter,
CUP], or the constitutive promoter, TEF2, ing yeast-MUCl immunotherapy
compositions. In each case, a fusion protein comprising a MUCl antigen was produced as
a single polypeptide with the following sequence elements fused in frame from N- to C-
us, represented by SEQ ID NO:18: SEQ ID NO:18 includes the following MUCl
antigens, in the following order from N- to C—terminus: (1) a first MUCl CD (positions 1—
72 of SEQ ID NO:18); (2) a second MUCl CD (positions 73-144 of SEQ ID NO:18); and
(3) a third MUCl CD (positions 6 of SEQ ID NO:18). This fusion protein further
included an N-terminal sequence designed to impart resistance to proteasomal degradation
and/or ize expression (represented in this fusion protein by SEQ ID NO:21). The
fusion protein could alternatively be ed using a MUCl signal sequence (e.g,
ons 1-30 of SEQ ID NO:14), a different synthetic N-terminal peptide as described
herein, or an N-terminal peptide from a yeast alpha leader sequence such as SEQ ID
NO:l9 0r SEQ ID NO:20. The complete fusion protein including the N—terminal peptide
and a hexahistidine C-terminal tag to facilitate identification and/or purification of the
n is a single polypeptide with the following sequence elements fused in frame from
N— to C—terminus (represented by SEQ ID NO:17): (l) a synthetic peptide represented by
SEQ ID NO:21 (positions 1-6 of SEQ ID NO:17); (2) a first MUCl CD (positions 7-78 of
SEQ ID ; (3) a second MUCl CD (positions 79—150 of SEQ ID NO:17); (4) a third
MUCl CD (positions 151-222 of SEQ ID NO:17); and (5) a hexahistidine tag (positions
223—228 of SEQ ID NO:l7). SEQ ID NO:17 is encoded by the nucleotide ce
represented by SEQ ID NO:16 (codon optimized for yeast expression).
Briefly, DNA encoding the MUCl antigens were synthesized, and then
inserted at EcoRI and Not] cloning sites behind the CUP] promoter (vector pGI-lOO) or
the TEF2 promoter (vectors p1u011) in yeast 2 um expression vectors. Nucleotide
sequences encoding a C—terminal hexahistidine e was added to the plasmid vector to
encode the complete fusion protein represented by SEQ ID NO:17. The resulting
plasmids were transformed into DHSu for plasmid storage, and into romyces
cerevisiae W3030t for production of the yeast-MUCI therapeutic compositions.
Transformation into Saccharomyces cerevisiae was performed by lithium
acetate/polyethylene glycol transfection, and primary transfectants were selected on solid
minimal plates lacking Uracil (UDM; uridine dropout medium). Colonies were ed
by growing in U2 (uridine dropout medium) or UL2 (uridine and leucine t medium)
medium at 30° C.
The yeast-MUCl therapy composition comprising a polynucleotide
encoding the human MUCl fusion protein represented by SEQ ID NO:17 under the
control of the CUP] promoter is also referred to herein as GI-6104.
Liquid cultures g uridine (U2) or lacking uridine and leucine (UL2)
(media recipes are provided in Example 1) were inoculated using the plates and starter
cultures described above, and were grown for about 24h at 30°C, 250 rpm. pH buffered
UL2 medium containing 4.2g/L of Bis-Tris (BT-UL2) was also inoculated from frozen
yeast banks to evaluate yeast-MUCl immunotherapeutics produced under neutral pH
manufacturing conditions (data not shown). Culturing in pH buffered UL2 medium
s B-glucans on the yeast cell wall and is believed to modify the cellular immune
responses induced by the yeast as a result of modifying the interactions with dectin
receptors on antigen presenting cells. The remaining culture conditions were the same
whether UL2 or BT-UL2 was used. Primary cultures were used to inoculate final cultures
of the same formulation.
] In initial ments comparing yeast-MUCl immunotherapeutic
itions under the control of different promoters, CUPI—driven (inducible
expression) yeast-MUCl expression was produced in a 2-step or 3-step culture; after
starter or intermediate culture reaches mid—log (1.5-4 , antigen expression was
initiated by the addition of 0.375 mM copper sulfate to final the culture diluted to 0.1 or
0.2 YU/mL from intermediate culture, and was continued until the culture d a
density of 1.5-3 Y.U. riven (inducible expression) yeast-MUCI expression was
also initiated by the addition of 0.375 mM copper sulfate after the final yeast- MUCl
culture reached a density of approximately 2 Y.U./ml, and was induced for 4-6 hours.
riven yeast- MUCl expression is constitutive, and growth of these cells was
continued until the es reached a density of between 1.1 to 4.0 Y.U./ml. The cells
from each culture were then harvested, washed and heat-killed at 56°C for 1 hour in PBS.
After heat—kill of the cultures, the cells were washed three times in PBS. Total
protein expression was measured by a TCA precipitation/nitrocellulose binding assay and
by n blot using an anti-his tag monoclonal antibody and an anti-MUCl (C—
terminus) antibody (so—6827, Santa Cruz). Protein content was quantified using semi-
quantitative digital imaging methods. 4 was expected to express the MUCl fusion
protein as a cytosolic protein of about 25 kDa.
Fig. 2C shows expression of the MUCl antigen in GI-6104 using anti-MUCl
(C-terminus) and is dies for detection. These s showed good expression
of the MUCl fusion protein. Fig. 2B shows the MUCl antigen of 4 after
deglycosylation with EdoH. This figure shows that the GI-6lO4 fusion n is not
expressed as a glycosylated product, since the size of the fusion protein is the same prior
to and after deglycosylation with EdoH.
Quantification of n expression in GI-6104 that was grown under
standard culture conditions was compared to GI-6104 grown under neutral pH conditions,
as described above. The levels of antigen expression were approximately the same using
either process (data not shown), demonstrating that the neutral pH process does not alter
the level of MUCl n expression by the yeast.
Example 3
The following example describes the production of a Yeast-MUCl t
immunotherapeutic composition known as GI—6105.
In this experiment, yeast (Saccharomyces cerevisiae) were engineered to
express a human MUCl agonist antigen under the control of the copper-inducible
promoter, CUP], producing a yeast-MUCl agonist immunotherapy composition. The
MUCl agonist antigen was designed using the antigen from the yeast-MUCl
immunotherapy composition of GI-6lOl (see Example I) as a template. Briefly, a fusion
protein sing a MUCl t antigen was produced as a single polypeptide with the
ing ce ts fused in frame from N- to C—terminus, represented by SEQ
ID N023: (1) MUCl signal sequence (positions 1—30 of SEQ ID N023); (2) a MUCl
SEA/ED segment (positions 31-89 of SEQ ID N023); (3) a VNTR segment comprising
two VNTR domains (positions 90-130 of SEQ ID N023); (4) a MUCl TM domain
(positions 131-158 of SEQ ID N023); (5) a MUCl CD (positions 159-230 of SEQ ID
N023); (6) a MUCl agonist e (positions 231-246 of SEQ ID N023) and (7) a
hexapeptide histidine tag (positions 247-252 of SEQ ID N023). SEQ ID N023 is
encoded by the nucleotide sequence represented by SEQ ID N022 (codon optimized for
yeast sion). The MUCl signal sequence (positions 1-30 of SEQ ID N023) could
be substituted with a different N-terminal sequence designed to impart resistance to
proteasomal degradation and/or stabilize expression, such as the peptide represented by
SEQ ID N021, or an N-terminal peptide from a yeast alpha leader sequence such as SEQ
ID N0:l9 or SEQ ID N020. hexahistidine C-terminal tag is optional, and facilitates
identification and/or purification of the protein. As compared to the antigen in GI—6101
(e.g, SEQ ID N0:l4 or 15), the sequence in GI-6105 contains the ing amino acid
substitutions to create a variety of agonist epitopes (substitution positions given with
reference to SEQ ID NO:23, with further reference to the location of the substitution in a
wild-type MUC1 represented by Accession No. NP_001191214): A96Y (position 161 in
wild-type MUC1), P97L (position 162 in wild-type MUC1), G104V ion 169 in wild-
type MUC1), S105Y ion 170 in wild-type MUC1), T106L (position 171 in wild-type
MUC1), A147Y (position 392 in wild-type MUC1), C161V (position 406 in wild-type
MUC1), T199L (position 444 in wild-type MUC1), D200F (position 445 in ype
MUC1), S215Y (position 460 in wild-type MUC1), and T239L (position 93 in wild-type
MUC1).
A plasmid containing the MUC1 agonist antigen for GI—6105 (SEQ ID NO:23)
was transfected into W3030t yeast and onnants were selected after 3 days of growth
at 30°C on uridine dropout agar (UDA). Single colonies were re-streaked onto uridine and
leucine dropout agar (ULDA) plates and incubated at 30°C for an additional 4 days to
select for cells with elevated plasmid copy number.
A single colony of 5 was d from the ULDA plate and used to
inoculate 25 mL ofUL2 liquid medium er culture). The starter culture was incubated
with shaking at 30°C to a density of 3.7 YU/mL, and then used to inoculate an
intermediate culture to 0.3 YU/mL. The intermediate culture and grown to a density of 3.0
YU/mL, and then used to ate a final culture to a density of 0.04 YU/mL. The final
culture was grown to a density of 3.6 YU/mL, then treated with 0.5 mM copper sulfate for
3h at 30°C to induce Mucl agonist V1.0 n expression.
The induced cells were washed once with PBS, heat killed at 56°C for 1h, then
thrice washed in PBS. Total protein content of the heat killed cells was measured by
Amidoschwarz assay and antigen t was ed by western blot, with a
onal antibody recognizing the C-terminal hexahistidine epitope tag. Antigen
quantity was determined by interpolation against a standard curve comprised of his tagged
HCV NS3 protein. As shown in Fig. 3, the antigen was expressed by the yeast, and the
antigen content for GI—6105 was estimated to be approximately 2801 Ng/YU.
Example 4
The following example describes the tion of a Yeast-MUC1 agonist
immunotherapeutic composition known as GI-6106.
In this experiment, yeast (Saccharomyces cerevisiae) were engineered to
express a human MUC1 agonist antigen under the control of the copper—inducible
promoter, CUP], producing a yeast-MUC1 agonist therapy composition. The
MUC1 agonist antigen was designed using a full—length wild-type MUC1 antigen having
Accession No. NP_001191214, gh other wild—type MUC1 proteins could be utilized
to design similar agonists. Briefly, a fusion protein comprising a MUC1 agonist antigen
was produced as a single polypeptide with the following sequence elements fused in frame
from N— to C-terminus, represented by SEQ ID NO:25: (1) an alpha factor leader
sequence disclosed elsewhere herein by SEQ ID NO:19 (positions 1—89 of SEQ ID
NO:25); (2) a linker sequence of Thr-Ser ions 90-91 of SEQ ID NO:25); (3) a full-
length MUC1 agonist n corresponding to a wild-type protein except for the
introduction of 11 agonist es ions 92—566 of SEQ ID N025) and (7) a
hexapeptide histidine tag (positions 567-572 of SEQ ID NO:25). SEQ ID NO:25 is
encoded by the nucleotide sequence represented by SEQ ID NO:24 (codon optimized for
yeast expression). The alpha leader sequence (positions 1-89 of SEQ ID NO:25) could be
substituted with a different inal ce designed to impart resistance to
proteasomal degradation and/or stabilize expression, such as the peptide represented by
SEQ ID N02], or an N-terminal peptide from a different yeast alpha leader sequence
such as SEQ ID NO:20, or by a MUC1 signal sequence. The hexahistidine C-terminal tag
is optional, and facilitates fication and/or purification of the protein. As compared to
the wild-type MUC1 protein used as a template, the sequence in GI-6106 contains the
following amino acid substitutions to create a y of agonist epitopes (substitution
positions given with nce to SEQ ID NO:25, with fiirther reference to the location of
the substitution in a wild-type MUC1 represented by Accession No. NP_001191214):
T184L (position 93 in wild—type MUC1), A232Y (position 161 in wild-type MUC1),
P233L (position 162 in wild-type MUC1), G240V (position 169 in wild-type MUC1),
S241Y (position 170 in wild-type MUC1), T242L (position 171 in wild-type MUC1),
A483Y (position 392 in wild-type MUC1), C497V (position 406 in wild-type MUC1),
T535L (position 444 in wild—type MUC1), D536F ion 445 in wild-type MUC1), and
S551Y (position 460 in wild-type MUC1).
A plasmid ning MUC1 agonist antigen for 6 was transfected into
W3030L yeast and transformants were selected after 3 days of growth at 30°C on e
dropout agar (UDA). Single colonies were re-streaked onto e and leucine dropout
agar (ULDA) plates and incubated at 30°C for an additional 4 days to select for cells with
elevated plasmid copy number.
A single colony of GI-6106 was removed from the ULDA plate and used to
inoculate 25 mL ofUL2 liquid medium (starter culture). The starter culture was incubated
with shaking at 30°C to a density of ~ 3 YU/mL, and then used to inoculate an
intermediate culture to 0.3 YU/mL. The intermediate e and grown to a density of 3
YU/mL, and then used to inoculate a final culture to a density of 0.04 YU/mL. The final
culture was grown to a density of 3 YU/mL, then treated with 0.5 mM copper sulfate for
3h at 30°C to induce Mucl agonist V2.0 antigen sion.
The induced cells were washed once with PBS, heat killed at 56°C for 1h, then
thrice washed in PBS. Total protein content of the heat killed cells was measured by
chwarz assay and the t n content was ed by western blot, with
a onal antibody recognizing a C-terminal hexahistidine epitope tag. Antigen
quantity was determined by interpolation t a standard curve comprised of his tagged
HCV NS3 protein. Results showed that the GI-6106 yeast sed the antigen (data not
shown); antigen content for GI-6106 was estimated to be approximately 2940 Ng/YU.
Example 5
The following examples describe the phenotypic and onal analysis of the
effects yeast-MUCl immunotherapy compositions on human dendritic cells.
[00205] In order to evaluate the effect of the MUCI immunotherapy
compositions described in Examples 1 and 2 on the phenotype and function of dendritic
cells, the following experiments were performed.
In a first experiment, human tic cells (DCs) were cultured for 48 hours
with: (1) media alone ated), (2) CD40L (1 ug/ml) plus enhancer for ligands (1
ug/ml) as a positive control; (3) control yeast (Control Yeast; yeast comprising an empty
vector (no MUCl antigen insert)); (4) the yeast-MUCl immunotherapy composition
known as GI-6101, grown under standard growth conditions as described in Example 1
(GI-6101); (5) the MUCl immunotherapy composition known as GI—6101, grown
under neutral pH growth conditions as described in Example 1 (GI-6101 (DEC)); (6) the
yeast-MUCl immunotherapy composition known as GI-6104 (GI-6104), grown under
standard growth conditions as described in Example 2; or (7) the yeast-MUCI
immunotherapy composition known as GI-6104, grown under neutral pH growth
conditions as described in Example 2 (GI-6104 (DEC)). Dendritic cells and yeast were
combined at a ratio of 1:10 (DC:yeast). DCs were harvested and analyzed by flow
cytometry for DC surface-marker expression. The results are shown in Table 1 below as
the percentage of positive cells and MFI (parentheses).
Table 1
ent of DCs CD80 CD83 CD86 CD54 Class I Class II
Untreated 6.4 28.6 97.6 96.3 99.2 80.9
(3088) (3352) (19731) (14463) ) (8678)
CD40L 59.3 79.6 99.8 99.6 99.9 81.6
(3932) (4364) ) (44958) (25589) (5908)
Control Yeast 41.2 54.7 99.1 96.0 99.3 93.7
(4479) (3953) (49674) (26634) (40996) (8953)
GI-6101 56.2 72.9 99.0 96.0 99.6 83.1
(5456) (4654) (59333) (41385) (43290) (7684)
GI-6101 (DEC) 65.3 74.3 99.6 98.2 99.9 87.0
(6090) (4149) (63934) (41984) (33384) 6304)
GI-6104 57.0 65.8 99.0 96.1 99.5 90.6
(5433) (4498) (5 9460) (40096) (42884) (6992)
GI-6104 (DEC) 52.0 63.0 99.2 97.6 99.9 88.7
5502 4012 55133 31823 35846 6423
The results show that yeast (control yeast and yeast expressing MUCl
antigens), regardless of the method of growth, upregulated the expression of CD80 and
CD83 on dendritic cells as compared to untreated cells. CD80, or B71, is a costimulatory
molecule ary for T cell activation and survival that is upregulated on activated
dendritic cells. CD83 is a marker of dendritic cell maturation. ingly, this
experiment shows that the yeast—MUCl immunotherapeutic itions can upregulate
DC maturation markers.
] In a second experiment, dendritic cell cytokine and chemokine production
were evaluated after culture with the yeast-MUCl immunotherapeutics. Briefly, human
DCs from a normal donor (a donor who was believed to be cancer-free) were cultured for
days with granulocyte macrophage-colony stimulating factor (GM-CSF) and eukin-
4 (IL-4), or treated with CD40L (1 ug/ml, Enzo Life Sciences) plus enhancer for ligands
(1 ug/ml, Enzo Life Sciences) for 24 hours, or with Control Yeast (empty vector), GI-
6101 cultured under standard growth conditions (GI-6101), GI-6101 ed under
neutral pH conditions 01 (DEC)), GI-6104 cultured under standard growth
conditions (GI-6104), or GI—6104 cultured under neutral pH conditions (GI-6104 (DEC))
for 48 hrs (DC:yeast ratio = 1:10). Cultured supernatants were collected and screened for
cytokine and chemokine production by multiplex cytokine/chemokine kit. s are
expressed in pg/ml, and shown in Table 2.
Table2
Treatment of DCs IL-2 IL-8 IL-12p701L-1B GM-CSF IFN-y IL-6 IL-10 TNF-a
CD40L 14.9 829.6 152.8 6.3 5069.8 22.3 933.2 74.3 8103.2
Control Yeast 2.8 129.4 316.1 1.8 4420.3 6.3 49.2 3.9 333.7
GI-6101 3.5 183.3 443.3 2.1 4174.8 5.9 75.3 4.4 487.1
GI-6101 (DEC) 1 1.5 866.6 864.2 4.3 3697.8 31.8 192.0 10.7 2148.2
GI-6104 4.5 315.7 568.0 1.9 4156.0 7.3 121.8 5.0 477.0
G1-6104 (DEC) 6.5 725.2 587.8 3 .2 3165.5 13.2 140.4 8.5 642.0
The results in Table 2 shown that the treatment of dendritic cells from a
normal donor with yeast-MUCl immunotherapy itions described in Examples 1
and 2 increases cytokine and chemokine production by these cells. Notably, interferon-y
(IFN—y) production was increased after exposure to yeast-MUCl immunotherapy
compositions grown under neutral pH ions, which is expected to enhance THl and
CD8+ T cell responses. In addition, yeast-MUCl immunotherapy compositions grown
under neutral pH ions induce higher cytokine and chemokine production by DCs,
with the yeast-MUCl immunotherapy composition known as 1 (neutral pH)
showing the highest stimulation of DC cytokine and ine production. Numbers
highlighted in bold type show cytokine/chemokine induction that is statistically
cantly improved as compared to untreated control (data not shown).
The experiment shown in Table 2 was ed using dendritic cells ed
from a different normal donor. The results (data not shown) are comparable to those
shown in Table 2 and confirm that MUCl immunotherapy itions induce
cytokine and chemokine production by dendritic cells, and that the yeast-MUCl
composition known as GI—6101, grown under neutral pH growth conditions, induces the
highest levels of cytokine and chemokine production by dendritic cells among the two
yeast-MUCl compositions grown under each condition.
Taken together, these results show that yeast-MUCl immunotherapy
compositions can activate dendritic cells and induce cytokine and chemokine production
that is associated with a productive immune response.
Example 6
The following example shows that yeast-MUCl immunotherapy compositions
of the invention can te MUCl-speciflc T cells.
TP93L is a MUC—l specific T cell line that specifically recognizes the
MUCl agonist peptide, denoted P93L, in the context of HLA—A2. P93L is a peptide
spanning ons 92-101 of a full—length MUCl protein (eg, ATWGQDVTSV;
positions 92-101 of SEQ ID NO: 1 1), except that the threonine at on 2 of this peptide
(position 93 in positions 92-101 of SEQ ID NO:1 l) is substituted with a leucine, creating
an agonist peptide. P93L binds to HLA-A2 at higher levels than the native (wild-type)
peptide, and is a better inducer of MUCl-specific T cells than the native peptide (higher
production ofTHI cytokines (see US. Patent Application Publication No. 2008/0063653).
The T cell line T—3—P93L can specifically lyse HLA-AZ-positive, MUCl-positive tumor
targets in vitro (data not shown). This T cell line is specific for a portion of MUCl that is
within the MUCl-N subunit.
In this experiment, DCs from a normal donor, prepared as described in
Example 5 were treated with the yeast-immunotherapy compositions bed in
es 1 and 2, or with control yeast (empty vector), CD40L (positive control) or
untreated (negative control) using conditions described above in Example 5. DCs treated
with control yeast or with CD40L were pulsed with or without the P93 L peptide (P93L
was used at 10 ug/ml). d DCs were then used as antigen ting cells (APCs) to
evaluate their ability to stimulate the MUCl-specific T cell line TP93L (T C ratio
= 10:1). 24 hour culture supematants were ted and screened for the secretion of
interferon—y ). The results are shown in Table 3, expressed as the amount of IFN—y
produced by the T cells in pg/ml.
Table 3
DCs ent MUC-l MUC-l-specific T IFN-y
peptide cells
_ None - + <15.6
+ CD40L - + <15.6
+ CD40L + + 217.1
+ Control yeast - + <15.6
+ Control Yeast + + 339.2
+ GI-6101 - + 342.1
+ GI-6101 (DEC) - + 393.5
+ GI-6104 - + 44.2
+ GI-6104 (DEC) - + 32.3
The results show that dendritic cells treated with GI-6101, produced under
both standard and l pH conditions, and which expresses VNTR domains of the
MUCl-N subunit, was able to stimulate the MUCl-N-specific T cells to produce
significant amounts of IFN—y. GI-6104, which does not express antigen from the MUCl-
N protein (GI-6104 only expresses MUCl antigen from the cytoplasmic domain (CD)),
did not stimulate the MUCl-N—specific T cells.
In a second experiment, the MUCl-C-specific T cell line, d T
P1240(lY), was stimulated with DCs that had been treated as in the experiment above, to
determine whether yeast-MUCl immunotherapy itions of the invention could
stimulate these T cells. The T—15-P1240(1Y) cell line is a MUC-l c T cell line that
specifically recognizes the MUCl agonist peptide, denoted P1240(lY), which is a MUCl-
C peptide, in the context of HLA—A2. P1240(lY) is a peptide spanning ons 1240—
1248 of a full-length MUCl protein (e.g., SLSYTNPAV; positions 1240-1248 of SEQ ID
NO:ll), except that the serine at position 1 of this peptide (position 1240 in positions
1240—1248 of SEQ ID NO:ll) is tuted with a lysine, creating an agonist peptide.
P1240(lY) binds to HLA-A2 as well or better than the native (wild-type) peptide, and is a
better r of pecific T cells than the native peptide (higher production of THl
cytokines. The T cell line TPl240(1Y) can specifically lyse HLA-A2-positive,
MUCl-positive tumor targets in vitro (data not shown). This T cell line is specific for a
portion of MUCl that is within the MUCl-C subunit, and specifically, the cytoplasmic
domain (CD).
In this experiment, DCs were generated from PBMCs of a healthy HLA-A2
positive donor, and prepared as described in Example 5. The DCs were treated with the
immunotherapy compositions described in Examples 1 and 2, or with CD40L
(positive control) or ted (negative control) using conditions described above in
Example 5. DCs treated with CD40L were pulsed with or without the P1240(lY) peptide
de was used at 10 ug/ml). Treated DCs were then used as antigen presenting cells
(APCs) to evaluate their y to stimulate the MUCl—specific T cell line T-15—
P1240(lY) (T cell:DC ratio = 10:1). 24 hour culture supematants were collected and
screened for the secretion of interferon—y ). The results are shown in Table 4,
expressed as the amount of IFN—y produced by the T cells in pg/ml.
Table 4
DCs Treatment MUCl-C MUCl-C- IFN-y
peptide specific T
cells
— — — + 106.1
+ CD40L - + <15.6
+ CD40L + + 2402.8
+ GI—6101 - + 852.1
+ 1 - - 67.4
+ GI—6101/ DEC - + 1667.9
+ GI—6101/ DEC - - 113.7
+ GI—6104 - + 583.6
+ GI—6104 - - 103.4
+ GI—6104/DEC - + 1155.1
+ GI—6104/DEC - - 63.6
The results show that both GI-6lOl and GI-6104, grown under standard or
neutral pH ions, were able to stimulate the -specific T cells to produce
cant amounts of IFN—y. Yeast-MUCl immunotherapy compositions grown under
neutral pH conditions (both GI-6lOl and Gl-6104) stimulated higher levels of IFN—y
production by the T cells than MUCl immunotherapy compositions grown under
standard conditions.
In a third experiment, the experiment described in Table 4 above was repeated,
but using different DC:T cell ratios for DCs treated with the yeast-MUCl immunotherapy
compositions GI-6101 and GI-6104. The results are presented below in Table 5.
Table 5
DCs Treatment MUC1-C DC:T cell -specific lFN-y (pg/ml)
peptide T cells
- GI-6101 - + 48
+ GI-6101 - - <15.6
+ GI-6101/ DEC - — <15.6
+ GI-6104 - - <15.6
+ GI-6104/DEC - - <15.6
+ GI-6101 - 10:] + 981.8
:] + 628.4
40:] + 426.4
+ GI-6101/DEC - 10:] + 2039.1
:] + 1074.3
40:1 + 768.4
+ GI-6104 - 10:] + 534.2
:] + 514.6
40:] + 330.9
+ GI-6104 /DEC - 10:] + 1177.8
:] + 824.4
40:] + 674.6
+ CD40 L + + 2275.4
The s again show that both Gl-6lOl and Gl-6104, grown under standard
or neutral pH conditions, were able to stimulate the MUCl—C-specific T cells to produce
significant amounts of lFN—y, and that the compositions grown under neutral pH
conditions stimulated higher levels of IFN-y production by the T cells than MUCI
immunotherapy itions grown under standard conditions. The results further show
a dose response as the number of DCs increases relative to the number of T cells.
Taken together, these results show that yeast-MUCl immunotherapy
compositions can activate MUCl-specific T cells in an antigen-specific manner, as
illustrated by the IFN-y release from T cells stimulated by DCs treated with the yeast-
MUCl immunotherapy compositions. These results also show an advantage for the
production of IFN-y by T cells as a result of using yeast-MUCl immunotherapy
itions grown under neutral pH conditions.
Example 7
The ing example trates that yeast-MUCl compositions of the
invention can expand and stimulate MUCl—specific T cells from cancer patients.
In this experiment, DCs are ed from the PBMCs of cancer patients (post
treatment with a cancer therapy, which can include chemotherapy or viral vaccine
treatment, and/or pre-treatment). The DCs are prepared in a 5-day culture in presence of
GM-CSF and IL-4, followed by incubation in presence of yeast (GI-6101 and/or GI-6104,
cultured under rd or neutral pH conditions). After 48-hours co-culture, the DCs are
used as APCs for stimulation of gous T cells by measuring cytokine production
and/or proliferation of CD4+ T cells. Yeast-MUC] immunotherapy compositions are
expected to expand and activate T cells from the cancer patients.
] In a second experiment, DCs are prepared from the PBMCs of cancer patients
(post ent with a cancer therapy, which can include chemotherapy or viral vaccine
treatment, and/or pre-treatment). The DCs are prepared in a 5—day culture in presence of
GM-CSF and IL-4, followed by incubation in presence of yeast (GI-6101 and/or 4,
cultured under standard or l pH conditions). After 48-hours co-culture, the DCs are
used as APCs for stimulation of autologous T cells. Each cycle of IVS consists of 3 days
in absence of IL-2, following by 4 onal days in presence of 20 U/ml of recombinant
IL-2. Tetramers specific for a MUCl peptide are used to detect the percentage of CD8+ T
cells that are expanded by the treatment with the yeast-MUCl immunotherapy
compositions. Yeast-MUCI therapy compositions are expected to expand and
activate T cells from the cancer patients.
In a third experiment, yeast-MUCI immunotherapeutic compositions are used
to generate MUCl-specific CTLs from PBMCs that lyse MUCl-expressing targets. In
this experiment, MUCl—specific T cells from normal donors and/or from cancer patients
(post treatment with a cancer therapy, which can include chemotherapy or viral vaccine
treatment, and/or pre-treatment), are expanded in vitro using DCs ted with yeast—
MUCl immunotherapy itions (GI—6101 or GI-6104) for 2 cycles of in vitro
ation (IVS). At day 5, CD8+ T cells are isolated and used in an overnight CTL assay
against tumor cells that express MUCl. These experiments are expected to demonstrate
that MUCl immunotherapeutic compositions can generate MUCl-specific CTLs
that are capable of killing a MUCl—expressing tumor cells.
Example 8
The following example demonstrates that immunization with a yeast-MUCI
immunotherapeutic composition reduces MUCl-expressing tumors in viva.
] In this experiment, mice receive tumor cells expressing a recombinant human
MUCl protein Via the tail vein (day 0). Four days post-tumor implantation, animals
receive weekly vaccinations with yeast control (YVEC, or empty vector yeast) versus
yeast-MUCl 01 or GI-6104), administered at a dose of lYU per site at four
different sites (4YU total per dose). At day 40 post—tumor implantation, animals are
sacrificed and the number of lung tumor nodules are evaluated. It is expected that the
yeast-MUCl immunotherapy compositions are capable of reducing MUCl-expressing
tumors in mice, as compared to mice receiving yeast alone (no MUCl antigen).
Example 9
] The following example describes a phase 1 al trial in subjects with
ositive cancer.
An open-label, dose-escalation phase 1 clinical trial is run using a yeast-
MUCl immunotherapy composition known as GI-6lOl described in Example 1 or GI—
6104 described in Example 2 (grown either under standard growth conditions or under
neutral pH conditions). 12-24 subjects with a MUCl-positive tumor are administered the
MUCl immunotherapy composition in a sequential dose cohort escalation protocol
utilizing dose ranges of 4 Y.U. (l Y.U. x 4 sites), 16 Y.U. (4 Y.U x 4 sites) and 40 Y.U.
(lO Y.U. x 4 , administered subcutaneously. The yeast-MUCl immunotherapy is
administered at 2 week intervals for 3 months, and then monthly. An expansion cohort of
patients (n=10) at maximum tolerated dose (MTD) or the observed best dose are selected
for onal study. The results monitor safety as a primary endpoint, and as ary
endpoints, antigen-specific T cell responses (e.g., MUCl-specific CD8+ T cells emerging
or expanding on treatment) as well as al activity.
[00230] GI-6lOl and GI-6lO4 are ed to be safe and well-tolerated with no
significant toxicities. In addition, GI-6lOl or GI-6104 are ed to produce treatment-
emergent MUCl-specific T cell responses or an improvement in pre-existing MUCl—
specific baseline T cell responses in a statistically significant number of patients. Some
ts are also expected to have stabilized disease.
e 10
The following example describes a clinical trial (Pl/P2) using Yeast-MUCl
immunotherapeutic compositions.
Increased MUCl expression has been ed in ~ 70% of the acute myeloid
leukemia (AML) cases, suggesting that elevated MUCl levels may be involved in
regulating the proliferative potential of the immature leukemic compartment.
In a first clinical trial, first—line use of the yeast-based immunotherapy product
known as GI—6lOl (see Example 1) is ented in the setting of MUCl-positive AML
(this trial design is also applicable to other yeast-MUCl immunotherapy itions,
such as GI-6104). The use of GI-6lOl is designed to complement existing cytotoxic
standard of care regimens, cytarabine and an anthracycline (e.g, daunorubicin), in an add-
on approach by ing immune killing of MUCl-positive leukemic cells, as well as
eliminating MUCl leukemic cells which can escape terminal differentiation (apoptosis)
pathways. Endpoints include ements in the induction of remission as well as
overall survival (pre— and post-transplant).
In a second trial, GI-6lOl is used in the bone marrow transplantation (BMT)
g to prevent relapse ofAML in ts with MUCl—positive disease (this trial design
is also applicable to other yeast-MUCl immunotherapy compositions, such as GI-6104).
Clinical strategies which evaluate the vaccination of bone marrow donors (adoptive
transfer) and/or vaccination of bone marrow recipients in the post transplant period are
used to reduce the rate of relapse after BMT.
(A) Clinical Study design for first line therapy ofMUCI-positive AML patients with
GI-6101 plus cytaribine and daunorubicin versus standard ofcare alone.
Patients receive induction herapy consisting of continuous intravenous
infusion of cytaribine (cytosine arabinoside) at 100-200mg/m2 per day X 7 days plus
enous daunoribicin (or ycin (daunomycin cerubidine)) 45mg/m2 on days 1, 2,
and 3 of cytaribine y, or an accepted variation of this regimen, ed by GI-6101
(or placebo) administration 14 days after completion of the induction cycle of
chemotherapy. GI-6lOl (or placebo) are then administered 14 days after re-induction
therapy or 14 days after every uent consolidation cycle of chemotherapy. After
induction, re—induction, and idation therapy, GI-6lOl (or placebo) are administered
each month for up to 3 years with the primary objective of preventing relapse of remission.
] It is expected that the use of GI-6lOl enhances the relapse of remission in
patients as compared to those receiving placebo.
(B) Clinical Study design for post-EMT therapy OfMUCI-positive AML with GI—6101
versus placebo.
For MUCl—positive AML patients who e myelo-ablative therapy
followed by bone marrow transplant, GI-6lOl (or placebo) are stered to the bone
marrow donor 7-14 days prior to the donation of bone marrow, and GI-6lOl (or placebo)
are administered to the bone marrow recipient on a monthly basis for up to 3 years after
bone marrow engraftment occurs. The primary objective is to reduce the rate of AML
relapse.
It is expected that the use of GI-6101 reduces the rate of relapse in AML
patients as compared to those patients taking placebo.
While various embodiments of the present invention have been described in
detail, it is apparent that modifications and adaptations of those embodiments will occur to
those d in the art. It is to be expressly understood, r, that such modifications
and adaptations are within the scope of the present invention, as set forth in the following
exemplary claims.
Claims (46)
1. A Yeast-MUC1 immunotherapeutic composition, n the immunotherapeutic composition comprises: a) a yeast vehicle; and b) at least one MUC1 agonist antigen expressed by the yeast vehicle, wherein the MUC1 agonist antigen comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:25 or to positions 92-566 of SEQ ID NO:25, and wherein the MUC1 agonist antigen comprises at least one of the following amino acid substitutions: T184L, A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
2. The Yeast-MUC1 immunotherapeutic composition of claim 1, wherein the MUC1 agonist antigen comprises an amino acid sequence that is at least 95% identical to positions 92-566 of SEQ ID NO:25, and wherein the MUC1 agonist n comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acid tutions: T184L, A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
3. The MUC1 immunotherapeutic composition of claim 1 or 2, n the MUC1 agonist antigen ses an amino acid sequence that is at least 95% identical to SEQ ID NO:25, and wherein the MUC1 agonist antigen comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acid substitutions: T184L, A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
4. The Yeast-MUC1 immunotherapeutic composition of Claim 1 or 2, wherein the MUC1 agonist antigen comprises an amino acid sequence that is at least 97% identical to positions 92-566 of SEQ ID NO:25, and wherein the MUC1 agonist antigen comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acid substitutions: T184L, A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
5. The Yeast-MUC1 immunotherapeutic composition of Claim 1 or 3, wherein the MUC1 t antigen ses an amino acid sequence that is at least 97% identical to SEQ ID NO:25, and wherein the MUC1 agonist antigen comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acid substitutions: T184L, A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
6. The Yeast-MUC1 immunotherapeutic composition of any one of claims 1 to 5, wherein the MUC1 agonist antigen comprises each of the ing amino acid substitutions: T184L, A232Y, P233L, G240V, S241Y, T242L, A483Y, C497V, T535L, D536F, and S551Y.
7. A Yeast-MUC1 immunotherapeutic composition, n the immunotherapeutic composition comprises: a) a yeast vehicle; and b) a MUC1 t antigen expressed by the yeast e, wherein the MUC1 agonist antigen comprises an amino acid sequence that is at least 98% identical to SEQ ID NO:25 or to positions 92-566 of SEQ ID NO:25.
8. The Yeast-MUC1 immunotherapeutic composition of claim 7, wherein the immunotherapeutic composition comprises: a) a yeast vehicle; and b) a MUC1 agonist antigen expressed by the yeast vehicle, wherein the MUC1 t antigen comprises an amino acid sequence that is at least 99% identical to SEQ ID NO:25 or to positions 92-566 of SEQ ID NO:25.
9. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 8, wherein the MUC1 agonist antigen comprises an amino acid sequence of SEQ ID NO:25.
10. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 8, wherein the MUC1 agonist antigen comprises an amino acid sequence of positions 92-566 of SEQ ID NO:25.
11. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 8, wherein the MUC1 agonist antigen consists of positions 92-566 of SEQ ID NO:25.
12. A MUC1 immunotherapeutic composition, n the immunotherapeutic ition comprises: a) a yeast; and b) a MUC1 agonist antigen that has been expressed by the yeast, wherein the MUC1 agonist n comprises an amino acid sequence that differs from an amino acid sequence of a wild-type MUC1 protein having Accession No. NP_001191214 by an amino acid substitution at 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 of the following amino acid positions of the wild-type MUC1 amino acid sequence: T93, A161, P162, G169, S170, T171, A392, C406, T444, D445, and S460.
13. The Yeast-MUC1 immunotherapeutic ition of claim 12, wherein the MUC1 agonist antigen has an amino acid sequence that differs from the amino acid sequence of the wild-type MUC1 n by an amino acid substitution at each of the following sequence positions of the wild-type MUC1 amino acid sequence: T93, A161, P162, G169, S170, T171, A392, C406, T444, D445, and S460.
14. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 13, wherein the yeast vehicle is a whole yeast.
15. The Yeast-MUC1 therapeutic composition of any one of Claims 1 to 14, wherein the yeast vehicle is heat-inactivated.
16. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 15, wherein the yeast e is from a mutant yeast strain that produces underglycosylated proteins, as compared to a wild-type yeast strain.
17. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 16, wherein the MUC1 antigen is expressed on the cell wall of the yeast vehicle.
18. The MUC1 immunotherapeutic composition of any one of Claims 1 to 16, wherein the MUC1 antigen is expressed in the asm or cytoplasm of the yeast
19. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 18, wherein the yeast vehicle is from Saccharomyces .
20. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 19, wherein the yeast vehicle is from Saccharomyces cerevisiae.
21. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 20, wherein the immunotherapeutic composition has been produced by culturing a whole yeast expressing the MUC1 antigen in a medium that was maintained at a pH level of between 5.5 and 8.
22. The Yeast-MUC1 immunotherapeutic composition of Claim 21, wherein the medium was buffered with a buffering agent.
23. The Yeast-MUC1 therapeutic composition of Claim 21, wherein the yeast was ed in a medium that was maintained at a pH level of between 6 and 8.
24. The Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 23, further comprising at least one biological response modifier.
25. The Yeast-MUC1 immunotherapeutic ition of any one of Claims 1 to 24, further comprising a pharmaceutically acceptable excipient.
26. The MUC1 immunotherapeutic composition of any one of Claims 1 to 25, wherein the immunotherapeutic composition has been formulated for injection.
27. Use of the Yeast-MUC1 immunotherapeutic composition of any one of Claims 1 to 26 in the ation of a medicament to treat a disease.
28. The use of Claim 27, wherein the disease is cancer.
29. The use of Claim 28, wherein the cancer is stage I cancer.
30. The use of Claim 28, wherein the cancer is stage II cancer.
31. The use of Claim 28, wherein the cancer is stage III cancer.
32. The use of Claim 28, wherein the cancer is stage IV cancer.
33. The therapeutic composition according to any one of Claims 1 to 26 for use in reducing, arresting, reversing or preventing the metastatic progression of cancer in an dual who has cancer.
34. The composition ing to claim 33, wherein the individual is at high risk for developing cancer.
35. The ition according to claim 33, wherein the individual has a precancerous
36. The composition according to claim 33, wherein the individual has cancer, but MUC1 expressing cancer cells have not been detected in the cancer.
37. The composition of Claim 33, further comprising an additional immunotherapeutic composition.
38. The composition of claim 37, wherein the additional immunotherapeutic compositions comprise a second cancer antigen that is a MUC1 antigen or a cancer antigen that is not a MUC1 antigen.
39. The composition of Claim 37, wherein the additional immunotherapeutic compositions comprise a yeast vehicle and a second cancer n that does not include MUC1 antigen.
40. The composition of Claim 38 or 39, wherein the second cancer antigen is selected from the group consisting of: mutated Ras, carcinoembryonic antigen (CEA), Brachyury, EGFR, BCR-Abl, MART-1, MAGE-1, MAGE-3, GAGE, GP-100, MUC-2, PSMA, tyrosinase, TRP-1 (gp75), NY-ESO-1, TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erb/B2, hTERT, p73, B-RAF, atous polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL), Rb-1, Rb-2, androgen receptor (AR), Smad4, MDR1, Flt-3, BRCA-1, BRCA-2, khr, ews-fli-1, HERV-H, , TWIST, Mesothelin, and NGEP.
41. The composition of Claim 38 or 39, wherein the second cancer antigen is selected from the group consisting of: mutated Ras, carcinoembryonic antigen (CEA) and Brachyury.
42. The composition of Claim 37, wherein the additional immunotherapeutic composition is a viral vector e.
43. The use of Claim 37, wherein the additional immunotherapeutic composition is a dendritic cell/tumor cell fusion.
44. Use of an immunotherapeutic composition ing to any one of Claims 1 to 26 in the preparation of a medicament to prevent or delay the onset of a MUC1- expressing cancer.
45. The use Claim 44, wherein the cancer is of epithelial cell origin.
46. The use of Claim 44 wherein the cancer is selected from the group consisting of: breast cancer, small ine cancer, stomach cancer, pancreatic cancer, kidney , bladder cancer, e cancer, ovarian cancer, testicular cancer, lung cancer, colon cancer, prostate cancer, melanoma, multiple myelogenous leukemia (MML), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), Burkitt’s lymphoma, Hodgkin’s ma, cancers of secretory tissues, and metastatic cancers thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161524407P | 2011-08-17 | 2011-08-17 | |
US61/524,407 | 2011-08-17 | ||
PCT/US2012/051299 WO2013025972A1 (en) | 2011-08-17 | 2012-08-17 | Yeast-muc1 immunotherapeutic compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ622335A NZ622335A (en) | 2016-07-29 |
NZ622335B2 true NZ622335B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11065318B2 (en) | Yeast-MUC1 immunotherapeutic compositions and uses thereof | |
AU2018202972B2 (en) | Yeast-Brachyury immunotherapeutic compositions | |
NZ622335B2 (en) | Yeast-muc1 immunotherapeutic compositions and uses thereof | |
NZ724797A (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ616696B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ724797B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ711188B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ711188A (en) | Yeast-brachyury immunotherapeutic compositions |